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Nutritional problems are common in inflammatory bowel disease. The
pathogenesis is multifactorial and the primary role of the disease and associated
immunological abnormalities are difficult to assess. In this thesis I have
investigated the direct contribution of inflammatory bowel disease in specific
nutritional problems such as osteopenia. I have also evaluated clinically applicable
objective measures of different aspects of gut inflammation so that the interface
between gut inflammation and nutritional abnormalities may be explored.
Bone mineral density and biochemical parameters of bone metabolism were
measured in patients with newly diagnosed inflammatory bowel disease prior to
medical therapy or surgery. I established that, at diagnosis, low bone mineralisation
was a feature of Crohn's disease but not ulcerative colitis. Disease activity,
anatomy of involvement, body mass index, smoking habits, sex, physical activity or
biochemical parameters did not account for this difference. Follow-up over a period
of one year did not show any further bone loss in spite of steroid therapy. Previous
studies which had not shown any difference between Crohn's disease and
ulcerative colitis had recruited unselected patients with predominantly long¬
standing disease. When I studied patients with long-standing inactive inflammatory
bowel disease, bone mineral density was equally low in both Crohn's disease and
ulcerative colitis. Adolescents with long-standing inflammatory bowel disease were
identified as a specially vulnerable group for osteopenia. Since bone is only one of
the compartments of the body, I next investigated methods to assess body
composition in clinical practice. Simple portable, user-friendly bioelectrical
impedance analysis machines have recently become available. I evaluated one
such machine by comparing it with a standard bioelectrical impedance machine
available in Medical Physics department and with dual energy X-ray
absorptiometry, a standard method of measuring lean body mass. The results
showed that this machine measured lean body mass as accurately as the more
expensive, non-portable machines. Furthermore, measurement of percent lean
clearly showed heterogeneity in body composition in subjects with similar body
mass indices.
The laboratory aspect of my thesis was to establish methods for clinical
analysis of various aspects of gut inflammation using the relatively new, non-
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invasive technique of whole gut lavage. The patients drank a polyethylene-glycol-
electrolyte solution and the first clear fluid passed per rectum was collected for
analysis. Cytology of whole gut lavage fluid proved to be a useful technique for
investigation of luminal migration of inflammatory cells and I observed previously
unrecognised differences between small bowel and colonic Crohn's disease. A
simple assay of granulocyte elastase was a good surrogate marker of neutrophils
in whole gut lavage fluid and allowed me to study neutrophil migration into the
lumen in samples from a large number of patients stratified according to anatomy,
treatment and disease activity. The technique also allowed the study of
chemokines involved in cell migration. A number of cytokines could be readily
measured in whole gut lavage fluid. Raised interleukin-ip concentration was a
feature of active inflammation, lnterleukin-8 concentration in whole gut lavage fluid
correlated with granulocyte elastase concentration in ulcerative colitis, but not in
Crohn's disease. This suggested that other luminal neutrophil chemoattractants
such as bacterial peptides might be important in Crohn's disease. I also
investigated the role of growth factor peptides such as insulinlike growth factor-1
and transforming growth factor-p in gut fibrosis and found detectable insulinlike
growth factor-1 in whole gut lavage fluid to be a feature of Crohn's disease and
other intestinal inflammatory conditions associated with fibrosis. These clinically
applicable techniques should allow future investigation of the role of immunological
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Inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative
colitis (UC) are chronic, incurable diseases of unknown aetiology. A number of
components of overall disability associated with IBD can be analysed in a
systematic way. These include disease activity, anatomical distribution of
destructive chronic inflammation, mechanical obstruction, complications such as
abscess or fistula, nutritional status, iatrogenic factors (medical and surgical),
psychological and social factors, and non-intestinal involvement. Though most of
these factors are inter-dependent, analysis of them individually can be useful in
understanding their separate contributions to overall morbidity and their influence
on therapeutic plans. This thesis is an attempt to investigate some specific aspects
of morbidity in IBD, namely, nutritional status, inflammation and tissue destruction,
and their possible inter-relationships.
1.1. Nutrition in IBD
Patients with IBD are at increased nutritional risk for deficiency of calories,
proteins, vitamins and minerals (Farmer et al 1975, Driscoll et al 1978, Beeken
1979). Specific subgroups such as children and adolescents, those with multiple
bowel resections, and those with complicated disease such as fistulae, are well
recognised to be at particular risk. The effect of CD on nutritional status is more
marked than that of UC (Barton et al 1990, Markowitz et al 1993). Though
nutritional deficiencies in IBD are a major concern, the database concerning
nutritional status of patients with IBD is relatively modest compared with data on
the pathogenic or therapeutic aspects of IBD. In addition, interpretation of the
available data can be difficult because many of the studies have methodological
shortcomings; some are retrospective with the use of historical controls, others are
uncontrolled, and still others concern heterogeneous cohorts of patients. Available
studies generally focus on patients from specialised centres with complicated
disease. In children with IBD, increased morbidity of children with CD in relation to
growth and development delay has been described in studies from our centre
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(Barton et al 1990, Ferguson et al 1994b) and other centres (Hildebrand et al 1994,
Griffiths et al 1993, Markowitz et al 1993, Motil et al 1993).
1.2. Multifactorial aetiology of malnutrition
Nutritional deficiency in IBD is multifactorial. Diminished intake,
malabsorption, increased intestinal losses of protein and blood, medical and
surgical therapy and sepsis contribute to malnutrition. Less well recognised is the
direct effect of the disease process on metabolism and nutrition; this has been
extensively researched in malignant diseases (Hansell et al 1986, Fredrix et al
1991) and in acquired immunodeficiency syndromes (Grunfeld et al 1992, Mildvan
et al 1992), but comparable studies are lacking in the area of IBD. Understanding
the role of the different variables on nutritional status, including the direct effect of
the disease itself, is one of the major challenges in this area of IBD management
and research.
1.3. Teasing out the contribution of disease process from the effects of
medical therapy, surgery and malabsorption.
It is difficult to study the direct effect of IBD on nutritional parameters as
there are many confounding variables. Prospective studies on patients carefully
stratified according to their medical therapy and surgical resections, anatomy of
disease and disease activity are needed to tease out the contribution of a single
variable. There are few studies on newly diagnosed patients who probably offer the
best opportunity to study the effect of the disease process before medical or
surgical therapy. Recruiting and prospectively studying patients at diagnosis may
take longer than cross-sectional studies, but the smaller number of variables in
matched cohorts make interpretation much easier and valid.
1.4. Children with IBD - a specially vulnerable group
Though studies from specialised centres dealing with complicated patients
have established that there is delayed rate of growth and development in a
considerable proportion of children with IBD, such data are lacking for unselected,
population- based cohorts of children with IBD. In Scotland, serious deficiencies in
recording growth and development parameters in IBD children attending NHS
hospitals have been highlighted (Barton et al 1989a). This makes longitudinal
3
studies based on retrospective analysis of hospital records difficult. Only an
improvement in monitoring resulting from greater awareness will permit longitudinal
analysis of growth and development in population-based surveys of juvenile-onset
IBD patients.
1.5. Importance of a compartmental approach to nutritional assessment
Traditional methods of assessing nutritional status rely heavily on
measurement of weight and height with some additional laboratory parameters.
Though this may generally be adequate for clinical monitoring of patients, it is
impossible to formulate hypotheses regarding the mechanism of undernutrition or
possible metabolic changes unless a more detailed assessment of body
composition is performed. Loss of weight may be attributable to loss of both fat and
lean, or may be the result of a relatively selective loss from one of the two
compartments; the underlying metabolic abnormality is likely to be very different in
these groups.
1.6. Investigating the effect of disease-objective methods of assessing
various aspects of inflammation
In order to conduct objective studies on the effect of IBD on nutrition,
various aspects of inflammation need to be objectively measured and correlated
with nutritional parameters. Currently, few methods provide a direct accurate
measurement of gut inflammation and its various components in a clinical setting
and novel approaches to clinical quantitative measurement of various aspects of
gut inflammation are needed.
1.7. Aims of this thesis
The general aim of this thesis was to assess the effect of IBD on specific
compartments of the body, such as bone, fat and lean and develop clinical
methods to investigate specific inflammatory processes so that any
interrelationship between body compartment changes and inflammation may be
investigated. I proposed to investigate the hypothesis that CD, a systemic disease
with a long premorbid phase, has direct effects on nutritional status unlike UC
which is characterized by inflammation localized to colonic mucosa only. The effect
of CD on nutrtition is likely to be multifactorial and involve diminished intake, the
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effect of inflammation on intermediary metabolism and the effects of diminished
physical activity, drugs and surgery. In uncomplicated starvation, fat compartment
is selectively depleted first in order to spare muscle protein (Cahill 1970). Pro¬
inflammatory cytokines such as TNF or IL-1 result in widespead disturbances in
intermediary metabolism and as observed in AIDS and in some cancer patients,
wasting is owing to loss of body cell mass with little loss of fat (Grunfeld and
Feingold 1992). Hence in this thesis, the lean/fat body compartment in patients with
IBD was studied. Another organ which in influenced by undernutrtion as well as by
inflammatory mediators is the bone compartment. I therefore studied the lean/fat
body composition as well as the bone compartment in an effort to detect
disturbances that may result from gut inflammation. I also attempted to develop
methods to study the gut inflammation in a relatively non-invasive manner.
1.7.1. Development of studies to investigate the direct effect of IBD on bone
mineral density
A number of studies have documented osteopenia in IBD (Compston et al
1987, Motley et al 1988, Pigot et al 1992, Clements et al 1992). Bone mineral
density can be measured objectively and accurately and may provide a distinct
compartment to study the direct effect of disease on nutritional status. The
metabolic influences on bones are well established and can be readily measured. I
therefore chose bone as the compartment to study the direct effect of IBD. I aimed
to study newly diagnosed patients prospectively before any therapy or surgery to
control for the many important confounding variables mentioned above. Patients
with long-standing IBD were also studied to determine the effects of medical and
surgical therapy and disease duration.
1.7.2. Development of bedside methods of studying body composition in IBD
patients
An ideal method of studying body composition in a clinical setting should be
safe, inexpensive, quick, free of hazards such as radiation, accurate and
reproducible. None of the currently available methods fulfils all or even most of
these criteria and I aimed to evaluate new technology that had the potential to
meet these clinical requirements.
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1.7.3. Investigation of bone density and growth parameters in adolescents
Since children and adolescents with IBD are specially vulnerable to
nutritional problems, I aimed to study them as a separate group regarding growth
parameters and bone mineral density. I had to establish first whether monitoring of
growth and development parameters in Scottish hospitals had improved sufficiently
to permit longitudinal retrospective population-based analysis.
1.7.4. Development and evaluation of laboratory methods of studying specific
aspects of gut inflammation
Inflammation is characterised by effector cells and their regulatory
mediators. My predecessors in the gastrointestinal laboratories have established
the technique of whole gut lavage using a polyethylene glycol-electrolyte solution
as an extremely useful method of assessing gut-derived protein loss and bleeding
(O'Mahony et al 1990, Brydon et al 1992, Brydon et al 1993). It can be applied to
the investigation of intestinal immunity and inflammation and I evaluated the
clinical usefulness of whole gut lavage in measuring neutrophil migration into the
gut lumen and in studies of the various regulators of inflammation such as
cytokines and growth factor peptides in the gut.
1.8. Approach
1.8.1. Study of bone mineral density in newly diagnosed patients with IBD
Dual Energy X-ray Absorptiometry (DEXA) is widely regarded as the most
accurate and reproducible method of measuring bone mineral density (Sartoris et
al 1989, Clements et al 1994, Compston et al 1995a and 1995b). I utilised the
facilities available at the Medical Physics department of the University of Edinburgh
to prospectively study a cohort of newly diagnosed patients with IBD and compare
CD with UC.
1.8.2. Study of bone mineral density in patients with long-standing IBD
I also recruited specifically a cohort of patients with long-standing inactive
disease to compare the effects of confounding variables such as steroid therapy or
surgery with the effect of disease in the newly diagnosed cohort.
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1.8.3. Pathogenesis of low bone density in newly diagnosed patients
A number of relatively non-invasive methods are now available to assess
bone turnover and the activity of osteoblasts. These include the determination of
plasma osteocalcin as a marker of osteoblastic activity and urinary pyridinium
crosslinks as markers of osteoclast activity. In collaboration with Dr Simon Robins
at the Rowett Research Institute in Aberdeen, I have measured these parameters
in a separate newly diagnosed cohort of IBD patients to assess the effect of
disease on bone turnover. This study is ongoing.
1.8.4. Study on a cohort of normal volunteers and diseased patients to
evaluate bedside measurement of body composition.
I evaluated bedside measurement of body composition using a user-friendly
machine to measure bioelectrical impedance and compared the results with those
obtained by DEXA absorptiometry and with a standard but less user-friendly
bioelectrical impedance machine.
1.8.5. Body composition and bone mineral density
DEXA was used to measure bone mineral density and lean and fat mass
simultaneously in a well-defined cohort of inflammatory bowel disease patients so
that bone density could be assessed in the context of total body composition.
1.8.6. Studies in adolescents with IBD
Children and adolescents with IBD are a specially vulnerable group from
the standpoint of nutritional problems. I have reported on bone mineral density in a
selected group of complicated IBD and on the growth and development parameters
in a community-based study on Scottish patients with juvenile-onset IBD, utilising
the Scottish Hospital Inpatients Statistics database (SHIPS) as a powerful
epidemiological tool to identify cases.
1.8.7. Study of neutrophil migration into the gut lumen
IBD is characterised by accumulation of neutrophils in the mucosa of the
gut followed by migration across the epithelium into the lumen of the gut. I used
cytology and granulocyte elastase assay of whole gut lavage fluid specimens to
perform a clinical analysis of the usefulness of investigating neutrophil migration
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into the gut lumen. The subjects studied included a large, heterogeneous cohort of
well characterised IBD patients, other diseased controls and normal controls.
1.8.8. Investigation of gut cytokines and growth factor peptides
An advantage of using whole gut lavage fluid to study cellular migration into
the lumen is that chemical mediators involved in chemotaxis can be studied
simultaneously. I have analysed the usefulness of investigating chemoattractants
such as IL-8 and its stimulators such as IL-ip. The role of growth factor peptides
such as IGF-1 and TGF-p in gut fibrogenesis was also studied using whole gut
lavage fluid.
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1.9. Structure of the thesis
1.9.1. Section I.
This section includes the introduction and a literature review. The review
focuses in a large measure on the interface between nutrition and immunity/
inflammation but also gives a selected review of body composition and bone
mineral density in IBD. Aspects of inflammation and its mediators in IBD are also
reviewed.
1.9.2.Section II.
This section describes the methods I used to study bone mineral density
and body composition and biochemical methods of studying calcium homeostasis.
It presents the results of my studies on bone mineral density at diagnosis and in
patients with long-standing IBD, mechanism of bone loss, evaluation of bedside
methods to measure body composition in health and disease and body
composition in IBD. The final chapter deals with studies on adolescents with IBD;
the results of my studies on bone mineral density and growth are presented. A
discussion at the end of this section sums up the implications of my findings.
1.9.3. Section III.
This section describes laboratory work. It describes the development of
methods to study neutrophil migration into the gut lumen by cytology and by
granulocyte elastase assay of whole gut lavage fluid. Clinically applicable methods
of studying cytokine production in the gut mucosa are described, and the
development of novel methods of studying gut fibrosis is explained. Results of my
studies on stratification of disease by neutrophil migration into the gut lumen and
studies on cytokine profile in whole gut lavage fluid are presented. The results of a
study on the potential usefulness of assaying growth factor peptides in whole gut
lavage fluid to investigate fibrogenesis in the bowel wall are recorded and
evaluated. In the final chapter, I have discussed the implications of the laboratory
results. An epilogue summarises the new hypotheses I have developed as a result





BACKGROUND AND LITERATURE REVIEW
2.1. Analysis of morbidity in patients with inflammatory bowel disease
(IBD)
The components of overall disability of patients with IBD may be analysed in a
systematic way, and this type of analysis can profoundly influence treatment plans.
Several components may be identified, such as extent and distribution of destructive
chronic inflammation, disease inflammatory activity, mechanical obstruction,
complications such as abscess or fistula, nutritional status, iatrogenic factors (medical
or surgical), social and psychological factors and intercurrent illnesses (such as
ankylosing spondylitis, gallstones etc.). Methods to measure these various
components objectively using clinically applicable tests can greatly assist analysis of
IBD and my predecessors have been involved in developing such methods to measure
various aspects of gut inflammation and immunity (Ferguson et al 1994a). In this
thesis, I have measured specific aspects of nutritional status such as bone mineral
density and body composition. Furthermore, I have investigated the direct effect of
disease on nutrition by studying newly diagnosed patients. In order to study the effect
of inflammation on nutrition, I developed and analysed new methods to study various
aspects of intestinal inflammation. These provided further information about the effects
of anatomy of disease, medical therapy and diagnosis on intestinal immunity and
inflammation in IBD. This chapter reviews these various concepts.
2.2. Nutrition in adults and children with IBD
In adult patients with Crohn's disease (CD) weight and body mass index (BMI)
are significantly lower than in the general population. This is irrespective of disease
localisation or inflammatory activity. Possible incriminating factors include low intake of
calories and specific nutrient malabsorption, gut losses of protein and blood, increased
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basal- and disease- associated metabolic rates, growth hormone deficiency and
impaired metabolic responses to growth hormone (Kirschner 1990). However resting
metabolic rate and total daily energy expenditure were normal in a series of stable IBD
out-patients (Kushneref a/1991). In growth retarded IBD children, growth hormone
responses are generally normal (Farthing et al 1981) but these patients have low
levels of plasma insulinlike growth factor-1 (IGF-1) (Kirschner et al 1986) and a similar
abnormality of IGF-1 has been reported in extremely malnourished adult IBD patients
(Clemmons et al 1985). Most reports of growth and development in young patients
with IBD have emphasised retardation of sexual maturation and of linear growth
(height). Growth delay has been recognised even before the onset of symptoms
(Kanof et al 1988) and growth spurts after surgery may be transient and unpredictable
(Homer et al 1977, Castile et al 1980, McLain et al 1990, Lipson 1990). Since intensive
nutritional repletion can reverse linear growth failure in growth retarded children with
CD, malnutrition is generally accepted as an important factor. (Seidman et al 1987).
Growth delay is less of a problem in ulcerative colitis (UC) than in CD. Adults who had
developed UC in childhood were found to be of normal weight and BMI (Ferguson et al
1994b).
Hence it is well established that malnutrition is a major problem that frequently
complicates the course of IBD patients, especially those with CD. The impact of this is
very considerable in prepubertal patients (Seidman et al 1989). The causes are likely
to be many, but several studies have emphasized the fact that inadequate calorie
intake is important. Though oral nutritional supplementation with polymeric liquid
formulae has yielded disappointing growth results over the long term, intermittent
courses of elemental diet therapy may reverse growth failure (Belli et al 1988).
Elemental diet treatment has several potential effects on the patients with CD,
immunological as well as nutritional.
Considerable progress has been made in understanding the wasting
syndromes; much information has come from studying patients with malignancies,
acquired immune deficiency syndrome (AIDS) or other chronic infections, such as
Leishmania or tuberculosis. The roles of cytokines as mediators of the metabolic
disorders which lead to wasting are being increasingly recognised. Considerable data
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exists on cytokines in IBD (Sartor 1994), but the link between these protein mediators
of inflammation produced by lymphocytes, macrophages and many other cells, and
the cachexia seen in some patients with CD, is unclear.
One of the central themes to emerge in the last few years has been that there
are striking differences from a metabolic standpoint between the wasting in malignant
and infectious diseases (exemplified by AIDS) and the wasting seen in uncomplicated
starvation. In starvation, fat tissue is selectively depleted in order to spare muscle
protein; the muscles waste only after fat stores are exhausted (Kotler et al 1985, Cahill
1970, Brennan 1977). In AIDS and in some cancer patients, metabolic disturbances
prevent nitrogen sparing but conserve adipose tissue (Kotler et al 1989, Brennan
1977). Many of the infections characterised by weight loss are associated with
hypertriglyceridemia whereas, in starvation, plasma lipid levels are low. It has long
been recognized that the degree of wasting correlates poorly with the infective burden
(Beisel 1975) and metabolic changes associated with infection can be reproduced by
administering non-viable extracts of bacteria (Kaufman et al 1976, Lang et al 1985). It
thus appears that a component of the host response causes the changes in
metabolism, now generally accepted to be proinflammatory cytokines (Grunfeld et al
1991).
It must also be noted that there are many ways in which nutrition can affect gut
immune state, either as part of a general effect of nutritional state on the host, or in
relation to the provision of certain nutrients in the microenvironment of the epithelial
and subepithelial tissues (Ferguson 1994c).
2.3. The 'Cachectin' hypothesis
Cerami's group recognized that many of the infections characterised by weight
loss are associated with hypertriglyceridemia. The latter may result from decreases in
lipoprotein lipase, the enzyme responsible for triglyceride clearance (Beutler 1987).
They sought a factor in plasma that might induce both hypertriglyceridemia and
wasting by the promotion of adipose tissue catabolism. Supernatants from cultures of
activated macrophages were tested and found both to induce weight loss when given
daily to rodents in vivo and to decrease lipoprotein lipase activity in cultured fat cells in
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vitro. The 'cachectin' factor responsible for these catabolic effects was purified by a
method that used its ability to inhibit lipoprotein lipase and was found to be the
cytokine 'tumour necrosis factor' (TNF). Other experiments confirmed that purified
recombinant TNF lowers lipoprotein lipase activity, decreases the synthesis of fatty
acids and promotes lipolysis in cultured fat cells (Patton et al 1986, Grunfeld et at
1991,). However interleukin-1 and interferons a, p and y have these same catabolic
effects on cultured fat cells (Keay et al 1980, Beutler et al 1985). Thus if the ability to
promote catabolism in cultured fat cells defines the cachectin factor, then a number of
cytokines shares this property. Beutler et al in 1985 purified cachectin to homogeneity
in cell culture and found it to be a polypeptide hormone with a subunit size of 17KD.
Cachectin accounted for 1-2% of the total secretory product of endotoxin activated
RAW 264.7 cells (Beutler et al 1985), a murine macrophage line, i.e., it occurs in
considerable abundance.
The catabolic effects of these cytokines on fat-cell metabolism are not reversed
by insulin, a hormone that enhances fat storage, (Grunfeld et al 1991, Patton et al
1986) suggesting that effects on fat cells in vitro may not reflect the disturbances in
vivo, since cachexia is characterized by decreases in muscle mass whereas the
changes in fatty tissue vary (Kotler et al 1985,1989). In the cachexia of lymphoma for
example, hyperalimentation (which results in hyperinsulinaemia) promotes the storage
of fat but does not increase muscle mass (Popp et al 1981). Likewise, in patients with
AIDS who have severe untreated secondary systemic infections, hyperalimentation
produces more effective fat storage than preservation of body cell mass (Kotler et al
1990).
2.4. The role of cytokines in wasting in IBD
2.4.1. Cytokines with important metabolic roles
2.4.1.1. Interleukin-1 (IL-1)
IL-1 is produced primarily but not exclusively by macrophages/monocytes and
consists of at least two 17KD polypeptides (IL-1 a and p) which are involved in a wide
spectrum of immunoinflammatory activities. These include fever, wasting, increased
vascular permeability, leukocytosis, lowering of plasma levels of iron and zinc,
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induction of acute phase protein synthesis in the liver, release of proinflammatory
mediators such as histamine, plasminogen, platelet-activating factor (PAF),
eicosanoids, collagen and collagenase, and induction of free oxygen radical
production. IL-1 also plays a crucial role in antigen-dependent T-cell activation by
providing an essential co-stimulatory signal for these cells to produce lymphokines,
particularly B-cell growth factors such as IL-2, IL-4, IL-5, IL-6 and IFN-y (Bendtzen
1989).
IL-1 has catabolic effects similar to TNF on cultured fat cells (Patton et al 1986
Grunfeld 1991 et al) and recombinant IL-1 suppresses lipoprotein lipase activity in
3T3-L1 cells (Beutler et al 1985). It has been shown to produce anorexia in rats
(Hellerstein 1989).
2.4.1.2. lnterleukin-6 (IL-6)
IL-1a, IL-1 p and TNF are all potent inducers of IL-6 in both macrophage/
monocyte and T cells (Bendtzen 1991a, 1991c). IL-6 may act as an important second
messenger of IL-1 and TNF. IL-6 plays a key role in the acute-phase response by
inducing increased acute-phase protein synthesis in hepatocytes (Bendtzen 1989).
Furthermore, IL-6 stimulates T and B cells, most likely because it increases the
responsiveness of these cells to IL-2 (Snick 1990).
2.4.1.3. Tumour Necrosis Factor (TNF)
TNF-a and p are 17KD polypeptides whose genes are located in the major
histocompatibility complex (MHC) region (Dunham et al 1987, Ragoussis et al 1988).
TNF-a and p are potent coactivators of T and B cells (Bendtzen 1991c). Elevated
circulating and local TNF-a concentrations have been found in many infectious and
non-infectious conditions, characterized by macrophage/monocyte and/or T-cell-
mediated injury, such as renal allograft rejection.
lit' . c-oiL <i i
2.4.1.4. Interferon-y (IFN-y)
IFN-y is a lymphokine that acts as a potent activator macrophage /monocytes.
IFN-y has a molecular mass of 20-25KD. It is produced by T-cells and activates several
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important inflammatory cells (Bendtzen 1991a). As mentioned before, it is likely that
when circulating monocytes are primed by IFN-y, synthesis of cachectin (TNF) is
greatly augmented.
2.4.2. Cytokines in IBD
Recent reviews (Brynskov et al 1992b, Sartor 1994) have summarised the data
available on the role of the various cytokines in IBD. These papers have concentrated
on the role of the cytokines as inflammatory mediators but far less data exists on the
metabolic abnormalities produced by them. Discussed below is the information on the
four putative 'suspects' of the wasting syndrome regarding their production in IBD.
(1)TNF: Several studies have failed to show significant differences in serum or
mucosal TNF-a levels between IBD patients and controls (Hodgson et al 1991, Hyams
et al 1991). However Murch et al (1991) suggested that production of
TNF-a may be associated with growth failure in children in relapse of colonic IBD.
They measured TNF-a concentrations by ELISA in the serum of 31 normal children
and during 65 episodes of clinical remission and 54 episodes of relapse in 92 children
with chronic IBD. An appreciable rise in TNF-a was found only in children with relapse
of UC and of colonic CD. The group of children with small bowel CD in relapse did not
show increases of TNF-a. Height velocity was depressed in children with relapse of
large bowel CD and UC compared with the equivalent condition in remission and
compared with small bowel CD alone.
(2) IL-1: IBD sera lack significant IL-1 activity as measured by either bioassay
(Satsangi et al 1987), or ELISA (Brynskov et al 1991). In patients with active IBD, the
production of IL-1 by isolated blood mononuclear cells in vitro has been found to be
either normal (Miura et al 1985) or increased using (Satsangi et al 1987, Suzuki et al
1991, Hodgson et al 1991). At the mucosal level both an increased spontaneous and a
lipopolysaccharide-induced production of IL-1 p have been consistently demonstrated
in vitro with mucosal mononuclear cells isolated from surgically removed bowel from
patients with active IBD (Mahida et al 1989). It has been shown that macrophages are
the major source of IL-1 in IBD mucosa (Mahida et al 1989). Further studies using
endoscopic mucosal biopsy specimens confirmed these findings (Ligumski et al 1990,
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Brynskov et al 1992a) and showed that elevated mucosal levels of IL-ip correlate with
the degree of histologic activity (Brynskov et al 1992a). These data indicate that
increased IL-1 production and release occurs both in vitro and in vivo at the mucosal
level in patients with active IBD. In spite of some similarities in the metabolic effects of
IL-1 and TNF, no studies have looked into the role of IL-1 in growth failure or wasting
in IBD. Hellerstein et al (1989) showed that IL-1 induces anorexia in rats. The anorexic
effect appears to be mediated by prostaglandins since pre-treatment with ibuprofen
completely blocked it. More interestingly, a fish oil based diet abolished the anorexic
effect of IL-1, while corn oil or chow diets had no effects. Placed in a wider context,
these findings add support to the concept that nutrients and inflammation are
intimately intertwined in a complex bi-directional fashion mediated by cytokines. Thus
dietary protein and source of fatty acids may alter IL-1 release (Hoffman-Goetz et al
1979), dietary fats may alter cytokine actions, carbohydrates, in theory, may be
involved as signals in their anorexic effects (Baile et al 1970, Van Itallie et al 1977,
Russek 1981, Sullivan et al 1985, Langhans et al 1985), and inflammatory mediators
not only alter metabolism of all classes of substrates (Feingold et al 1987, Tredget et
al 1988) but reduce their overall intake by causing anorexia. From a clinical
perspective, perhaps most interesting is the ability of a dietary supplement (fish oil) to
diminish anorexia caused by IL-1. This could be a potentially simple and safe
intervention in patients experiencing anorexia and weight loss in association with an
inflammatory illness. When 3g/d of EPA in fish oil capsules was added to normal
Western diets of human volunteers, a 50% reduction in IL-1 production occurred when
their blood leukocytes were stimulated ex vivo (Endres et al 1989).
(3) IL-6: Mahida et al (1991) detected high circulating concentrations of IL-6 in
active CD but not UC. Gross et al (1992) confirmed increased serum IL-6
concentrations in patients with CD compared with patients with UC and controls. There
was no correlation between serum IL-6 concentrations and clinical activity indices, but
this could be explained by the short circulatory lifetime and rapid hepatic clearance of
IL-6 from portal venous blood. Acute phase proteins induced by IL-6 have a longer
circulatory lifetime and several studies have shown that they are significantly
correlated with clinical activity indices (Mahida et al 1991, Gross et al 1992). Both
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mononuclear cells from peripheral blood and intestinal inflammatory cells might
contribute to increased serum IL-6 levels. Recent evidence suggests that
macrophages and colonic epithelial cells are the major cell types responsible for
elevation of IL-6 in IBD (Kazuo et al 1995).
(4) IFN-y: Cultured CD mucosal mononuclear cells spontaneously release IFN-
y, whereas blood mononuclear cells only release IFN-y after stimulation (Fais et al
1991). Their findings indicate that in CD the intestinal lymphocytes are stimulated in
vivo to produce IFN-y and that the spontaneous IFN-y production is compartmentalised
to the gut lymphocytes.
2.4.3. Effects of cytokines on lipid metabolism
In vivo administration of TNF in rats rapidly increases plasma triglyceride
concentrations by increasing the level of very low density lipoprotein of normal
composition (Feingold et al 1987, Krauss et al 1990). In contrast to the findings in
cultured fat cells, the effects of TNF on adipose tissue lipoprotein lipase were small
when the triglyceride concentration was increased (Semb et al 1987, Grunfeld et al
1989b, Chajek-Shaul et al 1989). In addition, TNF had no effect on muscle lipoprotein
lipase, whereas hepatic lipase and total post-heparin lipase levels were increased.
Consequently, TNF did not slow the clearance of triglyceride-rich lipoproteins
(Grunfeld ef a/1991, Feingold efa/1990). The administration of IL-1 also rapidly
increases plasma triglyceride concentrations without decreasing triglyceride clearance
(Feingold et al 1991). Both TNF and IL-1 increase plasma triglycerides by stimulating
hepatic lipogenesis and the production of very low density lipoprotein (Feingold et al
1991, Chajek-Shaul e/a/1989). In vivo experiments in rats (Feingold et al 1987) have
shown that TNF-a stimulates lipid synthesis by increasing hepatic lipogenesis. It does
not stimulate lipid synthesis in other tissues including adipose tissue. The doses of
TNF and IL-1 that stimulate the synthesis of hepatic fatty acids are similar to those that
induce fever (endogenous pyrogen activity), suggesting that hepatic fatty acid
synthesis will be increased during the normal response to infection (Adi et al 1992,
Feingold et al 1989). IL-6 and IFN-a also increase hepatic lipogenesis (Feingold et al
1989, Grunfeld et al 1990a). Hepatic lipogenesis normally increases when excess
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carbohydrate calories are consumed, so that energy can be stored more efficiently
(calories of fat weigh less than calories of glycogen). However, such storage may be
inappropriate during malnutrition, when the energy would be best used to maintain or
restore muscle protein.
In addition to increasing hepatic synthesis of fatty acids, TNF rapidly mobilizes
free fatty acids by stimulating peripheral lipolysis (Feingold et al 1990). The mobilized
fatty acids are re-esterified into triglyceride in the liver and are re-secreted, contributing
to the increase in very-low-density lipoproteins. Because very-low-density lipoproteins
are cleared normally in animals given TNF, 'futile cycling' results; fatty acids are
shuttled from adipose tissue to liver and back to adipose tissue without being used for
energy. Similar futile cycling has been described during infection (Wolfe et al 1985).
Daily injections of a constant dose of crude cachectin causes progressive
weight loss in rodents (Cerami et al 1985). In contrast, rodents given purified
recombinant TNF daily rapidly lose weight and then rapidly regain it (Patton et al 1987,
Sochar et al 1988, Stovroff et al 1988). The acute weight loss is due to decreased
intake of food and water accompanied by diuresis (Grunfeld et al 1989a, 1989b).
However, rats given repeated treatment with TNF have persistent hypertriglyceridemia
despite loss of anorectic or cachectic effects. The metabolic disturbances leading to
hypertriglyceridemia thus do not inevitably cause wasting. Each metabolic disturbance
must be placed in the context of total energy balance.
Mahony et al (1988) in an elegant study on pure strain NMRI mice model
compared the weight loss produced by TNF with that produced by a restricted food
and water intake (pair-fed controls), and by mitozolomide, a drug which in toxic doses
induces weight loss with a similar decrease in nutrient and water intake. TNF produced
a dose related weight reduction that was directly proportional to a decrease in both
food and water intake. With chronic administration over a 5-day period the major
weight loss was found to occur during the first 24-h after injection and thereafter the
weight of treated mice increased toward that of controls. Acute administration of TNF
produced hypoglycemia that was more severe than that observed with either
mitozolomide or in pair-fed controls; there was also a reduction in the circulatory level
of free fatty acids (FFA) and an increase in plasma triglycerides with TNF, while
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mitozolomide and pair-feeding had no effect on the level of blood glucose or plasma
triglycerides. Body composition analysis showed a loss of adipose tissue in TNF-
injected and pair-fed animals after both acute and chronic treatment. Acute
administration of TNF also induced a decrease in the total body water of treated
animals which was similar to pair fed controls. The study showed that the weight loss
produced by TNF arises from a combination of semi-starvation and a reduced water
intake, and the effect only occurred with the first administration of TNF.
2.4.4. Cytokines in the induction of anorexia and cachexia
Since daily injections of TNF were unable to produce cachexia similar to that
produced by crude cachectin, other experimental manipulations were tried. TNF can
induce weight loss when given in progressively increasing doses, when infused
continuously, or when secreted by tumours that are genetically engineered to produce
TNF (Tracey et al 1988, Michie et al 1989, Oliff et al 1987, Teng et al 1991). In each of
these models, however, TNF induces anorexia, and the weight loss or the negative
nitrogen balance does not exceed that in controls given identical food.
Anorexia may contribute to wasting even in disorders in which metabolism is
markedly disturbed. Colon cancers in rodents induce metabolic changes similar to
those produced by TNF, such as increased hepatic synthesis of fatty acids, but not all
colon tumours produce cachexia (Mulligan et al 1991). Animals that eat more to
compensate for these metabolic disturbances maintain weight, whereas animals that
do not eat more lose weight.
Although questions have been raised about the ability of TNF or IL-1 alone to
promote negative nitrogen balance, the simultaneous infusion of the two cytokines
leads to synergistic effects inducing hypermetabolism, glucose recycling, muscle
catabolism and negative nitrogen balance (Tredget et al 1988, Flores et al 1989).
Likewise the combination of IFN-alpha and TNF or IL-1 is synergistic in its effects on
lipid metabolism (Grunfeld et al 1990b). In tumours that are engineered to produce
TNF, there may be synergy between TNF and other tumour or host products, since
tumours themselves render the host more susceptible to the toxic effects of
exogenous TNF (Bartholeyns et al 1987). These studies suggest that synergistic
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interactions between cytokines may be necessary for the wasting syndrome to
develop.
A wide spectrum of metabolic disturbances can lead to wasting. Patients with
overwhelming infection or burns have striking hypermetabolism and profound negative
nitrogen balance (Brennan 1977, Wilmore et al 1974, Long et at 1979). In such
patients, negative nitrogen balance and even weight loss may persist despite
aggressive hyperalimentation (Brennan 1977). This situation can be contrasted with
that associated with some forms of cancer in which there is no hypermetabolism
(Dempsey et al 1984, Hansell et al 1986, Nixon et al 1988, Fredrix et al 1991). In yet
other cancers and infections, metabolic disturbances range between these extremes.
TNF-a has recently been implicated in the wasting in emphysema (Sridhar 1995) and
in severe chronic heart failure (Levine et al 1990).
The processes that lead to hypermetabolism are not fully understood. Among
them are futile or substrate cycling, the inappropriate use of substrates (such as the
synthesizing a compound intended for long term storage when immediate energy use
is needed), and the uncoupling of enzymatic events from energy formation. These
processes all waste energy. They are usually found in the wasting syndromes but few
data quantitatively link such disturbances to wasting.
In a study of serum levels of endogenous TNF in healthy people and patients
with neoplastic or infectious diseases, only patients with visceral leishmaniasis and
malaria were found to have a strikingly increased frequency of raised TNF levels. TNF
may play a part in host defences against parasitic infections but it may also contribute
to the striking wasting seen in these conditions (Scuderi et al 1986). Alveolar
macrophages in tuberculosis produce TNF. The work of Lahdevirta et al (1988) in
AIDS is of particular interest as it has suggested a correlation between TNF
concentration and the severity of the disease. The question may be raised whether the
wasting diathesis so commonly seen in AIDS is, at its root, attributable to unremitting
production of TNF. There is little doubt that chronic TNF administration to rodents can
by itself produce cachexia (Oliff et al 1987). Balkwill et al (1987) have reviewed the
evidence for TNF production in cancer. Putative manifestations of TNF such as fever
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may occur without producing a catabolic state thus once again reinforcing the
dissociation between metabolic manifestations and the clinical features.
2.4.5. Effect of cytokines on bone metabolism
When leukocytes are exposed to mitogens or antigens in vitro, they release
bone-resorbing activity into the culture supernatants which can be detected by
bioassay (Horton et al 1972, Mundy et al 1984). Like many lymphocyte-monocyte
product, this activity has been difficult to purify because of its low abundance in
activated leukocyte cultures and the unwieldy bioassay required to detect biological
activity. Partially purified preparations of this activity inhibit bone collagen synthesis in
organ cultures of fetal rat calvariae (Raisz 1988). As both TNF-a and TNF-p are likely
to be present in activated leukocyte supernatants, purified recombinant preparations
were tested for their effects on bone resorption and bone collagen synthesis in vitro
(Bertolini et al 1986). Both cytokines at 10"^M to 10"^M caused osteoclastic bone
resorption and inhibited bone collagen synthesis. These data suggest that at least part
of the bone-resorbing activity present in activated leukocyte culture supernatants may
be due to these cytokines. IL-6 has similar bone-resorbing activity. Experimental colitis
induced by instillation of trinitrobenzene-sulphonic acid with ethanol in a rat model
results in bone loss (Fries et al 1994), providing further evidence of the role of
intestinal inflammation in causing osteopenia.
A number of cytokines have been implicated in osteoclast formation. IL-1, TNF
and IL-6 have all been shown to affect osteoclast development (Suda et al 1992). It
has been recently shown that IL-11 derived from mesenchymal cells provides a more
central signal for osteoclast formation (Girasole et al 1994). IL-6 increases the
recruitment of osteoclast precursors to the osteoclast pool, but IL-6 may not play a role
in osteoclast development in physiological conditions, and may only become important
in oestrogen deficient states (Jilka et al 1992).
2.4.5.1. Bone resorption mediated by cytokines
Bone resorbing cytokines are generally active at low concentrations and IL-1 is
the most potent (Gowen et al 1986a). These act primarily as stimulators of osteoclast
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formation though they can affect mature osteoclast function as well (Thomson et al
1986). Both IL-1 and TNF-a stimulate multinucleated cell formation in long-term bone
marrow culture (Pfeilschifter et al 1989), and these agents act as growth factors for
osteoclast precursors, which are of the monocyte-macrophage lineage. Both GM-CSF
and M-CSF stimulate multinucleated cell formation in long-term bone marrow cultures
(MacDonald et al 1986). IL-6 has stimulatory effects on haemopoietic stem cell
proliferation in vitro (Brandt et al 1990), and as such may increase the availability of
osteoclast precursors. Some cytokines may have permissive effects on bone
resorption by maintaining adequate numbers of early osteoclast precursors (GM-CSF,
M-CSF and IL-6), whereas others act more locally and quickly to produce large
numbers of the relatively more differentiated osteoclast precursors required for
osteoclast formation (IL-1 and TNF-a). IFN-y may be a candidate factor responsible for
termination of osteoclast activity and inhibit basal and cytokine stimulated bone
resorption (Gowen et al 1986b). IFN-y decreases the number of osteoclasts and the
recruitment of osteoclast precursors rather than having direct calcitonin-like inhibitory
effects on mature osteoclasts (Klaushofer et al 1989). IL-4 has also been found to
inhibit bone resorption both in vitro and in vivo (Watanabe et al 1990, Watanabe et al
1991).
2.4.5.2. Bone formation mediated by cytokines
Cytokines have effects on both the initial phase of recruitment and
differentiation of osteoblast precursors and the later phase of bone matrix production
and mineralisation by the mature osteoblasts. Two groups of cytokines with effects on
bone formation can be identified. The first group contains those cytokines which
stimulate bone cell proliferation but have inhibitory effects on mature osteoblast
function. These agents are generally potent stimulators of bone resorption such as
IL-1 and TNF-a. The second group can be categorized as members of the TGF-p
family and includes TGF-p, IGFs and BMPs (Bone morphogenetic proteins). These
agents stimulate both precursor proliferation and mature osteoblast function (Oreffo et
al 1989).
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2.4.5.3. Local production of cytokines in bone
Local production of cytokines within the bone microenvironment may be by
non-skeletal haematopoietic or immunological cells, or by osteoblasts and osteoclasts.
Osteoblasts are capable of secreting most of the osteotropic cytokines in vitro.
Synthesis of local cytokines interacts with local cellular events (osteoclast activation or
initiation of bone formation) and the effect depends on the stage of development of
the skeleton (foetal versus adult) (MacDonald et al 1992).
2.4.5.4. Regulation of cytokine actions in bone
IL-1 has synergistic effects on bone resorption in vitro with TNF-a (Gowen
1988) and IL-6 (Black et al 1990). IL-1 also induces the synthesis and secretion of
TNF-a (Gowen et al 1990). TGF-p transcription however is regulated by osteotropic
hormones rather than cytokines and levels are reduced in vitamin D deficient animals
(Finkelman et al 1991). Control mechanisms include inhibitory effects of soluble
receptors or receptor antagonist proteins such as IL-1 receptor antagonist. Bone
metabolism is influenced by the combined effects of a number of cytokines and a high
degree of redundancy may exist with no cytokine having a unique role. Interaction with
the extracellular matrix or modulation of integrin expression may provide further
complicated regulation.
2.4.5.5. The role of cytokines in the pathogenesis of bone disease
Bone destruction in multiple myeloma, rheumatoid arthritis and post¬
menopausal osteoporosis may result from excess local or generalised production of
cytokines. The malignant plasma cells of myeloma release cytokines such as IL-6
(Kawano et al 1988), TNF-a (Garrett et al 1987) and IL-1 (Kawano et al 1989)
mediating osteoclast activity and bone destruction. Cytokine levels in the rheumatoid
joint favour osteoclast action and juxta-articular osteoporosis and bony erosions.
These include high levels of IL-1 (Nouri et al 1984), TNF-a (Saxne et al 1988), IL-6
(Houssiau et al 1988) and M-CSF (Firestein et al 1988), but low levels of IFN-y
(Firestein et al 1987). In post-menopausal osteoporosis, evidence supports the indirect
effect of oestrogen via modulation of cytokine production. Both IL-1 and TNF secretion
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by peripheral blood monocytes are raised in postmenopausal women (Pacifici et al
1987, Ralston et al 1990), and the administration of oestrogen to oophorectomized
women is associated with a normalisation of cytokine production (Pacifici et al 1991).
Osteoblast IL-6 production may also be modulated by oestrogen (Girasole et al 1990).
2.5. Body compartments: Lean Vs fat compartments
Most body composition methods are based upon the model in which the body
consists of two chemically distinct compartments, fat and lean or fat-free (Keys et al
1953, Lukaski 1987). The chemical composition of lean is assumed to be relatively
constant with a density of 1.1g/mL at 37°C (Keys et al 1953, Brozek et al 1963,
Behnke et al 1942), a water content of 72-74% (Pace et al 1945), and a potassium
content of 60-70 mmol/kg in men and 50-60 mmol/kg in women (Boddy et al 1973).
Fat, or stored triglyceride, which is anhydrous and potassium free, has a density of
0.900g/mL at 37°C (Mendez et al 1960a, Mendez et al 1960b). Any mixture of fat and
lean will result in an average density somewhere between 1.10 and 0.90. A variety of
methods to measure human body composition indirectly are available, but few can be
adapted for routine use at the bedside.
2.5.1. Methods of assessment of body composition
For the sake of convenience, I have divided these methods into simple
methods, which do not need complicated expensive equipment and sophisticated
methods which need equipment generally available only in Medical Physics
departments of tertiary care institutions.
2.5.1.1. Simple methods
(1) Anthropometry: This is currently the most widely used method clinically for
measurement of body composition. It depends on the fact that most of the fat stored in
the body lies immediately under the skin (Edwards 1950) and the thickness of a fold of
skin picked up indicates the amount of subcutaneous fat. The measurement of
skinfold requires skill and training (Ruiz et al 1971) and it is important to measure
triceps skinfold at exactly the correct site, otherwise false results are obtained. A
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theoretical limitation to the skinfold measurement is that it assumes a constant
relationship between subcutaneous and deep fat stores, which was not confirmed by
measurement at postmortem examinations (Alexander 1964). A single skilled, trained
observer may obtain reproducible results with an error of about 3% of body weight (i.e.
2 kg of fat in an average subject), but results will be very variable if unskilled, untrained
observers make the measurements. The limitations of anthropometric methods have
been highlighted in a review (Lukaski 1987). Hence, the method is not suitable for use
by nursing staff in a busy outpatients' clinic.
(2) Densitometry: The method assumes that the body is composed of two
distinct compartments, fat and lean, and that it is possible to determine each of these
compartments from the measured whole-body density. Underwater weighing (Akers et
al 1969) is widely used to determine body volume - though theoretically simple, it
requires cumbersome, expensive equipment and is only suitable for fit, healthy
subjects. Other instruments to measure body volume, such as body volumeter (Garn
et al 1963) and plethysmograph (Garrow et al 1979) suffer from the same limitations
and are not suitable for routine clinical application.
(3) Quetelets's index: The use of Quetelet's index (Weight in kg/Height in
metre2) as a measure of fatness has been analysed by Garrow et al (1985). Though a
useful measure in obesity, its value in under-nourished states has not been rigorously
evaluated. In this thesis, I have used Quetelet's index to compare other methods of
measurement of body composition.
(4) Urinary creatinine excretion: Although many tissues take up creatine, the
preponderance (98%) of it is located in the skeletal muscle, mostly in the form of
creatine phosphate (Borsook et al 1947). Creatinine is formed by non-enzymatic
hydrolysis of free creatine liberated during the dephosphorylation of creatine
phosphate. It has generally been accepted that urinary creatinine excretion is related
to lean mass and muscle mass (Boileau et al 1972, Forbes et al 1976). Large
individual variability in daily urinary creatinine excretion (Greenblatt et al 1976, Ransil
et al 1977), influence of dietary creatine intake (Crim et al 1975) and the need for
accurately timed urine collections make urinary creatinine excretion a generally
unreliable method of measurement of body composition.
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2.5.1.2. Sophisticated methods
(1) Measurement of total body water: Water occupies a relatively fixed fraction
(73.2%) of the lean mass and is not present in fat compartment (Pace et at 1945).
Hence, lean mass is equal to total body water divided by 0.73. Investigators have used
the isotopes of hydrogen, deuterium and tritium, to quantitate body water volumes by
isotope dilution in healthy and diseased individuals (Lukaski 1987). Implementation of
this technique is difficulty outside of a specialized research laboratory.
(2) Measurement of total body potassium: Potassium is essentially an
intracellular cation that is not present in stored fat. Potassium is labelled with the
natural radioactive isotope,40 K, so that each gram of potassium emits about three
gamma rays of high energy (1.46 MeV) each second, which can be detected by
suitable apparatus and the total body potassium can be estimated (Boddy et al 1976,
Smith et al 1979). Quantitation of total body potassium requires specially constructed
counters that consist of a large shielded room (to reduce background radiation from
cosmic and terrestrial sources) containing a gamma ray detection system connected to
a suitable recording device. The cost of such determinations, including instrumentation
and technical support, may be prohibitive for clinical application.
(3) Neutron activation analysis: The development of in-vivo total body neutron
activation analysis has provided a reliable technique for measurement of the absolute
content of sodium, chloride, phosphorus and nitrogen (Vartsky et al 1979, Vartsky et at
1984). Facilities for this investigation are available in only a few specialist centres and
the high cost, need for skilled operators, lack of portability and the use of ionizing
radiation preclude wide application of this technique.
(4) Absorptiometry: The ability of bone mineral to absorb energy from a photon
beam of given energy is known. The mass of bone mineral in a limb can be estimated
by scanning across a limb with a beam of photons of known energy and observing the
energy which emerges at the other side (Mazess 1971, Christiansen et al 1977). With
single-photon absorptiometry, the bone must be enclosed in a constant thickness of
soft tissue and water baths, tissue-equivalent substances and local compression have
been used as control materials for this purpose. It is not feasible to scan the total body
with the single-photon technique. Also, the use of single-photon absorptiometry
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measurements of the appendicular skeleton may not be as sensitive a predictor of
osteoporosis as are determinations, made by dual- photon absorptiometry of the
spine, a prime target of demineralisation. This method is not used for total body
composition analysis.
Total body bone mineral content and lean body mass are measurable using
dual-photon absorptiometry (DPA), which eliminates the need for constant soft-tissue
thickness across the scan path. This method uses a whole-body rectilinear scanner
and a high activity source of gadolinium-153 which emits energy at two discrete peaks
(44 and 100 keV). Body composition measured by dual-photon absorptiometry and
densitometry are well correlated (Mazess et al 1984).
Dual energy X-ray absorptiometry (DEXA) is an accurate and reproducible
method for measuring lean body mass and agrees well with that measured by prompt
neutron activation analysis and by total body water methods (Hannan et al 1993). I
have used this technique to validate bioelectrical impedance analysis results and also
relate bone mineral density to lean body mass in IBD patients. Details are given in
chapters VII and VIII. All absorptiometric techniques need trained personnel and
expensive equipments.
(5) Computerised tomography (CT): This has provided valuable information
about the relative proportions of fat which are subcutaneous or intra-abdominal (Kvist
et al 1988) and highlighted limitations of anthropometry based only on subcutaneous
fat. Practical constraints limit the general use of CT scanners for body composition
analysis. The examination takes quite a long time, significant radiation doses are
involved and the cost and general availability of modern CT scanners prevent the
routine use of this technique for only body composition assessment.
(6) Magnetic resonance imaging (MRI): MRI does not involve ionising radiation
and can generate images in response to intrinsic tissue variables. In addition to
hydrogen, MRI can image phosphorus and future prospects include carbon, nitrogen,
sodium and chlorine. It can quantitate total fat mass and discriminate differences in
regional fat distribution (Mallard 1986). High cost, restricted availability and technical
problems with spatial resolution make this technique investigational at present.
27
(7) Electrical conductivity: Two methods have been developed which depend
on the difference in electrical conductivity of lean tissue (which is virtually an
electrolyte solution, and a good conductor) and fat, which is a non-conductor.
The first method, bioelectrical impedance analysis (Lukaski et al 1986, Lukaski
1987) uses a pair of electrodes attached to the left hand and left foot of the subject. A
current of 800 pA at a frequency of 50 MHz is passed between the outer electrodes,
and the voltage drop is measured at the proximal electrodes, from which the
resistance (strictly impedance, since it is an alternating current) of the tissues is
calculated. The measured impedance is entered into a regression equation, together
with anthropometric data such as weight, height, age and gender. The coefficient of
variation of this method, determined in 14 men in whom impedance was measured on
five consecutive days, was <2% (Lukaski et al 1985). Comparison of densitometrically
determined and impedance predicted lean body mass yielded an error of prediction of
2-2.5 kg and a calculated error of relative body fatness of 2.7% (Lukaski et al 1986).
Relative to densitometry the observed error of calculated body fatness was larger by
anthropometry (3.9%) than by impedance (2.7%). User-friendly bioelectrical analysis
machines (Smye et al 1993, Fuller et al 1994) offered a technique that could readily be
used by untrained staff in busy outpatient clinic settings. I evaluated one of these
machines in IBD patients (chapter VII).
In total body electrical conductivity (TOBEC) system the subject lies within a
solenoid coil through which radiofrequency pulses are fed at a frequency of 5 MHz
(Segal et al 1985). This generates an alternating magnetic field within the coil which
induces a response in the subject depending on the conductivity of the tissues, and
the strength of the evoked field is measured by a secondary coil. The advantage of
this system is that it is very quick; the disadvantage is that the evoked field depends
on the shape of the subject in addition to his fat content. Second generation
equipments are more reliable, but TOBEC is much more expensive than bioelectrical
impedance analysis.
(8) Other methods: Infrared interactance, endogenous urinary 3-methylhistidine
excretion, plasma creatinine and ultrasonography have been used to analyse body
28
compartments; these are not in common use and have been reviewed elsewhere in
details (Lukaski 1987).
2.6. Pathophysiology of bone loss
2.6.1. Types of bone
There are two types of bone tissue in adults, cortical or compact bone and
spongy or cancellous bone. Eighty percent of the skeletal mass is cortical. The
remaining cancellous bone comprises trabecular plates and rods of tissue which
interconnect with each other (Kanis 1994). The disposition of trabecular plates and
rods is oriented predominantly according to lines of stress.
2.6.2. Matrix and mineral
Bone comprises an organic matrix, a mineral phase and bone cells. The
majority of the matrix is composed of collagen. Adult bones contain type 1 collagen
laid down by osteoblasts. Each unit of collagen (tropocollagen) comprises a protein
heterotrimer consisting of two a-1 chains and one a-2 chain. Post-translational
modification of synthesised protein consists of hydroxylation of proline and lysine.
Hydroxyproline and hydroxylysine release during.the metabolism of bone can be
utilized as an index of bone breakdown. Glycosylation and the formation of cross-links
with other tropocollagen macromolecules permit their assembly to form collagen fibrils
and evidence of such activity can be measured in serum and urine. Other proteins
incorporated within the collagen matrix during or after its formation include
proteoglycans, glycoproteins, osteocalcin and osteonectin. Osteocalcin is used to
assess the rate of bone turnover in the evaluation of osteoporosis. Hydroxyapatite
crystals composed of calcium, phosphate and carbonate form the mineral phase of
bone. The crystals also contain other ions such as sodium, magnesium and fluoride.
2.6.3. Bone cells
All bone surfaces are covered by cells with distinct morphological and
functional features (Kanis 1994). These include osteoblasts, osteoclasts and
osteocytes. The osteoblast is the cell responsible for the synthesis of collagen and
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other bone proteins. Osteocytes are osteoblasts which have been trapped within the
bone matrix during the process of bone formation. The osteoclast is a multinucleated
cell which is responsible for bone resorption. It degrades fully mineralized bone by
attaching onto a bone surface and secreting acids and lysosomal enzymes.
2.6.4. Bone loss
Bone remodelling is a constant process in adult bone. Old bone is removed by
osteoclasts and replaced by new bone formed by osteoblasts. The term coupling
refers to the sequence of bone resorption followed by formation, and the term balance
describes the equality of these two processes within individual remodelling units
(Compston 1995b). Mechanical stimuli and endocrine factors such as sex hormones,
glucocorticoids, thyroxine, growth hormone and parathyroid hormone exert important
effects on bone cells. These effects may be mediated through prostaglandins, nitric
oxide, cytokines and growth factors (Russell 1989, Lanyon 1992, MacDonald et al
1992). There are two mechanisms of bone loss in osteoporosis:- (1) Increased bone
turnover where the number of remodelling units is increased. This results in an
increase in the percentage of bone surface occupied by resorption cavities. (2)
Negative remodelling imbalance where the bone loss results from bone formation
being less than resorption within a remodelling unit.
Increased bone turnover are associated with an increased likelihood of
trabecular penetration and erosion, with loss of connectivity of the cancellous bone
structure. Remodelling imbalance is associated with trabecular thinning and relatively
greater preservation of bone architecture.
2.6.5. Corticosteroids and bone loss
Corticosteroids affect both bone resorption and formation. Resorption is
mediated partly by increased parathyroid hormone secretion secondary to calcium
malabsorption and increased renal losses. Corticosteroids directly affect osteoblast
proliferation, differentiation and activity, and also inhibit bone formation by reduced
local production of prostaglandin E2 and insulinlike growth factor 1. Reduced
production of gonadal hormones by the adrenal gland, ovaries and testes may
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contribute to corticosteroid -induced bone loss (Compston 1995b). Cancellous bone is
metabolically more active than cortical bone and is preferentially affected in
corticosteroid induced bone loss. Thus, the spine and ribs are especially vulnerable.
Histomorphometric studies in patients with corticosteroid-induced osteopenia have
shown low or normal bone turnover with negative remodelling imbalance due to
reduced bone formation (Bressot et al 1979). Calcium kinetic studies suggest that
increased bone turnover may occur during the early stages of treatment (Cannigia et
al 1981).
2.6.6. Physical activity and bone mass
Epidemiological data suggest that lack of physical activity is a risk factor for
osteoporotic fracture.
2.7. Measurement of bone mineral density
Osteoporosis is characterised by low bone mass and disruption of bone
architecture, leading to reduced bone strength and increased fracture risk.
Measurement of bone mineral density (BMD) provides the best prediction of future
fracture risk (Wasnich et al 1985, Hui et al 1988, Cummings et al 1993). DEXA is the
most accurate and reproducible method of measuring BMD (Compston et al 1995a). It
involves a low radiation dose and can measure bone mass in both axial and
appendicular skeleton. DPA, single photon absorptiometry, single X-ray
absorptiometry, broadband ultrasonic attenuation and quantitative CT scanning are
also accurate, alternative methods of measuring BMD (Compston 1995b). Single
photon absorptiometry and single X-ray absorptiometry are suited for BMD
measurement at the radius, whereas broadband ultrasonic attenuation is suited for the
os calcis. Axial bone mass may be determined by DEXA, DPA and quantitative CT.
Prospective studies have demonstrated an increasing fracture risk with decreasing
BMD. A reduction of 1 SD in BMD is associated with a two- to threefold increase in
fracture risk (Wasnich et al 1985, Hui et al 1988, Cummings et al 1993).
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Lateral radiograph of the dorsal and lumbar spine provide evidence of subtle
changes in vertebral shape. Bone biopsy should be considered in severe osteopenia
to exclude osteomalacia.
2.7.1. Osteopenia in IBD
Vitamin D deficiency in CD and associated bone disease has been described
(Driscoll et al 1982), though osteopenia with normal vitamin D metabolites (Hessov et
al 1984) is more common. Genant et al (1976) using spinal X-rays and measurements
of metacarpal metacarpal cortical thickness and bone mineral content, found a
significantly reduced bone mass in adolescents and adults with IBD. A number of
studies established the high prevalence of osteoporosis in IBD, both CD and UC
(Compston et al 1987, Motley et al 1988, Pigot et al 1992). Decrease in total body
calcium has been described (Ryde et al 1991) and histomorphometric data are
consistent with reduced bone turnover (Croucher et al 1993). These aspects are
discussed in details in subsequent chapters and will not be repeated here.
2.8. Characterisation and stratification of IBD: review of predecessors'
work on whole gut lavage fluid
In order to study the gut immune system and inflammation in IBD, a range of
components should be assessed. With very few exceptions, tests on components of
the systemic immune system are virtually useless as indices of mucosal immunity at
gut level. Some general information on the function of the mucosa-associated
lymphoid tissues can be obtained from studies of saliva or tears, but these materials
cannot provide organ-specific information relevant to the gut.
The technique of whole gut lavage with non-absorbable polyethylene-glycol-
based solution has been widely applied in clinical practice for cleansing of the bowel
prior to barium enema, colonoscopy or colonic surgery. After gut cleansing is
complete, the clear fluid passed per rectum, whole gut lavage fluid (WGLF) is
essentially a whole gut perfusate. Our studies in adults and children have shown that
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this material can be used for biochemical and immunochemical assays to assess
intestinal immunity, inflammation and gut losses of protein and blood.
2.8.1. Gastrointestinal protein loss - index of activity in IBD
Fluid obtained by whole gut lavage normally contains traces of IgG, albumin
and ai - antitrypsin. Normal values, based on results for 63 immunologically normal
patients or volunteers are: IgG (by ELISA) 1-10 pg/mL; albumin (by
immunoturbidimetry) 1-26 pg/mL; ai - antitrypsin (by immunoturbidimetry)
1-19 pg/mL (Choudari et al 1993). My predecessors' work has shown that higher
concentration of these proteins were found in WGLF from patients with IBD (O'Mahony
et al 1990, Brydon et al 1993). A prospective study of gut lavage in IBD patients
(Choudari et al 1993) in whom disease activity was simultaneously assessed by using
the Crohn's Disease Activity Index (CDAI) (Best et al 1976) or the Powell Tuck Index
(PTI) (Powell-Tuck et al 1978). For IgG, concentrations in lavage fluid correlated
closely with activity indices. In CD, r = 0.723 (p<0.0001), in UC, r = 0.714 (p<0.0001)
for CDAI or PTI plotted against WGLF IgG. Results forWGLF albumin and en -
antitrypsin concentrations were generally similar to those for IgG, but less sensitive in
detecting active disease.
When serial samples were collected after the first clear specimen, no
significant differences in the concentrations of these proteins could be detected
between the serial samples (Sallam et al, submitted) - these data established WGLF
as a gut perfusion system. WGLF analysis also showed that data based on analysis of
faeces may be highly misleading (Ferguson et al 1995).
2.8.2. Measurement of gastrointestinal blood loss
Occult gastrointestinal bleeding can be measured by using a highly sensitive
technique, Hemoquant, for assay of haemoglobin in WGLF (Brydon et al 1992). In
patients with a normal gastrointestinal tract, WGLF haemoglobin concentration ranged
from 0.5 - 5.1 pg/mL equating to an estimated daily occult blood loss of 0.1 -1.2 mL.
High values were found not only in patients with colorectal cancer, but also in active
IBD.
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2.9. Neutrophil migration into the gut lumen in IBD
Neutrophils are the predominant effector cells within the active lesions of IBD
and probably mediate much of the tissue damage. Indium111 - labelled leukocyte
studies have demonstrated rapid accumulation of radiolabeled cells in the inflamed
intestine, followed by migration into the crypts and thence into the intestinal lumen
(Saverymuttu et al 1983a,b,c, 1986a). These studies showed that monitoring
neutrophil migration could be of potential value in the clinical assessment of IBD
patients. The introduction of "mTc - HMPAO as a leukocyte label further refined the
technique and provided much better scans (Scholmerich et al 1988).
There are several groups of molecules which may be acting as neutrophil
chemoattractants in IBD. These include complement, eicosanoid and cytokine families
and proinflammatory bacterial peptides. Recent studies have focused attention on IL-
8, a non-glycosylated single peptide chain which mediates activation and chemotactic
attraction of neutrophils (Baggiolini et al 1989). The human neutrophil expresses at
least two distinct receptors, high and low affinity, for IL-8 (Holmes et al 1991, Murphy
et al 1991). This cytokine was originally isolated from endotoxin-treated monocytes,
but a variety of other cells may be induced to produce IL-8, and stimuli include IL-1
and TNF-a. Evidence that IL-8 may be implicated in the local tissue lesion of IBD
comes from rectal and sigmoid perfusion studies, which show that myeloperoxidase
released from neutrophil granules correlates with IL-8 in the perfusate in UC (Raab et
al 1993).
Mitsuyama et al (1994) demonstrated that raised IL-8 content of affected
colonic mucosa in active IBD correlates with neutrophil counts in the mucosa. This is
strong evidence of a central role for IL-8 in the pathogenesis of neutrophil infiltration.
These workers also observed that mucosal IL-8 levels in macroscopically unaffected
areas of the colon were similar to those in colonic biopsies from immunologically
normal control patients. Measurement of serum IL-8 concentration was unhelpful.
An important unanswered question is the source of IL-8 in IBD. Mucosal
monocytes and macrophages are known to produce IL-8, and IL-8 is also expressed
by human epithelial cell lines (Eckmann et al 1993). There may be bi-directional
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communication between intestinal epithelial cells and mucosal immune cells, whereby
IL-1 and TNF-a released by activated macrophages may result in increased IL-8
secretion by intestinal epithelial cells. However, caution is needed in extrapolating data
from in vitro studies - epithelial cell lines also express IL-1 and yet
immunohistochemical and in situ hybridization studies have shown that lamina propria
mononuclear cells and not epithelial cells are the source of IL-1 in intestinal mucosal
biopsies (Youngman et al 1993).
One potential mechanism of action of IL-8 is via regulation of expression of
leukocyte adhesion molecules. Binding of neutrophils to the vascular endothelial cells
may be mediated through well characterized adhesion molecules such as
CD11a/CD18 complex (LFA-1) which binds to CD54 (ICAM-1). In active IBD, the
expression of CD54 is strikingly increased (Malizia et al 1991). Another family of
adhesion molecules, the LEC-CAM, present on neutrophils and endothelium, mediate
adhesion by a lectin domain. This promises to be one of the central areas for future
research and therapeutic intervention.
Some of the traditionally investigated chemoattractants such as leucotriene-B4
may be a secondary consequence of neutrophil infiltration, while other mediators such
as those of the complement family (C3b, C5a) may be important in the final pathway of
tissue injury by perpetuating the inflammation. Though several groups have
investigated the role of platelet-activating factor (PAF) in IBD, no correlation between
degree of tissue inflammation or disease activity and PAF has been reported. An
important area that needs further experimental clarification is the relationship of
neutrophil chemoattractants of bacterial origin such as formyl-methinyl-leucyl-
phenylalanine (FMLP) and production of tissue mediators such as IL-8.
2.10. Role of inflammatory mediators in wound healing and stricture
formation in the intestine
Intestinal smooth muscle cell has the capacity to respond to inflammation by
proliferating and synthesizing collagen. The inflammatory cytokines involved in this
response include transforming growth factor-p (TGF-p), IL-1, TNF-a, insulinlike growth
factor-1 (IGF-1), fibroblast growth factor (FGF), platelet derived growth factor (PDGF),
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prostaglandins and leukotrienes (Graham 1994). It is probable that under certain
circumstances, the smooth muscle cells are synthesizing these cytokines themselves
(Raines et al 1989).
TGF-Pi is a homodimeric polypeptide involved in the regulation of growth and
differentiation of both normal and transformed cells. It stimulates the synthesis of
extracellular matrix components and inhibits matrix degradation, resulting in the
formation of fibrosis and tissue repair (Moses et al 1990, Ignotz et al 1986). It is
supposed to be the mediator of fibrosis in many disease processes, such as liver
cirrhosis (Castilla et al 1991), glomerulonephritis (Okuda et al 1990), or idiopathic
pulmonary fibrosis (Broekelmann et al 1991). Evaluation of the expression of
TGF-p in tissues affected by IBD has not yet been studied in a comprehensive
manner. TGF-p exhibits a variety of effects which may play a role in IBD (Podolsky
1994). Initial studies demonstrate high levels of TGF-p expression, both mRNA and
bioactive peptide, in actively inflamed IBD tissues relative to normal tissues (Rossiter
et al 1990). The enhanced expression of TGF-p is similar in mucosa involved by either
UC or CD.
Insulinlike growth factor I and II (IGF-1 and II) are produced by intestinal
epithelial cells and model cell lines (Brown et al 1986, Laburthe et al 1988, Jaffe et al
1990). These proteins facilitate proliferation of epithelial cells and may also have
effects on other cell populations within the inflamed intestine as well. As yet, the
expression and effects of IGF in IBD have not been examined. Many cell types,
including neoplastic cells, are capable of synthesizing IGFs and responding to IGFs
locally. Thus, the physiologically relevant IGF levels include both the tissue and the
circulating levels. IGFs have mitogenic activity, but they also promote functions in
differentiated cells. Soluble specific binding proteins (BP s) are present in blood,
extracellular fluids and cell culture media and can inhibit or augment the actions of
IGFs at the membrane receptor level. IGF-1 is a potent mitogen for fibroblasts
(Conover et al 1989) and smooth muscle cells (Elgin et al 1987) and induces collagen
synthesis in vitro (Hock et al 1988, Goldstein et al 1989). IGF-1 appears to play an
important role in tissue remodelling and repair (Mueller et al 1991). Emerging evidence
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suggests that proinflammatory cytokines such as IL-1 may induce IGF-1 in vitro, linking
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Chapter III
METHODS OF INVESTIGATING BONE MINERAL DENSITY
AND BODY COMPOSITION
I have described below the method used for measuring bone mineral
density (BMD), the sites chosen for testing and the confounding variables that were
considered. The methods used for measuring body composition are also
described. These include established methods to measure lean body mass in a
Medical Physics Department as well as use of a newly available machine that can
be used at the bedside by personnel with no specialised training.
3.1. Measurement of bone density - consideration of the confounding
variables
BMD is affected by a number of variables (Stevenson 1989). The following
variables were recorded in a questionnaire administered to each patient by me.
3.1.1. Physical activity: validation of questionnaire
The level of physical activity at the time of diagnosis and the pre-morbid
level of physical activity when the patient was last free from IBD manifestations
were recorded on a 1-5 scale as follows:
1. Predominantly homebound.
2. Walks once a week for shopping.
3. Average activity; no formal exercise or hard work.
4. Active: gymnasium, games, formal exercise at least once per week.
5. Regular athletic activities.
The level of physical activity at the time of follow-up measurement of bone
density was also recorded.
The scale of physical activity was validated against the Baecke habitual
physical activity questionnaire, a reliable self-administered measure of physical
activity (Baecke et al 1982). Seven study patients, 10 IBD patients not in the study
and 10 healthy volunteers completed the Baecke habitual physical activity
questionnaire and were also graded on the scale given above. Age range of the
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participants was 18-57 years (16 male; 11 female). The Baecke questionnaire
scores three dimensions of physical activity, namely, (a) work, (b) sport, (c) leisure-
time. Grades 1 and 2, grade 3 and grades 4 and 5 significantly differed from each
other in the mean scores of all the three dimensions. Grade 1 significantly differed
from grade 2 only in 'work' score and grade 4 differed from grade 5 only in "sport'
score.
3.1.2. Smoking
Smokers have lower bone mineral density than non-smokers (Daniell 1976,
Stevenson et al 1989). All patients were categorized as smokers, non-smokers or
ex-smokers. The duration of smoking and the average number of cigarettes
smoked per day were also recorded.
3.1.3. Menstrual history
Secondary amenorrhoea and postmenopausal oestrogen deficiency are
well known risk factors for osteoporosis (Richelsen et al 1984, Stevenson et al
1982, Stevenson et al 1989). All patients were questioned regarding their
menstrual history, intake of oral contraceptive pill and hormone replacement
therapy. They were also asked whether they had been commenced on hormone
replacement therapy because of osteoporosis.
3.1.4. Developmental stage in children: bone age
All patients aged less than 20 years had bone age assessed from a
radiograph of the left wrist and hand (Greulich and Pyle). All radiographs were
reported by a single, experienced radiologist.
3.1.5. Alcohol
Alcohol abuse is associated with decreased bone mineral density though
this effect has been demonstrated only in heavy drinkers (>40 units per week for at
least 2 years) (Feitelberg et al 1987, Stevenson 1988). A history of alcohol intake
was recorded from all patients.
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3.1.6. Drugs
Drugs which may affect bone density such as thyroxine, oestrogen and
corticosteroids were recorded. In case of corticosteroids, a detailed record of doses
and duration were kept so that cumulative corticosteroid use could be calculated.
3.1.7. Other diseases
None of the patients was pregnant and none suffered from known
cholestasis, renal disease, hypogonadism, previous gastric surgery or thyroid or
parathyroid disorders.
3.2. Measurement of bone density
3.2.1. The machine and setting
A Hologic QDR-1000/W (Hologic Inc, Waltham, MA, USA) scanner was
used to obtain dual energy X-ray absorptiometry (DEXA) measurements of BMD.
The principle underlying this method has been reviewed in chapter II. Figure 3.1
shows the DEXA scanner in the Medical Physics department of the Western
General Hospital. Figure 3.2 and 3.3 show typical bone scans obtained from the
spine and forearm respectively.
3.2.2.Reproducibility
For scan-rescan measurements at our centre, the coefficient of variation for the
lumbar vertebrae is 0.8% and that for the forearm is 0.5%. The details of the










Dual Energy X-ray Absorptiometry (DEXA)
Figure 3.1. Hologic QDR-1000/W DEXA scanner.
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Forearm BMC
Mid Distal CoV = 1.91%
Ultra Distal CoV = 1.09%
Total CoV = 1.40%
Forearm BMP
Mid Distal CoV = 0.65%
Ultra Distal CoV = 0.85%
Total CoV = 0.53%
3.2.3. The sites of measurement
The two sites of measurement chosen were lumbar L1-L4 vertebrae
(Newton et al 1993) and of right forearm (both radius and ulna). These two sites
have the best scan-rescan reproducibility and the Medical Physics department has
extensive experience in these scanning at these two sites. In our centre,
measurement of BMD at the femoral neck has quite a low test-retest reliability. For
scan-rescan measurements the coefficient of variation for the lumbar vertebrae
was 0.8%, whereas that for the femoral neck was 2% (Newton et al 1993). The
lumbar vertebrae also contain 50% trabecular bone which is more metabolically
active than cortical bone found in the femoral neck and is therefore, theoretically
more likely to show early bone density changes. Total body bone density has a
large coefficient of variation, often depends on precise positioning of the body and
it has not been shown that whole body DEXA would give additional information
regarding BMD. It was however used for body composition data. The forearm sites
chosen had a narrow coefficient of variation, and measured a combination of
trabecular and cortical bone as mentioned below. The bone mineral content (BMC)
divided by the area of the bone gave the BMD in grams/cm2. The average BMD
values for L1-L4 and for the 3 forearm sites were used for calculations. The
Hologic forearm application protocol defines a global region of interest
encompassing 3 individual forearm sites which are: i) the 1/3 distal region is
defined as a region 20mm wide centered at a distance equal to 1/3 of the forearm
length measured from the distal tip of the ulna and contains mostly cortical bone; ii)
the ultra distal region is 15mm in length positioned proximal to the end plate of the
radius. This region excludes the end plate of the radius and contains mostly
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trabecular bone; iii) the mid distal region is the region between the 1/3 and ultra
distal regions and contains both trabecular and cortical bones. At our centre,
dominant and non-dominant forearms were found to be comparable.
3.2.4. Controls
Normal values for BMD readings with the Hologic QDR-1000/W scanner
were available as mean BMD (±SD). The normal values for L1-L4 were available
from age 0-85 for both males and females; for forearm measurements normal
values were available from age 20-85 for both males and females. The normal
values were provided by Hologic reference database. The manufacturers supplied
data obtained from healthy Caucasian volunteers of either sex (spine: 605 female,
294 male subjects; forearm: 366 female, 70 male subjects). None were on steroids,
anticonvulsants, fluoride, diuretics or oestrogens. Subjects aged over 60 years had
a lateral spine radiograph and if there was evidence of vertebral fractures or spine
BMD below 0.82g/cm2, subjects were excluded. Statistical thresholds were set and
individuals below the first and above the 99th percentiles were excluded. In order
to ensure that the Hologic reference database (based on an U.S. population) was
satisfactory in the UK, 100 healthy normal volunteers from the local Scottish
population were recruited. BMD values obtained from locally recruited control
subjects were not significantly different from the Hologic reference database and
hence the manufacturers' database was used for our control values.
3.2.5. Typical scans
Figure 3.4 and 3.5 illustrate a spine and a forearm scan from the same
patient with marked osteopenia. The BMC divided by the area of the bone gives
the BMD. This can then be plotted on a nomogram derived from normal subjects as
shown in the figure or a Z-score may be derived as discussed below.
3.2.6. Analysis of results using the Z-score
Z-score is a standard statistical method (Harper 1982) of assessing the
deviation of a measurement from the mean of a normal population when the
standard deviation of the normal population is known. Z scores were calculated for
each patient using the formula:
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Measured BMD - Normal BMD(age and sex matched)
Standard Deviation of the normal BMD
Z scores were available for all BMDs from L1-L4; Z scores for forearm could only
be calculated for patients aged 20 or over.
3.3. Biochemical assessment of Ca++ homeostasis
All these investigations were available as routine assays in the clinical
chemistry department of the Western General Hospital.
3.3.1. Routine serum and urinary analysis
1) Plasma calcium and urinary calcium/creatinine ratio measured in a 24-hr
sample of urine collected in a special container containing HCI, 2) Plasma
phosphate and urinary phosphate/creatinine ratio measured in a 24-hr sample of
urine. 3) Plasma albumin. 4) Plasma alkaline phosphatase. 5) Plasma 25-
hydroxyvitamin D 6) Plasma immunoreactive parathyroid hormone (iPTH) 7)
Urinary hydroxyproline/creatinine ratio measured in a 24-hr sample of urine
collected in a special container with toluene.
Blood samples were taken after an overnight fast in order to avoid any
influence of meals on serum phosphate concentration. Plasma total calcium,
phosphate, alkaline phosphatase and urinary calcium, phosphate creatinine
concentrations were measured by standard routine methods (Kodak, Ektachem
E700C autoanalyser, USA). Urinary hydroxyproline was measured by colorimetric
method (Varley 1980).
3.3.2. 25-OH-vitamin D
25-OH-D levels were measured in 4 patients in winter, 8 in spring, 8 in
summer and 10 in autumn, and compared with seasonally adjusted reference
values. Plasma 25-OH-Vit D (D2+D3) was measured by a competitive binding
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mineral density (BMD) is
expressed in g/cm2. The
total is the average of
the regions included in
the ROI. This measure¬
ment is plotted on the
reference database
curve (+ symbol) and
can be tracked with
serial scans to deter¬
mine rate of bone loss
or gain over time.
PHYSICIAN
COMMENT
This area of the refer¬
ence database screen
is reserved for physician
comments about the
patient's scan values.
The information can be
stored permanently
with the scan record
on archive media.
■T SCORE
The T score indicates
the amount of bone
loss, by quantifying the
difference between
the patient's BMD at
his/her current age,
and the peak bone
mass for young
normals. The young
normals age is noted
in parenthesis.
-Z SCORE
The Z score normalizes
the patient's BMD in a
different way, by
assessing the amount
of bone loss compared
to the expected loss for
age matched peers.
Figure 3.2. An example of a spine DEXA scan. L1-L4 vertebrae are imaged. The
information provided by the printout are highlighted.
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Figure 3.3. An example of a forearm DEXA scan. The three regions-of-interest as
described in the text are illustrated.
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Beg ion BMD T(30 .0) Z
LI 0.697 -2.03 697 -2.83 69x
L2 B.800 -2.67 737 -2.67 73x
L3 0.032 -2.46 757 -2.46 757
L4 0.777 -3.35 687 -3.35 687
L1-L4 0.780 -2.83 717 -2.83 717
♦ Age and sex matched
T = peak bone mass
Z = age matched TK 04 Nov 91
Figure 3.4. Spine BMD scan from a patient with long-standing Crohn's disease. He
was osteopenic with a Z-score of -2.8.
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F rl i nhurnh
Reg ion BMD T Z
1/3 0.693 -2.31 842 -2.29 842
(20 .0)
MID 0.554 -2.57 802 -2.56 802
(20 .0)
UD 0.308 -3.60 602 -3.57 612
(20 .0)
TOTAL 0.529 -2.77 782 -2.76 782
(20 .0)
♦ Age and sex matched
T = peak bone mass
Z = age matched PS 25 Oct 91
Figure 3.5. Forearm BMD scan from the same patient as in figure 3.4. Osteopenia
with a Z-score of -2.8 is illustrated.
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3.3.3. iPTH
Plasma iPTH was measured by immunoradiometric assay (Nussbaum et al
1987) (Nichols Allegro immunoradiometric assay, Nichols Institute Diagnostics,
Geneva, Switzerland). Plasma was separated within 15 minutes of blood collection
and stored at -70°C.
3.4. Measurement of body composition
All had height measured without shoes (in cm) as described in detail by us
(Ferguson et al 1994) and weight measured, wearing indoor light clothes on the
same, accurately calibrated machine (in kg). In adult subjects, BMI was calculated
by the formula:
BMI = Weight (kg)/Height (m)2.
3.4.1. Dual Energy X-ray Absorptiometry (DEXA)
DEXA measurements to determine body composition were done with a
Hologic QDR-1000W scanner (Hologic Inc., Waltham, MA, USA) operated in the
total body mode. Analyses were done with the software version 5.51 P. The
effective radiation dose was 6p.Sv. Lean body mass was determined from the sum
of bone and lean tissue components. The coefficient of variation of measurement
of lean body mass was o.44%. The DEXA equipment was housed in a dedicated
room with standard radiation protection measures.
3.4.2. Bioelectrical impedance
3.4.2.1. The machines
Bioelectrical impedance was measured using two machines:
1. A standard four terminal bioelectrical impedance plethysmograph (RJL systems
Inc, model 101, Detroit, Ml, USA), housed in and operated by staff of the Medical
Physics Department (Figure 3.6). The machine gives a value for measured
resistance, which is then used to calculate lean body mass on a personal
computer, using a formula and software supplied by the manufacturer. This is
hereafter referred to as the in-house machine.
50
2. Hand-held bioelectrical impedance machine (Bodystat-1500, Bodystat Ltd, Isle
of Man, UK) body composition unit. This is a single frequency, lightweight, menu-
driven bioelectrical impedance analyser that can store and recall data from 100
consecutive measurements (Figure 3.7). Results may be read out directly from the
machine's display. The machine needs input of age, sex, height and weight, and
directly displays lean body mass (as percentage of total body weight and in kg), fat
mass (as percentage of total body weight and in kg), total body water (as
percentage of total body weight and in litres), estimated basal metabolic rate and
impedance in ohms. This is hereafter referred to as the hand-held machine.
3.4.2.2. The method
Impedance was measured between the right wrist and right ankle by a
tetrapolar electrode method. The subjects were lightly clothed but without shoes or
socks, and lay supine with arms separated from the body and legs not touching
each other. Adhesive aluminium foil electrodes were positioned in the middle of the
dorsal surface of the hands and feet proximal to the metacarpo- phalangeal and
metatarsophalangeal joints (Figure 3.8 and figure 3.9); a second electrode was
positioned more proximally between the distal prominence of the radius and the
ulnar styloid and between the medial and lateral malleoli at the ankle. An excitation
current of 800pA at 50kHZ was applied to the distal electrodes and the voltage
drop was detected by the proximal electrodes.
3.4.2.3. Calculation of lean body mass from impedance value
The in-house machine had software supplied by the manufacturer for
calculation of lean body mass. The hand-held machine was programmed to run on
the manufacturer's prediction equation. The exact prediction equations used were
not disclosed by the manufacturers. For patients with an eating disorder, a
prediction equation based on the readings from the in-house impedance machine
compared with DEXA data, had been previously derived in our institution by
multiple stepwise regression (Hannan et al 1990):
Lean body mass (kg) = 0.344 W + 0.328 (H2/R) + 0.576 SW - 9.63
where W is body weight (kg), H is height (cm), R is resistance (ohm) and SW is
shoulder width (cm).
In the group of patients with an eating disorder, I used the value for
impedance measured by the hand-held machine in this equation, and compared
the result with that of the LBM derived automatically and displayed in the machine.
In IBD patients, the prediction equation derived by Jeejeebhoy's group
(Royall et al 1994) was used in addition to the manufacturer's equation. This is as
follows:
Lean body mass = 0.25 H2/R + 0,29 W + 3.63
0.733
3.4.2.4. Difference between in-house and hand-held machines
This is shown in table 3.1 along with the features of DEXA for comparison.
The main advantage of the hand-held machine is its user-friendliness.
3.4.2.5. Precautions and caveats
Since lean body mass includes total body water, clinical conditions
characterised by abnormal accumulation of fluid may render interpretation of the
lean compartment difficult. Hence, ankle oedema or ascites were specifically
looked for and patients manifesting these signs were excluded. Intake of food or
emptying of the bladder has minimal effect on measurement of bioelectrical
impedance and hence these variables were not controlled for.
Table 3.1. Characteristics of the different methods of body composition
measurement
Feature In-house BIA Hand-held BIA DEXA








Cost £2200 £400 £80000
Weight 3.5Kg 420g 1200Kg
Trained operator yes no yes
BIA= Bioelectrical impedance analysis
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Bioelectrical Impedance Analysis (BIA)
50 kHz: radiofrequency signal at 800 //A.
Controls:'FFM from RJL prediction equation
Anorexics:
FFM (kg) = 0.344W -t- 0.328(H?/R) 0.576SW - 9.63
W <= body weight (kg), H = height (cm),
R resistance (JT2), SW = shoulder width (cm)
Figure 3.6. The 'in-house' bioelectrical impedance plethysmograph (RJL systems
inc. model 101) in the Medical Physics Department.
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Figure 3.7. The 'hand-helcf bioelectrical impedance analysis machine (Bodystat-
1500). Three simple buttons control all functions.
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Figure 3.8. Method of bioelectrical impedance analysis. The subject lies supine and
electrodes are connected to the hand and foot.
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Figure 3.9. A close-up showing the position of the electrodes on the hand. The
distal and proximal electrodes are colour-coded red and black respectively.
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3.5. Measurement of urinary excretion of pyridinium crosslinks of
collagen and plasma osteocalcin
Urine samples passed between 8-1 Oam were collected on two consecutive
days.from newly diagnosed patients with IBD described in chapter VI. These were
stored at -20°C and then transported on dry ice to the Rowett Research Institute,
Aberdeen. The assays were performed at the Biochemical Sciences Division. The
method for the assays has been described in publications from this institute (Black
et al 1988, Seibel et al 1989, Robins et al 1991). The pyridinium compounds
measured were pyridinoline (Pyd) and deoxy-pyridinoline (Dpd) and the results
were expressed as nmol/mmol creatinine, the latter being measured in
unhydrolysed portions of the urine (Folin et al 1965).
For osteocalcin assays plasma was separated within 15 minutes of
collection and stored at -70°C. All samples were collected between 8 am and 10
am. Frozen samples were transported to the Rowett Research Institute on dry ice.
Plasma osteocalcin was measured by a radioimmunoassay.
3.6. Statistical methods
Statistical methods used for analysing results are mentioned in the results
sections of the individual chapters that follow. Both BMD and body composition
data had normal distributions and parametric statistics were used. The Minitab




BONE MINERAL DENSITY IN CROHN'S DISEASE AND
ULCERATIVE COLITIS AT DIAGNOSIS
4.1. Introduction
Low bone mineral content has been convincingly demonstrated in unselected
groups of patients with IBD (Compston et al 1987, Stallmach et al 1988, Pigot et al
1992, Clements et al 1992) but the pathogenesis of the osteopenia is incompletely
understood. No correlation between bone loss and serum parameters of bone
metabolism has been demonstrated (Stallmach et al 1988). Though the deleterious
effects of corticosteroids on trabecular bone mass are well documented (Smith 1990,
Hahn et al 1974), longitudinal studies in patients with IBD have failed to show any
significant correlation between the rate of bone loss and prednisolone therapy (Motley
et al 1988). Conflicting evidence from cross-sectional studies however, indicated that
cumulative corticosteroid use may be an important (Weldman et al 1993, Tromm et al
1993) or even the sole cause (Bernstein et al 1993) of osteopenia in patients with IBD.
This is contradicted by other cross-sectional studies (Bjarnason et al 1993).
Various factors such as small intestinal resection (Hylander et al 1981), ileal
involvement (Tromm et al 1993),vitamin D deficiency (Driscoll et al 1982), smoking
(Weldmann et al 1993), body mass index (Motley et al 1988) and height (Issenman et
al 1988) have been correlated with osteopenia in IBD reflecting the heterogeneous
nature of the patient cohorts studied by various workers. It is still not known the extent
to which bone mineral loss in IBD occurs as an integral manifestation of the disease as
distinct from the secondary osteopenic influences of corticosteroid therapy, surgical
intervention, inactivity, malabsorption of calcium and vitamin D or the cachexia of
inflammation.
There has been no comparative study on bone mineralisation in patients with
Crohn's disease (CD) and ulcerative colitis (UC). CD may be considered a systemic
disease whereas UC is more limited to colonic mucosal inflammation; CD also has
important immunological differences from UC (Shanahan 1993).
I have studied bone mineral density (BMD) in a series of newly diagnosed
patients with CD and UC. Both spine and forearm BMDs were studied so that
trabecular and cortical mineralisation could be assessed, as there are metabolic
differences between these two types of bones (Compston 1990). Newly diagnosed
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patients were studied in order to avoid most of the secondary osteopenic influences
mentioned previously. The measurement of BMD was repeated about a year after
diagnosis to assess progressive bone loss and the effects of therapy.
4.2. Materials and Methods
4.2.1. Subjects
A total of 30 consecutive patients (17 men, 13 women) aged 14-83 years
(median=26 years) with newly diagnosed IBD were studied between March 1991 and
August 1993. The diagnosis and disease extent in all patients were confirmed by
histology, endoscopy and radiology. In 15 patients (9 men, 6 women) aged 14-83
years (median=24 years) CD was diagnosed. In another 15 patients (8 men, 7 women)
aged 14-63 years (median=28 years) UC was diagnosed. The distribution of disease is
given in table 4.1.
Table 4.1. Macroscopic distribution of disease in newly diagnosed IBD patients



















The logistics of setting up BMD studies normally meant a delay of 2-3 weeks.
For ethical reasons, we did not attempt to delay appropriate medical treatment during
this interval. As a result, BMD measurements were made in 14 of the 30 patients
shortly after the start of oral corticosteroids; in 13 patients the duration ranged from 4-
14 days and in one case 19 days.
4.2.2. Clinical assessments
The patients were clinically assessed by me and each patient completed a
diary card for a week prior to bone density measurements for calculation of Crohn's
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disease activity index (CDAI) (Best et al 1976). The haematocrit for CDAI was obtained
from the full blood count. For patients with UC, both CDAI and Powell-Tuck index (PTI)
(Powell-Tuck et al 1978) were calculated. Smoking status, bone fracture history and
experience of contraceptive pill and hormone replacement therapy were recorded.
CDAI with or without PTI were again calculated just prior to follow-up measurement of
bone density. Height and weight were recorded and the body mass index (BMI) was
calculated as weight (kg) divided by height (metre)^. The estimated duration of
disease in weeks before diagnosis was also recorded. In one 28-year-old male UC
patient, forearm BMD was not available.
Bone density measurements were done after diagnosis and at follow-up 1 year
later.
4.2.3. Methods
Assessment of physical activity and biochemical measurements are described
in chapter III. BMDs at lumbar 1-4 vertebrae and right forearm were measured by
DEXA as detailed in chapter III.
4.2.4. Statistical Analysis
Comparison between CD and UC was made using the unpaired t-test.
Comparison of initial measurements with follow-up measurements was made by the
paired t-test. Correlation coefficients were calculated with the Pearson's correlation
test.
4.2.5. Ethical considerations
The study was approved by the Medicine Subcommittee of the Lothian Area
Ethics of Research Committee. Each patient gave informed verbal consent.
4.3. Results
The age and sex distribution, duration of symptoms prior to diagnosis, physical
activity grade and duration of steroid use prior to diagnosis for CD and UC are
summarised in table 4.2. The mean spine Z-score for 17 male patients was -0.56 (SD
1.07) and that for 13 female patients was -0.48 (SD 1.25; p=NS). The mean of the 12
forearm Z-scores available from male patients was not different from the mean of 9
forearm Z-scores available from female patients (-0.41+1.49 vs -0.66+0.99; p=NS).
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Table 4.2. Clinical features of CD and UC
Features CD UC
Age (year) 24 (14-83) 28 (14-63)
Sex(M:F) 9:6 8:7
Estimated duration of 18.6 (18.6) 12.3 (15.5)
disease before diagnosis
(weeks)
Duration of steroid use 1.2 (1.1) 0.5 (0.8)
before BMD measurement
(weeks)
Grade of physical activity
Premorbid 3.7 (0.6) 3.9 (0.3)
Active disease 2.8 (0.6) 3.1 (0.9)
BMI 21.38 (3.17) 22.36 (4.33)
Active disease (CDAI > 150
or Powell-Tuck index >4) 11 10
Note: All values are expressed as mean (SD) except age, which is given as median
(range).
The mean BMIs in patients with CD and UC are also given in table 4.2. The
spine and forearm Z-scores obtained from bone mineral content per unit area
expressed as standard deviations from the age and sex matched means were not
significantly correlated with BMI (r=0.20 and 0.11 respectively). However, spine and
forearm total bone mineral content significantly correlated with BMI (r=0.76 and 0.75;
p<0.05) which implied that increasing BMI was associated with larger bones and
hence a larger area of interest.
Four patients (2 UC, both females; 2 CD both males) were less than 16 years
old. The UC patients were on the 90th and greater than 97th centile in height.The CD
patients were on the 90th and 3rd centile in height. The 14-year-old boy with CD with
height on the 3rd centile had a bone age of 12. The bone age of the remaining three
adolescents were appropriate for age. A further 4 patients ( 3 UC, 1 CD) were aged
18-19 years and none of them were short-statured (2 male UC=182 and 178cm; 1
female UC=157cm; 1 female CD=155cm) - their bone ages were that of mature
adults. The mean height of 7 men aged 20 years and over with CD (173cm SD 4cm)
was not different from the mean height of 6 men aged 20 years and over with UC
(173cm SD 5cm). The mean height of 5 women aged 20 years and over with CD
(158cm SD 6cm) was not significantly different from the mean height of 4 women aged
20 years and over with UC (166cm SD 4cm).
The mean CDAI in patients with CD was 196 (SD 70). CDAI was calculated for
patients with UC and this was not different from that for patients with CD (mean 164,
<6i
SD 105; p=NS). Eleven out of the fifteen patients with CD had a CDAI over 150
indicating active disease. Ten out of the 15 patients with UC had a PTI > 4 indicating
active disease (table 4.2). There was no correlation between the CDAI and spine or
forearm Z-score (r= -0.17 and r= -0.20 respectively) in patients with CD. Likewise,
there was no correlation between spine or forearm Z-score and the PTI (r= -0.26 and
-0.22 respectively) in patients with UC. In the entire cohort of IBD patients, indices of
systemic inflammatory activity such as CRP (r= -0.3, p=NS), platelet count (r=0.1,
p=NS) and white cell count (r= -0.2, p=NS) were not significantly correlated with spine
BMD Z-scores.
Nine patients with CD had colonic involvement only and 6 patients with CD had
small bowel involvement. The spine and forearm Z-scores in these two groups of
patients are depicted in table 4.3. The Z-scores for the two CD groups with different
anatomical regions involved did not differ significantly.
Table 4.3. Z-scores in CD according to region of involvement
Site Colonic {mean (SD)} Small bowel {mean (SD)}
Spine Z score
Forearm Z score
-1.09 (1.12) (n=9) -1.02 (0.41) (n=6)
-0.86 (0.67) (n=8) -1.35 (1.17) (n=4)
Fourteen out of the 30 patients were smokers and the remainder were non or
ex-smokers. The mean spine Z-score in the 14 smokers was -0.26 (SD 1.15) and in
the 16 non/ex-smokers was -0.74 (SD 1.11). The difference was not significant. The
forearm Z-scores were available for 10 smokers and 11 non/ex smokers; the mean Z-
scores were not different (-0.58+0.65 vs -0.47+1.51; p=NS). Among patients with CD,
eight were smokers and their spine and forearm Z-scores were not different from those
of the non-smokers.
Two patients with CD were on hormone replacement therapy for more than 5
years and their spine Z-scores were -2.9 and -1.0. In neither case was bone disease
the reason for prescribing hormone replacement therapy. Secondary amenorrhoea
was present in 1 CD patient (spine Z-score=-1.5) and 1 UC patient (spine Z-score=
-1.1). Three patients with CD were on oral contraceptives (spine Z-scores= -0.6, 0.6,
-1.2) and 4 patients with UC were on oral contraceptives (spine Z-scores= -0.4, -0.5,
1.3,-1.2).
Table 4.4 depicts the biochemical parameters in CD and UC. None of the
parameters was significantly different in the two groups of patients. Plasma Ca++
levels were low in two patients with severe UC, both of whom had low plasma albumin
<32
levels; corrected Ca++ levels were normal. Though urinary hydroxyproline excretions
were above the upper limit of normal (168 umol/24hr/sq.cm of body surface) in 8 out of
the 30 patients, urinary hydroxyproline/creatinine ratios were within normal limits in all
patients.
Table 4.4. Biochemical markers of calcium homeostasis
Bone biochemistry CD UC
(normal range) {mean (SD)} {mean (SD)}
Total calcium (mmol/L)* 2.29 (0.04) 2.30 (0.04)
(2.25 -2.50)
Urinary Ca++/creatinine 0.26 (0.20) 0.29 (0.39)
Plasma P04 (mmol/L) 1.11 (0.16) 1.22 (0.17)
(0.87 -1.45)
Urinary P04/creatinine 0.50 (0.29) 0.80 (1.12)
Urinary OH- 16.07 (4.46) 15.93 (3.88)
proline/creatinine
25-OH vitamin D (nmol/L) 36 (11) 41 (13)
Summer (15-100) 45 (12) 47 (14)
Winter (15-50) 28 (10) 37 (11)
Alkaline phosphatase (U/L) 45 (12) 47 (14)
Adult (30-140)
Children (250-800)
Immunoreactive 39 (15) 41 (17)
parathyroid hormone
(ng/L) (10-55)
* Total calcium corrected for albumin where appropriate
4.3.1. Bone density of lumbar spine
Fig. 4.1 shows the lumbar BMD values related to age in patients with CD and
UC separately for males and females. The mean spine BMD (0.88+0.17) in patients
with CD was significantly less than that in patients with UC (1.03+0.14; p<0.02). The
rest of the comparisons between CD and UC are based upon Z-scores as these are
indexed against age and sex matched controls.
Fig.4.2 shows the Z-scores of lumbar spine for patients with CD and UC. The
mean spine Z-score for patients with CD was -1.06 (SD 0.86) while the mean Z-score
of patients with UC was -0.03 (SD 1.16). This difference is significant (p<0.02). The
mean Z-score of the 7 patients with proctitis was 0.16 (SD 1.2) and this was not
different from the mean Z-score of the 8 patients with more extensive UC (-0.2 + 1.17;
p=NS).
The 14-year-old boy with height on the 3rd centile had his spine Z-score
recalculated using his bone age. This altered his spine Z-score from -1.5 to -0.5 but
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Figure 4.1a. BMD of lumbar vertebrae L1-L4 in male patients with IBD. Squares
represent values for patients with CD and triangles represent values for patients with
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Figure 4.1b. BMD of lumbar vertebrae L1-L4 in female patients with IBD. Squares
represent values for patients with CD and triangles represent values for patients with
UC. The dotted lines indicate 1 standard deviation from the mean.
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Figure 4.2a. Lumbar spine BMD Z-scores in patients with CD and UC at diagnosis.
The horizontal bars represent mean values.
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Figure 4.2b. Forearm BMD Z-scores (mean of the three sites of measurement) in
patients with CD and UC at diagnosis. The horizontal bars represent mean values.
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4.3.2. Bone density of forearm
Figure 4.3 shows the forearm BMDs for patients with CD and UC separately for
males and females. Forearm Z-scores were available for 12 patients with CD and for 9
patients with UC who were aged 20 years or more (figure 4.2). The mean forearm Z-
score for patients with CD disease was -1.04 (SD 0.86) while the mean forearm Z-
score for patients with UC was 0.11 (SD 1.24). This difference is significant (p<0.05).
The three different measurement sites of the forearm were separately analysed
as shown in table 4.5. The Z-scores for all three sites were significantly lower for
patients with CD compared to patients with UC.
Table 4.5. Z-scores for the three forearm BMD measurement sites in CD and UC
Diagnosis One-third distal Middistal Ultradistal
{mean (SD)} {mean (SD)} {mean (SD)}
CD -1.67 (0.77)* -1.43 (0.82)** -0.60 0-98)*
UC -0.70 (1.00) -0.32 (1.19) 0.87 (1.53)
*
p < 0.02; ** p < 0.01
4.3.3. Relation between forearm and spine bone density (Fig.4.4)
Forearm Z-scores were available for 21 out of the 30 patients studied. The
forearm Z-scores of these patients were significantly correlated with spine Z-scores
(r=0.52; p=0.02).
4.3.4. Follow-up
Follow-up data could be obtained in 11 out of the 15 CD patients.
All of them had received systemic steroids. In addition four patients had received rectal
steroids. The mean cumulative corticosteroid dose between the initial and follow-up
bone mineral density measurement was 2.82g (SD 3.75g). One patient was receiving
azathioprine. Two patients had resectional surgery within this period (colectomy=1;
ileal resection=1). The mean CDAI (86+58) had come down significantly (p<0.02).
Only one patient had a CDAI above 150 at the time of follow-up. The mean physical
activity grade at follow-up was 3.1 (SD 0.8) and this was not significantly different from
that at diagnosis. The mean BMI at follow-up was 21.45 (SD 3.85) and this too was not
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Figure 4.3a. BMD of forearm in male patients with IBD. Squares represent values for
patients with CD and triangles represent values for patients with UC. The dotted lines
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Figure 4.3b. BMD of forearm in female patients with IBD. Squares represent values for
patients with CD and triangles represent values for patients with UC. The dotted lines
indicate one standard deviation from the mean.
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Correlation Between Spine and
Forearm Z-Scores
Spine z-score
Figure 4.4. Correlation between forearm and spine BMD Z-scores in the 30 patients
with IBD.
71
Comparison of Spine Z-Scores at

















At diagnosis After 1 year
Crohn's disease
Ulcerative colitis
Figure 4.5a. Comparison of lumbar spine BMD Z-score values at diagnosis with Z-
score values at follow-up after one year. Continuous lines ( ) represent CD and
broken lines (—) represent UC. The horizontal bars represent mean values.
7Z
Comparison of Forearm Z-Scores at
Diagnosis with Z-Scores at Follow-Up
-2-
-3 -J T ■
At diagnosis After 1 year
Crohn's disease
Ulcerative colitis
Figure 4.5b. Comparison of forearm BMD Z-score values at diagnosis with Z-score
values at follow-up after one year. Continuous lines ( ) represent CD and broken
lines (—) represent UC. The horizontal bars represent mean values.
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In these 11 patients with CD a repeat measurement of bone density was
performed after 1 year (fig. 4.5). The mean spine Z-score after 1 year was -1.37 (SD
0.82) and this was not significantly different from the mean spine Z-score at diagnosis.
Forearm Z-scores were available in 8 of these patients and the mean score
was -1.17 (SD 0.95); this too was not significantly different from initial measurements.
In the single patient with CDAI over 150, spine and forearm Z-scores at follow-up were
-1.6 and 0.4 respectively compared with -1.5 and 0.4 respectively at diagnosis.
Follow-up data were available for 12 out of the 15 UC patients. Nine out the 12
patients with UC had received systemic steroids and rectal steroids while the
remaining 3 patients had received rectal steroids only. The mean cumulative systemic
corticosteroid use over this period was 2.25g (SD 2.80g). The mean physical activity
grade was 3.4 (SD 0.7) and the mean BMI 22.50 (SD 4.33) and none of these was
significantly different from the relevant value at diagnosis. Two patients underwent
panproctocolectomy with ileoanal pouch during this period. The mean PTI had come
down to 3.4 (SD 2).
Twelve patients with UC underwent repeat bone density measurements Figure
4.5). The mean spine Z-score a year after the initial measurement was 0.04 (SD 1.06)
and the mean forearm Z-score (9 patients) was 0.11 (SD 1.07). None of these were
significantly different from previous measurements.
Both spine and forearm Z-scores continued to be significantly lower in CD
compared with UC (p<0.02).
4.4. Conclusion
We have found that BMD of lumbar vertebrae and forearm is reduced at
diagnosis in patients with CD compared with UC. This is unassociated with
abnormalities of calcium homeostasis, BMI, smoking or prednisolone use. Treatment
with corticosteroids does not necessarily result in further bone mineral loss. However,
owing to the small number of patients studied, the likelihood of identifying any single
factor that might have influenced the BMD of patients with CD versus those with UC is
low. The potential influence of smoking or menstrual status could not be studied by




BONE MINERAL DENSITY IN ADULT PATIENTS WITH
LONGSTANDING INFLAMMATORY BOWEL DISEASE.
5.1. Purpose of this study
None of the previous studies on bone mineral density (BMD) in IBD patients
had documented any difference between Crohn's disease (CD) and ulcerative
colitis (UC). However, none of these studies had recruited only newly diagnosed
patients as was the case for the work described in the previous chapter. A survey
of the results from previous studies clearly showed that their cohorts of IBD
patients had long-standing disease, as shown in the table 5.1 below. It is likely that
in such cohorts, many confounding variables will have been present, particularly,
prolonged steroid therapy and surgical intervention along with complex nutritional
deficiencies, so that any primary effect of the disease would be masked.
5.1.1.Results of previous studies (table 5.1)
Table 5.1. Duration of disease in IBD patients included in previous studies
Authors(year) No of CD & UC patients Average duration of
disease
Compston etal1987
Clements et al 1992
Pigot et al 1992
Clements et al 1993
Abitbol et al 1995
Bernstein et al 1995
45 CD, 17 UC
33 CD, 17 UC
27 CD, 34 UC
22 CD, 25 UC
34 CD, 50 UC
50 CD, 24 UC
10yrs
7.9yrs
5yrs (CD), 6yrs (UC)
12yrs
6.3yrs
15yrs (CD), 9yrs (UC)
5.1.2. Selection bias:
If unselected patients are recruited from outpatient clinics of a tertiary
referral hospital, it is probable that the cohort will be biased towards patients with
long-standing, complicated disease because such patients attend for consultation
most frequently and will contribute inappropriately to a cross-sectional cohort. The
study design and the cohort characteristics of the studies represented in the table
above would suggest that such a selection bias had occurred.
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In the study described in this chapter, I present the results of BMD
measurements in a cohort of patients with long-standing CD and UC. I wanted to
test the hypothesis that in patients with long-standing IBD, there is no difference in
BMD between CD and UC, unlike that at diagnosis.
5.2. Patients
5.2.1. Entry criteria
The following criteria were set for patient recruitment:
1. Disease duration from diagnosis > 5 years
2. Inactive disease (CDAI<150 or Powell-Tuck index<4)
3. Duration of steroid therapy>6 months
4. Age 20-65 years
5.2.2. Exclusion criteria
1. Cholestatic liver disease such as primary sclerosing cholangitis, thyroid
disorders, renal failure, hypogonadism.
2. Drugs such as hormone replacement therapy, thyroxine.
5.2.3. Patients
Fourteen patients with CD and 13 patients with UC were recruited in the
study. Their characteristics are described below:
Table 5.2. Clinical characteristics of chronic IBD patients
Features CD UC
Age (years) 34 (22-65) 33 (21-64)
Sex (M/F) 8/6 7/6
Duration of disease (years) 8 (5-18) 7 (5-14)
Cumulative steroid dose. 9.5 (3.6 - 20.2) 8.6 (3.2-18.9)
Median (range) gm
Duration of steroid use 21 (8-45) 19 (7-42)
(months)
Grade of physical activity 3.4 (2-4) 3.7 (2-5)
BMI 21.2 (18.1-24.6) 22.8 (20.2-31.1)
No. of resectional 2(1-6) <1 (0-2)
operations. Median (range)
76
Out of the 14 CD patients, 7 had colonic disease, 6 had small bowel
disease and 1 patient had involvement of both the small bowel and colon. Of the
13 patients with UC, 10 had pan or extensive colitis and 3 had left sided colitis.
5.3. Methods
BMDs at lumbar spine and forearm were assessed by DEXA as described
in chapter III. Biochemical tests of calcium homeostasis were less extensive than in
the newly diagnosed patients. The tests done comprised plasma calcium,
phosphate (non-fasting), alkaline phosphatase, albumin and 25-OH-vitamin D. A
number of previous studies (Compston et al 1987, Pigot et al 1992, Abitbol et al
1995, Hessov et al 1984) had extensively investigated calcium homeostasis
parameters in patients with long-standing inflammatory bowel disease and found
no significant abnormalities. However, low levels of vitamin D had been found
commonly in patients in some other studies (Driscoll et al 1982, Vogelsang et al
1989) and hence this was monitored. BMD was also measured in 10 patients with
CD and 4 patients with UC who did not fulfill criteria for the study as they did not
have a disease duration after diagnosis of > 5 years. The BMD of these patients,
as well as the newly diagnosed patients described in chapter IV were utilised to
analyse the correlation between disease duration and BMD. These data are
presented at the end of the results section of this chapter.
Comparisons between UC and CD were made by the Student's t-test. The
study was approved by the Medicine Subcommittee of the Lothian Area Ethics of
Research Committee.
5.4. Results
The age and sex distributions, duration of the disease from diagnosis and
physical activity were similar in UC and in CD. The spine BMD in the 15 male
patients (mean -1.2, SD 0.8) was not significantly different from that in the 12
female patients (mean -0.9, SD 0.9, p=NS). Similarly, the forearm BMD in the 15
male patients (mean -1.1, SD 1.3) was not significantly different from that in the 12
female patients (mean -0.8, SD 0.7, p=NS). None of the female patients was on
hormone replacement therapy. Two patients, one patient with CD and one with UC
were on an oral contraceptive pill. Three patients with CD and two with UC were
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postmenopausal. All patients had inactive disease as defined on the basis of CDAI
or Powell-Tuck index since this was a criterion for their inclusion.
5.4.1. Spine Z-scores (Figure 5.1)
The mean Z-score for spine BMD in CD was -1.1 (SD 1.0) and in UC was
-1.0 (SD 0.6) p=NS. Compared to the newly diagnosed IBD patients described in
chapter IV, the mean spine Z-score in patients with long-standing CD was not
significantly different, whereas in UC the difference was significant (p<0.02).
5.4.2. Forearm Z-scores (Figure 5.2)
The mean Z-score for forearm BMD in CD was -1.0 (SD 1.3) and in UC was
-1.0 (SD 0.6), p=NS. The forearm Z-scores in newly diagnosed UC patients
described in chapter IV was significantly higher compared to this cohort of long¬
standing UC patients (p<0.05), whereas there was no difference between newly
diagnosed and long-standing CD. Two patients, both with CD, had spine BMD Z-
score lower than -2.5.
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Figure 5.1. Spine bone mineral density Z-scores for patients with long-standing
Crohn's disease and ulcerative colitis. The horizontal lines represent mean values.
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Figure 5.2. Forearm bone mineral density Z-scores in patients with long-standing
Crohn's disease and ulcerative colitis. The horizontal lines represent mean values.
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5.4.3. Biochemical parameters (Table 5.3)
Plasma calcium, phosphate, alkaline phosphatase levels were normal in
both CD and UC. Plasma 25-OH-vitamin D levels were normal in the patients in
whom it was measured.
Table 5.3.Biochemical markers of calcium homeostasis
Bone biochemistry CD mean (SD) UC mean (SD)
n=14 n=13
Plasma Calcium (mmol/L)* 2.34 (0.06) 2.36(0.05)
Plasma phosphate 1.22(0.18) 1.26(0.18)
(mmol/L)
Alkaline phosphatase (U/L) 84(26) 72(24)
25-OH-D 37(16) (n=10) 45(14) (n=9)
Total calcium corrected for albumin where appropriate
5.4.4. Effect of macroscopic anatomy of disease
The mean spine and forearm Z-scores of the 7 patients with colonic CD
were -0.9 (SD 1.3) and -0.9 (SD 1.1) respectively. This was not significantly
different from the mean spine and forearm Z-scores of the 6 patients with small
bowel CD (-1.3, SD=1.5 and -1.2, SD=1.4 respectively). In UC, the number of
patients with left sided colitis (n=3) were too small for statistical comparison with
the group with extensive colitis - spine Z-scores in these 3 patients, were 0.4, -1.0
and -1.2 and forearm Z-scores were 0.4, -1.2 and -1.4.
5.4.5. Effect of disease duration
Disease duration from diagnosis was plotted against spine and forearm Z-
scores in both CD and UC. In CD, 14 patients with long-standing disease, 15 newly
diagnosed patients (11 of whom had a repeat measurement in 1 year) and 10
patients with disease duration between 1-5 years had spine and forearm Z-scores
measured (total no. of patients = 50). There was no correlation between disease
duration and spine (r = -0.2, p=NS) or forearm (r = -0.2, p = NS) BMD Z-scores.
In UC, 13 patients with long-standing disease, 15 newly diagnosed patients
(12 of whom had a repeat measurement in 1 year) and 4 patients with disease
duration between 1-4 years had spine and forearm Z-scores measured (total no. of
patients = 44). Disease duration and BMD Z-scores were correlated significantly
(spine r=-0.5,p=0.002;forearm r= -0.6,p<0.001).
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In CD cumulative steroid dose was not significantly correlated with spine or
forearm Z-scores (r= -0.22 and -0.26 respectively); in contrast, in UC cumulative
steroid dose was significantly correlated with spine and forearm Z-scores (r = -0.61
and -0.65 respectively; p<0.01).
5.5. Conclusions
Unlike at diagnosis, there is no difference in BMD between CD and UC
when the disease is long-standing. This is likely to be the explanation why previous
studies had failed to detect a difference between CD and UC. BMD is negatively





PATHOGENESIS OF LOW BONE MINERALISATION IN
INFLAMMATORY BOWEL DISEASE
6.1. Introduction
A number of biochemical markers of bone metabolism are now available,
enabling analysis of osteopenia in terms of bone turnover. Bone mineral density
(BMD) is determined by a balance between osteoblast and osteoclast activity.
Plasma osteocalcin is a marker of osteoblast function, while urinary pyridinium
crosslinks are markers of osteoclast function. Two pyridinium compounds,
pyridinoline (Pyd) and deoxy-pyridinoline (Dpd), are maturation products of the lysyl
oxidase-mediated crosslinking pathway of collagen (Robins 1983; Ogawa et al
1982). Pyd is the major crosslink of cartilage and is prevalent in the collagen of
bone and several other tissues, whereas Dpd is primarily located in bone (Robins
et al 1987; Eyre 1984). There is very little data on whether the osteopenia in IBD is
due to increased bone resorption or decreased bone formation. A recent study has
described diminished osteocalcin levels suggesting failure of bone formation
(Abitbol et al 1995). However, increased bone resorption markers have also been
described in an abstract (Bjarnason et al 1994). After detecting osteopenia in newly
diagnosed patients with Crohn's disease (CD), I aimed to recruit a fresh cohort of
newly diagnosed patients with IBD to measure these bone turnover markers and
compare CD with ulcerative colitis (UC). This study is ongoing, but, in this brief
chapter, I will present the results in a small number of patients.
6.2. Subjects and methods
6.2.1. Subjects
Ten newly diagnosed IBD patients were recruited into this study during
1994-95. Six patients (4 males, 2 females, aged 23-61 years, median 29 years)
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suffered from CD and 4 (2 males, 2 females, aged 33-51 years, median 38 years)
from UC. This was a different cohort from the newly diagnosed patients described
in chapter IV. All investigations regarding bone metabolism were done prior to
commencement of therapy. None of them had other concurrent illnesses that might
affect bones such as primary sclerosing cholangitis or thyroid disorders. None were
on calcium, vitamin D supplements or hormone replacement therapy.
6.2.2. Methods
The two pyridinium compounds, Pyd and Dpd were measured in urine. The
measurements were carried out in the laboratory of Dr S.P. Robins, Biochemical
Sciences Division, Rowett Research Institute, Aberdeen and the method used has
been described in chapter III. Creatinine concentration in the urine was also
measured and the results expressed as Pyd/creatinine and Dpd/creatinine ratio.
The normal adult range of Pyd/creatinine is 15-55 and Dpd/creatinine is 4-15.
Previous studies have indicated that there were no marked sex differences nor
variations with age in adults (Beardsworth et al 1990, Black et al 1988, Seibel et al
1989). Also, no significant changes in crosslinks excretion were found which were
dependent on diet or levels of exercise (Black et al 1988). Physiological
nyctohemeral variations in the urinary excretion of total pyridinium crosslinks of
collagen expressed relative to creatinine are minor in comparison to the changes
resulting from arthritic or bone diseases (McLaren et al 1993). Hence in this study,
a spot morning sample of urine was collected on two consecutive days and stored
at -20°C. Blood was collected between 9 and 9.30am and serum separated and
stored at -70°C. This was assayed for plasma osteocalcin and bone alkaline
phosphatase using the methods described in chapter III at the Rowett Research
Institute. The normal adult range for osteocalcin is 2-7 ng/mL and for bone alkaline
phosphatase is 10-23 U/L. Plasma calcium, albumin and alkaline phosphatase
were measured. BMD was measured at spine and forearm by DEXA, and the sites
of measurement were as described in chapter III. Blood and urine collection were
done on the same day as the DEXA scan and the patient returned within two days
with another urine sample. The patients were asked to keep a CDAI diary card for a
week prior to their visit for the scan.
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6.2.3. Statistical analysis
Student's t-test was used to compare results between CD and UC.
6.2.4. Ethical considerations
The study was approved by the Medicine Subcommittee of the Lothian Area
Ethics of Research Committee. Each patient gave informed verbal consent.
6.3. Results
Though the number of patients were small, the results again confirm low
BMD in newly diagnosed patients with CD compared with UC (figure 6.1). The
mean spine Z-score in patients with CD was -0.94 (SD 1.1) and in UC 0.1 (SD
0.83), but the difference did not reach statistical significance. The mean forearm Z-
score was -0.68 (SD 1.0) in patients with CD, and this was significantly lower
(p<0.05) than that in UC (mean 0.50; SD 0.28).
Figures 6.2 and 6.3 show the results of urinary pyridinium crosslinks,
plasma osteocalcin and bone alkaline phosphatase in patients with CD and UC.
Mean urinary Pyd/creatinine was 75.5 (SD 66.6) in patients with CD and 36.2 (SD
13.7) in patients with UC (p=NS). Mean urinary Dpd/creatinine was 19.5 (SD 15.3)
in patients with CD and 10.9 (SD 2.5) in patients with UC (p=NS). Urinary
Pyd/creatinine and Dpd/creatinine were significantly correlated (r=0.96; p<0.0001).
Three out of 6 patients with CD, but none with UC had pyridinium crosslinks
excretion in the urine higher than the upper limit of normal. Mean plasma
osteocalcin was not different in CD compared with UC (3.2 vs 2.6 ng/mL). Mean
plasma bone alkaline phosphatase too was not different (19.8 vs 20.2 U/L). Bone
formation markers were within or close to the normal range in all patients.
Urinary pyridinium crosslinks were not correlated with either spine or
forearm Z-scores. Plasma calcium and alkaline phosphatase were normal in all
patients.
6.4. Conclusion
This is a small study and hence conclusions drawn from it must be treated
with caution. It confirms low bone mineral density in newly diagnosed patients with


































Figure 6.1. Spine and forearm BMD values in newly diagnosed patients with CD
and UC in whom metabolic markers of bone metabolism were measured. The




































Figure 6.2. Bone resorption markers, Urinary Pyd/creatinine and urinary














































Figure 6.3. Bone formation markers, plasma osteocalcin and plasma bone alkaline
phosphatase in patients with CD and UC. The horizontal lines represent normal
ranges.
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patients with CD but in none of the 4 with UC. Bone formation markers were
generally within or close to normal limits. Owing to the small number of patients




BODY COMPOSITION AT THE BEDSIDE
7.1. Introduction
Appraisal of nutritional status is still a frequently neglected component of
clinical examination (Barton et al 1989). In many situations it should be mandatory
to measure body weight accurately, or, alternatively, to calculate the body mass
index (BMI), which takes account of appropriateness of weight for height, and
allows patients and healthy individuals to be categorised as underweight, normal
(in the range 20-25 kg/m2), or overweight (Owen 1988).
For any more sophisticated analysis of body composition, it is necessary to
differentiate in some way between body fat and fat-free or lean body mass (LBM).
This can, for example, be approached by densitometry - direct measurement of
body specific gravity by underwater weighing - a method used by physiologists but
unsuitable for clinical practice. In many settings, body fat content is calculated from
multiple measurements of skinfold thickness, an apparently simple and inexpensive
approach. However the assumptions underlying this method - that subcutaneous
fat reflects total body fat, and that the chosen site of measurement of
subcutaneous fat represents its average thickness - are both incorrect (Lukaski
1987, Heymsfield et al 1979). In recent years several different body composition
analysis methods have been developed for research purposes, including neutron
activation analysis, 40K counting and dual energy X-ray absorptiometry (DEXA). All
give broadly comparable results, despite their very different theoretical bases, and
at present, there is no a priori reason for choosing any one technique as the gold
standard (Lukaski 1987). In my institution, DEXA has proved to be a precise and
reproducible method of measuring lean body mass (Hannan et al 1993).
Recently, medical physicists have exploited the fact that electrical
conductivity is much greater in lean tissues than in fat, and have built machines
that measure the bioelectrical impedance of the body; from this information the
lean:fat ratio can be derived. User-friendly versions of these machines have found
a place in sports medicine and nutrition/slimming clinics but are rarely if ever used
in clinical practice, partly because doctors do not appreciate that the technique is
entirely valid scientifically. I have evaluated the accuracy and ease of use of one
90
of these small, hand-held, menu driven, bioelectrical impedance analysis
machines. The present account also illustrates the useful information that this
simple instrument can provide on the body composition of adult patients with
gastro-intestinal or nutritional diseases.
7.2. Subjects and methods
7.2.1. Subjects
One hundred and fourteen subjects were recruited for a technical
comparison of various body composition measurement methods. Fifty-eight (2
males; 56 females) were healthy teenage volunteers(11-13 years;median 12 years)
taking part in an ongoing growth study based on DEXA and bioelectrical
impedance plethysmography. Measurement of bioelectrical impedance by the hand
held machine was added to the protocol. The remaining 56 subjects were adults.
They were: (a) 17 patients with eating disorders (all female; median age 26 years,
range 16-44 years; one grossly obese and 16 underweight); (b) 7 patients with
chronic pancreatitis (6 males, 1 female; median age 47 years, range 33-58 years).
These two groups were participating in ongoing studies of body composition based
on DEXA and in-house bioelectrical impedance plethysmography and
measurement by the hand-held machine was added to the protocol, (c) 14 healthy
volunteers (hospital staff) (5 males, 9 females; median age 32 years, range 20-43
years); (d) 18 patients with inflammatory bowel disease (IBD) (9 males, 9 females;
median age 34 years, range 21-64 years). Fourteen patients had Crohn's disease
(CD) (active disease in 3 patients) and 4 patients had ulcerative colitis (UC) (1 had
active disease).
7.2.2. Methods
The subjects were weighed and their height measured. LBM was measured
by two bioelectrical impedance machines and by DEXA. The details of the
machines and methods are described in chapter III. All measurements were made




Pearson's correlation coefficient was used to examine relationships
between the measurements by different methods. Comparison between LBM
measured by the DEXA method and in house bioelectrical analysis method was
also performed by the Bland and Altman method which plots the paired difference
between LBM measured by the two methods against the mean of these two
readings. The mean difference (d) provides an estimate of the bias, and the limits
of agreement is given by the interval d-2s to d+2s, where s is the standard
deviation of d (Bland and Altman 1986).
7.3. Results
Trained Medical Physics personnel are required to operate the DEXA and
the in-house bioelectrical impedance machine (RJL systems), and to calculate the
results. With DEXA, imaging time was typically 12 minutes and analysis time 14
minutes. Bioelectrical impedance analysis using the in-house machine typically
took about 10 minutes to perform and 10 minutes to analyse.
Doctors learned to use the hand-held, menu-driven machine after about 30
minutes reading of the instruction manual. The machine was easily operated by
nursing staff after 10 minutes of verbal instruction and demonstration. It typically
took 8 minutes to make the measurements; the machine displays the results
immediately. The coefficient of variation for repeated measurements of electrical
impedance was 0.4% when measured by the in-house bioelectrical impedance
analyser and 0.7% when measured by the hand-held machine.
7.3.1. Technical comparison of the in-house Vs hand-held bioelectrical
impedance analyser
In the entire series of 114 subjects, impedance results measured by the
hand-held machine correlated very closely with results from the in-house machine,
both resistance (r=0.996; p<0.0001; Figure 7.1), and impedance (r=0.996;
p<0.0001). The regression equations show that the two methods give virtually
identical results.
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7.3.2. Comparison of lean body mass measured by DEXA with results from
the hand-held bioelectrical impedance analyser
It is likely that the prediction equation for LBM from impedance will be
different in children and adults. As there are as yet no validated equations for
children, I confined comparison of calculated LBM to the data from adult subjects.
Figure 7.2 shows the lean body mass (kg) measured by DEXA plotted against that
measured by the hand-held machine in the 56 adult subjects. The two
measurements were significantly correlated (r=0.960; p<0.0001). The values were
virtually identical over the range of lean body mass - the regression equation was y
= 3.36 + 0.952x. This also held true for the individual patient groups (Healthy adult
volunteers r=0.970; patients with an eating disorder r=0.974; chronic pancreatitis
group r=0.979; IBD group r=0.937).
In the eating disorder patients, the prediction equation previously described
was also used to calculate the lean body mass directly from the impedance values
- this gave an r value of 0.959 against DEXA measurements. In IBD patients, the
prediction equation derived by Jeejeebhoy's group was also used to calculate the
lean body mass from impedance values - this gave an r value of 0.904 against
DEXA measurements.
The agreement between the two methods of measuring BMD was also
analysed by the Bland and Altman method. There was no correlation (r=0.1; p=NS)
between the difference and the mean of the paired observations. The bias was
2.6% and the limits of agreement -9.2% to 14.4%.
7.3.3. Relationship of BMI with body composition
BMI, which is an index of over- or under-weight, is, not unreasonably, often
also used to infer that patients are over- or under-nourished. I investigated the
relationship between BMI and body composition, using lean body mass expressed
as percentage lean (LBM X 100/body wt). For the whole group of 56 adult subjects,
BMI correlated weakly and inversely with percentage lean as measured using
DEXA (r=-0.573, p<0.0001) and using the hand-held machine (r=-238,p=NS).
There was a better correlation between BMI and lean body mass (kg)/height(m)2
measured using DEXA (r=0.862,p<0.0001) and using the hand-held machine
(r=0.857,p<0.0001). This is of course, identical to the relationship between lean
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Figure 7.1. Correlation between resistance measured by the in-house bioelectrical
impedance machine and impedance measured by the hand-held bioelectrical
impedance machine (n=114). The dotted line on either side of the regression line
represent 95% confidence intervals. Dashed vertical and horizontal lines of
equivalence are shown.
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Lean body mass (DEXA) Kg
Figure 7.2. Correlation between LBM in Kg measured by DEXA and the hand-held
bioelectrical impedance machine in the 56 adults. Dotted line on either side of the
regression line represents 95% confidence interval, dashed vertical and horizontal
lines of equivalence are shown.
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7.3.4. Information obtained from consideration of percentage lean in relation
to BMI
Table 7.1 shows the lean body mass, percent lean, BMI and body weight in
the groups of adult subjects. Percent fat can readily be calculated (i.e. 100 -
percent lean). Relationships between percent lean and BMI in males and females
are shown in figures 7.3 and 7.4. Those with BMI < 20 were classified as
underweight. The 5 healthy men had a BMI range of 23.2-26.5 and their percent fat
(i.e. 100-percent lean) ranged from 14.2-20.8. Seven of the 9 healthy women had a
BMI > 20 (range 21.3-27.6) and their percent fat ranged from 26.8 - 36.1. For these
similar BMI ranges, two-compartment body composition figures for men and
women are significantly different (p<0.01). Two healthy women had BMI < 20
(19.4,19.7) and their percent fat values were 24.1 and 29.1 respectively. Results
for the chronic pancreatitis patients show generally normal BMI values but a lower
proportion of lean than in the healthy subjects in the same BMI range. Three of the
9 men and four of the 9 women with IBD were underweight and five of these (two
men, three women) had lower percent fat than the normal men. In contrast, the
patients with IBD who had BMI > 20 had a similar percent fat to the normal
volunteers. This suggests that underweight IBD patients (none of whom was
acutely ill) were depleted of fat rather than lean. The percent fat in the 13
underweight eating disorder women had a much wider spread (11.2-41.3)
indicating that some had lost both fat and lean tissue. One of this group, with a BMI
of 11, 58.1% lean, 41.3% fat was clinically marasmic.
7.3.5. Monitoring of clinical progress in undernourished patients
Is"1 it 1 O
When severely undernourished patients receive intensive nutritional
support, progress is generally monitored by changes in body weight and in
biochemical parameters such as serum albumin. Analysis of body composition has
rarely been used, as most of these patients are very ill and methods such as
neutron activation analysis or DEXA are impractical. A portable, menu driven
machine can, however, be used in this situation, if fluid balance is stable and the
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patient is mobile enough to be weighed. Figure 7.5 presents data for a patient with
complicated CD.
Table 7.1. Lean Body Mass measured by the hand-held bioelectrical
impedance machine in different diagnostic groups.
Subject group (n) Lean Body %Lean Body Body mass Body weight
mass Kg. Mass. Mean index Kg/m2 Kg. Mean
Mean (SD, range) Mean (SD, (SD,range)
(SD, range) range)
Healthy adult volunteers
Men(n=5) 62.8 (7.2) 81.5 (2.9) 25.0 (1.5) 77.1 (8.1)
(54.4-69.1) (79.2-85.8) (23.2-26.6) (67.9-86.5)
Women(n=9) 41.9 (5.5) 69.52 (3.9) 23.3 (3.0) 60.5 (9.3)
(31.0-51.7) (63.9-75.9) (19.4-27.7) (43.7-79.0)
Women with eating
disorder
Undernourished (n=16) 37.2 (8.1) 76.5 (7.0) 17.6 (2.9) 48.3 (8.5)
(17.0-46.0) (58.6-88.8) (11.0-21.5) (29-59)
Overweight (n=1) 49.3 62.9 30.3 78.4
Chronic pancreatitis
Men(6) 57.2 (10.8) 74.0 (3.5) 25.5 (5.4) 77.5 (15.6)
(43.7-72.5) (70.7-80) (19.1-32.7) (57.8-101.3)
Woman(1) 38.1 65.8 21.5 57.9
IBD
Men(n=9) 55.4 (5.3) 84.6 (6.7) 22.7 (3.6) 66.6 (8.3)
(45.1-63.7) (78.9-90.3) (17.9-27.4) (54.0-78.8)
Women(n=9) 43.0(3.6) 73.8 (9.7) 21.7 (3.9) 59.3 (10.4)
(36.5-47.9) (60.0-90.9) (17.6-29.2) (48.2-77.5)
7.4. Conclusion
It is increasingly important that medical and nursing staff understand and
use the simple principles of anthropometry, including the two compartment model
of body composition. My experience shows that a portable bioelectrical impedance
machine can be introduced easily into clinical practice. At present there are no
standard population-based tables on the percent lean values related to age, sex,
stature, or body frame, but with a simple machine such as that which I have used,































Figure 7.3. Percent lean in different groups of adults plotted against their BMI in
male patients. BMI less than 20 is considered underweight. A horizontal line is













































Figure 7.4. Percent lean in different groups of adults plotted against their BMI in
female patients. BMI less than 20 is considered underweight. A horizontal line is
drawn through 75% lean for reference.
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BODY COMPOSITION IN PATIENTS WITH INFLAMMATORY
BOWEL DISEASE AND RELATIONSHIP TO BONE MINERAL
DENSITY
8.1 Introduction
Bone is part of the lean compartment as discussed in chapter II. Hence, it
was of interest to determine the relationship between bone mineral density (BMD)
and lean body mass in patients with Crohn's disease (CD) and ulcerative colitis
(UC). In other words, the aim was to investigate whether changes in body
composition occur in association with low BMD.
8.2. Patients and methods
Thirtythree patients with inflammatory bowel disease were recruited from
the outpatients clinic for both measurement of body composition and BMD
simultaneously. These patients were derived from cohorts already described in
chapters V and VI. Twenty-three of these patients had CD and 10 patients had UC.
The patient characteristics are shown in table 8.1.
Table 8.1. Patient characteristics
Crohn's disease Ulcerative colitis
n 23 10
Median age (range) 33 (22-71) 43 (22-61)
Sex M:F 13:10 3:7
Median disease duration 5 (0-21) years 4 (0-16) years
(range)
Median BMI (range) 21 (16-27) 23 (18-38)
Duration of steroid therapy 18 (0- 84) months 16 (0-76)
Spine and forearm Z-scores were compared with percent lean, so that both
male and female patients could be pooled together and compared. BMD and body
composition were measured by DEXA at the same time. The details of the methods
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are given in chapter III. Accurate height and weight were recorded and body mass
index (BMI) was calculated.
8.2.1. Statistical analysis
Student's t-test and Pearson's correlation test were used for statistical
analysis.
8.2.2. Ethical considerations
The study was approved by the Medicine Subcommittee of the Lothian Area
Ethics of Research Committee. Each patient gave informed verbal consent.
8.3. Results
Figures 8.1 and 8.2 show the BMI and percent lean of patients with CD and
UC separated by sex. As is anticipated, male IBD patients had a significantly higher
percent lean (mean 83.0; SD 5.8) compared with female IBD patients (mean 70.7;
SD 6.7; p<0.0001). For both male and female patients, the percent lean increases
(i.e. the fat percent falls) as the BMIs decrease. Table 8.2 shows the percent lean
results for CD and UC patients by sex.
Table 8.2. Percent lean in male and female IBD patients by sex.
Mean percent lean SD Range P
Male
Crohn's disease 81.1 6.4 70.9 - 88.8
(n=l3)




Crohn's disease 72.1 5.5 63.1 - 78.9
(n=10)
Ulcerative colitis 67.7 7.7 55.1 - 78.5
NS
(n=7)
Figures 8.3 and 8.4 show spine and forearm BMD Z-scores plotted against
percent lean in patients with CD. There is a significant inverse correlation of spine
(r=-0.59, p=0.003) and forearm (r=-0.44, p<0.05) Z-scores with percent lean. In
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Figure 8.1. Body mass index (BMI) Vs percent lean in male IBD patients. BMI < 20
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Figure 8.2. Body mass index (BMI) Vs percent lean in female IBD patients. BMI <
20 is considered underweight and, all but one underweight patients suffered from
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Figure 8.6. Forearm Z-scores plotted against percent lean in patients with
Ulcerative colitis.
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percent lean, and hence decreased percent fat. There was no correlation of either
spine (r=0.09, p=NS) or forearm (r=0.08, p=NS) Z-scores with the BMI.
Figures 8.5 and 8.6 show spine and forearm BMD Z-scores plotted against
percent lean in patients with UC. In contrast to CD, there is no correlation of spine
(r=-0.1, p=NS) or forearm (r=0.31, p=NS) Z-scores with percent lean.
8.4. Conclusion
In CD, but not in UC, BMD is inversely related to percent lean, i.e., depletion




BONE MINERAL DENSITY AND GROWTH IN ADOLESCENTS
WITH LONGSTANDING INFLAMMATORY BOWEL DISEASE - A
SPECIALLY VULNERABLE GROUP
9.1. Introduction
Growth failure and developmental delay are common in children with
inflammatory bowel disease (IBD) and should be monitored closely (Kirschner et al
1990, Barton et al 1990, Mock et al 1986). However, data on growth and nutrition in
adolescents tend to be from tertiary care centres caring for complicated, difficult
disease (Motil et al 1993, Hildebrand et al 1994, Kirschner 1993) and data from
unselected patients from the community are lacking. The Scottish Hospitals'
Inpatient Statistics provides a unique epidemiological database which records and
links data on all patients admitted to NHS hospitals in Scotland (Kendrick et al
1993). Previous work reported serious under-recording of growth and development
parameters in a geographically derived cohort of Scottish children with IBD
diagnosed during 1968-83 (Barton et al 1989a). It is not known whether these
parameters have been better monitored recently.
It should be noted that, though there is a large amount of data on growth
and nutrition in adolescents with IBD, similar data on bone mineralisation are
lacking. Genant et al (1976) reported that adolescents were particularly severely
affected with osteopenia and growth retardation.
The investigation of adolescents in this thesis involved two separate
projects.
1. Investigation of bone mineralisation in adolescents with IBD seen at the Western
General Hospital, Edinburgh (i.e. a tertiary referral centre) - to test the
hypothesis that they have more severe osteopenia than adults for a given
disease duration.
2. An audit of monitoring of growth and development parameters in a
geographically defined cohort of Scottish children with IBD and investigation of
their morbidity in terms of growth and developmental delay.
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9.2. Bone mineral density in adolescents with IBD
I aimed to investigate the effect of IBD on bone mineralisation in
adolescents and compare it with that in adults.
9.2.1.Patients:
Spine bone mineral density (BMD) was measured in 5 male and 4 female
patients with juvenile -onset Crohn's disease (CD). The median age was 15 years
(range 11-19 years). The median duration of disease from the onset of symptoms
was 5 years (range 2-13 years). The median duration of corticosteroid use was 17
months. The details of these patients are given in table 9.1. These patients were all
complicated, needed prolonged corticosteroid and in 5 patients, immuno¬
suppressive therapy with azathioprine, and all but one patient (with orogenital CD)
had one or more operations, with resectional surgery. Forearm Z-scores were not
calculated in these patients as I lacked a suitable age- and sex- matched control
population database.
The spine BMD was also measured in 3 adolescents (2 male, 1 female) with
ulcerative colitis (UC). They were aged 11, 13 and 16 years. No statistical
comparisons were made either with adults with UC or with children with CD,
because of small numbers.
Table 9.1. Patient details - adolescents with IBD
CD
Malc:Femalc 5:4
Median age (range) years 15 (11-19)
Median duration (years) 5 (2-13)






Age (years) 11, 13, 16
Disease duration (years) 4, 5,6




Spine BMD was measured by DEXA as mentioned in chapter III. The results
were expressed as Z-scores compared with chronological age-sex matched
adolescents. Plasma calcium, phosphate (non-fasting), alkaline phosphatase,
albumin and 25-OH-vitamin D levels were measured. Radiological bone age was
determined in all patients by an experienced radiologist using the Greulich and
Pyle reference atlas.
Statistical comparisons were made using the Student's t-test. Correlation of
the duration of disease with BMD was made by Pearson's correlation coefficient.
The study was approved by the Medicine Subcommittee of the Lothian Area Ethics
of Research Committee. Each patient gave informed verbal consent.
9.2.3. Results
The confounding variables that need to be considered in children in
interpreting BMD are different from that in the adults. Since calculation of a Z-score
depends on a age-sex matched population, delay in growth may affect the
apparent Z-score value quite profoundly. Sex hormones have an important role in
bone metabolism, and hence a delay in puberty too may affect BMD. The effect of
illness on physical activity can be more marked in children than in adults, as their
premorbid physical activity is often high.
Two out of the 9 adolescents with CD had clinically severe osteopenia with
multiple vertebral collapses (figure 9.1 and 9.2) and back pain needing analgesia.
Both were vitamin D deficient and both had particularly complicated, longstanding
disease which had needed multiple surgical interventions, prolonged steroid and
immunosuppressive therapy and prolonged hospitalisations. At the time of bone
density measurements the CDAI scores for these patients were 126 and 92. One of
these patients had a bone biopsy at the same time as having a colonic resection;
this showed features of osteomalacia in spite of the fact that the patient was on
oral vitamin D and calcium supplements.
Figure 9.3 shows the spine Z-scores for bone mineral density in
adolescents with longstanding CD. The spine Z-scores for adult patients with
longstanding CD discussed in chapter V are also shown for comparison. The mean
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spine Z-score in adolescents was -3.1 (SD 1.5) and this was significantly lower
(p<0.01) than that in the adults (mean -1.1; SD 1.0). It is noteworthy that the two
lowest Z-scores in adults were in men with longstanding disease commencing in
their teens. There is a significant correlation between duration of disease in years
and the spine Z-scores in adolescents with CD (r = -0.76; p<0.02; figure 9.4).
Figure 9.5 shows the spine Z-scores in the 3 adolescents with UC. The
spine Z-scores in adults with longstanding UC discussed in chapter V are also
shown. The duration of disease from symptom onset was 5, 6 and 6 years.
Though no statistical comparisons were possible in this group, the mean spine Z-
score of the 12 adolescents with IBD (-2.9; SD 1.4) was significantly less compared
with that in the 27 adult patients with longstanding IBD discussed in chapter V
(mean = -1.1; SD 0.8; p < 0.001).
The biochemical parameters of calcium metabolism and radiological bone
age for each patient are shown in table 9.2.
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Figure 9.1. Multiple vertebral collapses in a 18-year-old boy with long-standing
complicated Crohn's disease. He was vitamin D deficient and had multiple surgical
interventions, total proctocolectomy and received prolonged steroid and
immunosuppressive therapy. He had lost 2 cm in height and had severe back pain.
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Figure 9.2. Lateral spine radiograph of the boy with Crohn's disease illustrated in































Figure 9.3. Spine BMD Z-scores in adolescents with long-standing Crohn's disease
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Figure 9.4. Correlation between duration of disease in years and spine BMD Z-























Figure 9.5. Spine BMD Z-scores in adolescents with long-standing ulcerative colitis
compared with that in adults.
118
Table 9.2. Plasma calcium and 25-OH-vit D concentrations and radiological
bone ages in adolescents with IBD.
Patient Chrono¬ Sex Diagnosis Plasma Plasma 25- Radio¬
logical age Ca++(2.1- OH-vitD logical
2.6 (15-100 bone age
mmoI/L)vF nmol/L) (years)
RS* 15 M CD 2.45 45 13
MM* 11 F CD 2.26 32 11
LF 13 F CD 2.34 36 12
DF 16 M CD 2.20 10 14
ST 19 M CD 2.36 44 adult
JF 14 M CD 2.40 48 13
CC 18 M CD 2.24 8 adult
MD 16 F CD 2.44 28 16
CS* 13 F CD 2.32 34 12
FE 13 F UC 2.42 48 12
PR 16 M UC 2.30 36 15
CM*# 11 M UC 2.24 24 11
* pre-pubertal; # primary sclerosing cholangitis; VF note change in normal range compared with that
in chapter IV.
9.3. Growth and development parameters in juvenile onset IBD
I aimed to determine whether the records of monitoring of growth and
development parameters in Scottish NHS hospitals had improved in a more
recently diagnosed geographically derived cohort compared with the earlier cohort
diagnosed during 1968-83 which was audited by my predecessors. I then
investigated the morbidity in terms of growth and developmental delay in this
cohort of juvenile onset IBD.
9.3.1. Patients and methods:
Children who had a diagnosis of IBD (UC or CD) and were aged 16 years or
less at first admission to a NHS hospital in Scotland were included in this study.
The previously reported cohort (Barton et al 1990) consisted of 105 children (56
boys and 49 girls), 68 with CD and 37 with UC, who were first admitted between
1968-83. The more recently diagnosed cohort consisted of 41 children (28 boys
and 13 girls), 27 with CD and 14 with UC, who were first admitted to NHS hospitals
between 1984-88. The inclusion criteria are summarised below:
1. A diagnosis of UC or CD.
2. Age at 1st admission < 17 years.
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3. First admission: 1968-83 or 1984-88.
4. Geographically defined cohort:
1968-83-Lothian, Highland, 10% of rest of Scotland who fulfilled
inclusion criteria,
1984-88-Lothian, Highland, Borders, Fife.
The patients were identified by searching the SHIPS database. Permission
was obtained from the consultants caring for the identified patients and case
records were obtained from Medical Records department. The case records were
scrutinised to confirm the diagnosis and note records of height, weight, radiological
bone age and sexual development. Any mention of sexual development was noted
though this was often descriptive and not systematically staged. The specialties of
the patients' consultants were also noted. A detailed record of date of onset of
symptoms, date of diagnosis, surgical interventions, medical therapy, periods of
hospitalisations and outpatient visits and all height and weight measurements were
entered into a database. The patients were then invited to attend for a structured
interview and physical examination. The clinical details of the 1968-83 and 1984-88
cohorts are shown in table 9.3a. Analysis of the 1968-83 cohort was done at a
mean of 7 years follow-up, which was the same as the 1984-88 cohort.
The results were analysed using the chi-squared test with Yates' correction.
Table 9.3a. Clinical details of the two cohorts
1968-83 1984-88
CD uc CD UC
n 68 37 27 14
M:F 34:34 22:15 21:6 7:7
Age (yrs) at the








in diagnosis 4.8 (0-42) 2 (0-61) 3.7 (0-31) 3 (0-10)
(range) months
Disease Small bowel:21 Pancolitis:17 Small bowel:12 Pancolitis:8 Left
anatomy lleocolonic:26 Left sided: 10 lleocolonic:5 sided:6
Colonic:19 Rectum:10 Colonic:10 Rectum:0
Others:2
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I carried out a structured interview and physical examination of 35 out of the
41 patients in the 1984-88 cohort; the remaining patients had moved addresses
and could not be contacted. The clinical details of those interviewed are given in
table 9.3b. Height and weight were measured in all patients and radiological bone
age was determined in all patients aged 16 years or less and also in patients where
a growth delay was suspected. Patients were asked about their parents' heights (or
the parents were asked, if present at interview). Mid-parental height centile, an
indicator of adult stature, was calculated from father's and mother's height. For
boys, his father's height (cm) and his mother's height + 12.5 cm were plotted on a
standard nomogram. For girls, her mother's height (cm) and her father's height -
12.5 cm were plotted on a standard nomogram. The height midway between these
two points was read from the nomogram and the mid-parental height centile range
equals ± 8.5cm of this height.
Table 9.3b. Clinical details of the patients from the 1984-88 cohort who
attended the interview anc physical examination.
CD (n=23) UC (n=12)
Male: female 18:5 5:7
Median age at interview
(range)
male 21 (11-24)yr 21 (17-23)yr
female 17 (16-20)yr 17 (7-23)yr
Disease distribution Small bowel: n=9 Pancolitis: n=7
lleocolonic: n=4 Distal colitis: n=5
Colonic: n=10
Active disease at interview 6 2
(CDAI>150)
Median follow-up from
onset to interview (range)
male 7 (5-11)yr 9 (6-10)yr
female 6 (5-6)yr 6 (5-7)yr
Non-attenders: CD - 4 patients (3 male, 1 female); similar disease distribution and
morbidity as the interviewed group. UC - 2 patients (both male); 1 patient had mild
distal colitis, the other had panproctocolectomy and ileostomy.
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9.3.2. Results of the audit in the two cohorts
9.3.2.1. Monitoring of growth and development
Height and weight records were considered to be completely unsatisfactory
when no records or only one record was available at the time of scrutiny of the
case notes. The frequency of growth and development records in the two cohorts
is presented in table 9.4. In the 1968-83 cohort, 57 of 105 patients (53%) had
completely unsatisfactory height records - it was never recorded in 36 and recorded
once in 21 patients. In the 1984-88 cohort, only 6 of 41 patients (15%) had
completely unsatisfactory height records (never recorded = 5, recorded once = 1) -
a significant improvement (p<0.001). The median number of height records in CD
disease had significantly improved (p<0.02) from 1 (range 0-14) in the 1968-83
cohort to 12 (range 0-37) in the 1984-88 cohort. The corresponding data for UC
was 1 (range 0-18) and 17 (0-56) (p<0.02). Weight records were completely
unsatisfactory in 13 of the 105 (12%) in the 1968-83 cohort (never recorded = 9,
recorded once = 4); however, ail patients in the 1984-88 cohort had weight
recorded at least thrice (p<0.05). The median number of weight records in CD and
UC was 5 (range 0-15) and 5 (0-42) in the 1968-83 cohort and 23 (range 3-41) and
22 (range 3-56) in the 1984-88 cohort (p<0.05).
Radiological bone age was determined in 19 out of 105 patients (18%) in
the 1968-83 cohort, but in 17 out of 41 (41%) in the 1984-88 cohort (p<0.01).
Sexual development was recorded in 29 of the 105 patients (28%) in the 1968-83
cohort and in 22 of the 38 (3 children were excluded as they were still prepubertal
at review) patients (58%) in the 1984-88 cohort (p<0.01). However, mention of
sexual development was frequently only descriptive and not systematically staged.
In both the 1968-83 and 1984-88 cohort, documentation of growth and
development parameters were similar for rural and urban regions and for teaching
and district hospitals. In the 1984-88 cohort, a total of 407 outpatient clinic visits for
the 27 patients with CD were scrutinised - each patient was seen a median of 55%
of visits by a consultant (range 0-100%). The 14 UC patients needed a total of 282
outpatient clinic visits - each patient was seen a median of 66% of visits by a
consultant (range 38%-94%).
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Table 9.4. Comparison of growth and development records in the two cohorts
of children with inflammatory bowel disease.
Records 1968-83 1984-88











































24(35%) 5(14%) 17*(65%) 5(42%)
*p<0.05; **p<0.02
9.3.2.2. Growth parameters in the two cohorts at diagnosis
Table 9.5 shows the frequency of height retardation at diagnosis in the two
cohorts, where this data had been recorded in the case notes. There was no
statistically significant difference between the two cohorts, either for male or for
female patients. Height retardation was a feature of CD but not of UC. In the two
cohorts, 14 out of the 61 patients with CD were below the 3rd centile in height,
whereas only 1 out of 26 patients with UC was below the 3rd centile in height
(p<0.05).
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Table 9.5. Frequency of low height at diagnosis:
1968-83 1984-88
CD UC CD UC
(n=68) (n=37) (n=27) (n=14)
< 3rd centile
Male 6/19 (32%) 0/10 3/16 (19%) 0/4
Female 5/21 (24%) 1/5 (20%) 0/5 0/7
3-50th centile
Male 4/19 (21%) 7/10 (70%) 11/16 (69%) 2/4 (50%)
Female 16/21 (76%) 2/5 (40%) 4/5 (80%) 4/7 (57%)
Table 9.6 shows the frequency of low weight at diagnosis in the two
cohorts. Again there was no significant difference in frequency between the two
cohorts. Fortyfour out of the 81 patients in the two cohorts with CD where records
were available were below the 3rd centile in weight, while only 1 out of 41 patients
with UC was below 3rd centile in weight (p<0.001). Females with CD were
underweight significantly more frequently than males (p<0.01). Hence, height and
weight retardation at diagnosis is a feature of CD but not UC. It may be noted from
table 9.3a that the delay in diagnosis (symptom onset to diagnosis) had not
changed in the more recently diagnosed cohort.
Table 9.6. Frequency of low weight at diagnosis
1968-83 1984-88
CD UC CD UC
(n=68) (n=37) (n=27) (n=14)
<3rd centile
Male 11/28 0/17 8/19 0/5
(39%) (42%)
Female 21/28 0/12 4/6 1/7
(75%) (67%) (14%)
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It is interesting that there was no significant improvement in the frequency
of height and weight retardation at diagnosis in the 1984-88 cohort compared to
the 1968-83 cohort, because there were other aspects of morbidity which showed
evidence of improvement in the 1984-88 cohort compared with the 1968-83 cohort.
These are shown in tables 9.7- 9.10. There was a significant reduction in the
number of patients with CD having resectional surgery or laparotomy in the more
recently diagnosed cohort (table 9.7). There was also a significant reduction in the
inpatient hospital stay for patients with CD in the more recently diagnosed cohort
(table 9.8), though the number of admissions were unchanged. All deaths occurred
prior to 1978. The results would indicate that though there was no change in
morbidity in growth and development at diagnosis, better medical management in
the more recently diagnosed cohort led to shorter hospital stay and fewer surgical
resections in CD. It may be seen from table 9.10 that juvenile onset CD patients
were more frequently treated with systemic steroids, azathioprine and enteral




CD UC CD UC
(n=68) (n=37) (n=27) (n=14)
No. having 49 (72%) 11 (30%) 13* (48%) 3 (21%)
major surgery
No. having gut 39 (57%) 8 (22%) 11** (41%) 3 (21%)
resection
No. with 10 (15%) 8 (22%) 1 (4%) 1 (7%)
perm, stoma
Ileoanal pouch 0 0 0 2 (14%)
*p<0.05; **p<0.01
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No of deaths 5* 1* 0 0
*AII deaths occurred in the early part of the study period before 1978.
Table 9.10. Medical therapy
Treatment 1968-83 1984-88
CD UC CD UC
(n=68) (n=37) (n=27) (n=14)
Steroids
Systemic 48(71%) 21(57%) 25(93%)* 12(86%)
Local 15(22%) 22(59%) 6(22%) 12(86%)
none 5(7%) 6(16%) 2(7%) 1 (7%)
SZP 49(72%) 33(89%) 19(70%) 11(79%)
Other 0 0 12(44%) 3(21%)
5ASA
Azathioprine 10(15%) 2(5%) 12(44%)** 3(21%)
Metronidazole 7(10%) 1 (3%) 5(19%) 0
Cyclosporin 0 0 1 (37%) 0
Enteral 11(16%) 1 (3%) 12(44%)** 1 (7%)
nutrition
*p<0.05; **p<0.02
9.3.2.3. Growth parameters at the time of interview
Height and weight were measured in the 35 out of the 41 patients who
attended for interview. The heights of the patients were indexed against the
calculated mid-parental height centile, an indicator of adult stature obtained from a
standard nomogram. Mid-parental height centiles could be calculated in 33 out of
the 35 patients. The results are shown in table 9.11.
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Table 9.11. Patients' height compared with the mid-parental height centile
range
Crohn's disease Ulcerative colitis
No. below mid-parental
centile range
male 5*/16 (31%) 0/5





* three patients less than 16 years old and one 17 years old but still growing.
** two patients still growing.
a aged 7 and 10 years.
a one patient still growing.
Table 9.12 shows the percent ideal body weight of the 1984-88 cohort of
juvenile-onset IBD patients at the time of interview. Six patients with CD and two
with UC had active disease at interview (table 9.3b) and the percent ideal body
weights of these patients are compared with those with inactive disease in figure
9.6. The median percent ideal body weight of the patients with active disease (n=8;
79%; range 59-113%) was significantly lower (p<0.01; Mann-Whitney U- test) than






















Juvenile-onset IBD patients at interview (1984-88 cohort)
Figure 9.6. Comparison of the percent ideal body weights of those with active
juvenile-onset IBD with those with inactive disease.
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Table 9.12. Percent ideal body weight (median & range) of the patients
interviewed. One female patient with ulcerative colitis was pregnant at the time
of interview and her data is not included.
Crohn's disease ulcerative colitis
Male (n=23) 86 (59- 114) 97 (93- 159)
Female (n=11) 90 (70- 116) 90 (73- 112)
Table 9.13 shows the radiological bone ages and chronological bone ages
in the 6 patients less than 16 years old at interview, and in the 3 patients older than
16 years where growth delay was suspected. Four out of the 6 patients with CD
and one out of 3 patients with ulcerative colitis had growth delay.






CD M 14.7 14
CD M 11.3 11
CD F 15.6 13
UC F 7 7
UC F 10 10
UC F 14.9 13
CD M 16.1 12
CD M 17.3 16
CD M 17.2 14
9.4. Conclusions
Adolescents with chronic IBD referred to a tertiary centre are more severely
osteopenic than adults with a similar duration of disease at the same tertiary
centre. The growing bones probably suffer the brunt of the osteopenic effects of
disease and treatment. Serious vertebral collapse and loss of height may occur.
The bone mineral density is inversely correlated with duration of disease.
Significant improvements in recording growth and development parameters
had taken place in the 1984-88 cohort compared to the 1968-83 cohort. Our
previous report of the deficiencies in recording these parameters was published in
1989 and hence the improvement in the 1984-88 cohort cannot be ascribed to the
greater awareness resulting from this publication - the frequency of recording these
parameters was not greater after 1989 compared to that prior to 1989 for the 1984-
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88 cohort. Deficiencies were however still present in recording height, sexual
development and bone age. Greater awareness of this aspect of morbidity of
inflammatory bowel disease in children is needed.
Height and weight retardation at diagnosis were features of juvenile onset
CD but not UC. The frequency of height and weight retardation at diagnosis had
not changed in the more recently diagnosed cohort, though other aspects of
morbidity, such as the frequency of surgical resections and inpatient stay in
hospital had improved, probably as a result of better medical management.





DISCUSSION : BONE MINERAL DENSITY AND BODY
COMPOSITION IN INFLAMMATORY BOWEL DISEASE
In this chapter I have discussed the results presented in chapters IV - IX.
Discussion of bone mineral density (BMD) in IBD is followed by discussion of body
composition in adults and analysis of data specifically relevant to children.
10.1. Bone mineral density in newly diagnosed IBD
I have not only confirmed many other reports of low bone mineralisation in
IBD but have clearly shown that at the time of diagnosis this is a feature of Crohn's
disease (CD) but not ulcerative colitis (UC). The two groups of patients were well
matched with regard to age, sex, severity and estimated duration of disease prior
to diagnosis. The lower BMD in patients with CD applies equally to trabecular bone
comprising 50% of the lumbar spine (Newton et al 1993) and to cortical bone found
in the forearm, and the degree of bone demineralisation is not correlated with CDAI
or the BMI. Though physical activity was reduced at the time of diagnosis
compared with usual activity levels, the grades of activity were similar for UC and
CD patients. Malabsorption is unlikely to be a major factor in the aetiology of bone
loss as patients with colonic disease had bone densities similar to those with small
bowel involvement. This is further supported by the fact that bone metabolic
parameters were normal and there were no differences between patient groups.
However, calcium or vitamin D deficiency may exist in spite of normal biochemistry
and bone histology would be needed to definitely exclude this possibility.
In view of the small numbers involved, the lack of difference in BMD
Z-scores between small bowel and colonic CD, and between smokers and
nonsmokers must be interpreted with caution as type 2 errors cannot be excluded.
Further studies with larger number of patients are needed before firm conclusions
may be reached. Only 1 UC patient was an ex-smoker. She had stopped smoking
3 years prior to presentation after smoking for 5 years. Her spine Z-score was -0.5
and forearm Z-score 0.1. Excluding her from the nonsmoker group did not alter the
statistical lack of significance between smokers and nonsmokers.
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The results of this study underline the fact that CD and UC are different
diseases. CD is a systemic disease with a long pre-morbid phase, while UC is a
mucosal disease with an acute onset. It had been shown previously in a study of
Scottish children with IBD that 11 out of 40 young children with CD were below the
third centile for height while none out of the 14 children with UC was below the third
centile for height (Barton et al 1990).
Maintenance of BMD should not be equated with the important issue of
linear growth in growing children. The effect of IBD and its treatment on growth in
children has been studied by various workers including my predecessor (Barton et
al 1990). The present study is predominantly on an adult population and
extrapolation to growing children should be done with caution. Interpretation of
BMD in adolescents need additional considerations. Adolescents going through
puberty at different ages may be an important confounding factor in interpreting
serial BMD measurements, particularly if the patients are going through puberty at
different ages from the control adolescents. In this study, however, only 4 patients
(2 CD, 2 UC) were going through puberty and only 1 patient with CD had delayed
puberty. All the remaining patients were sexually mature adults. The patient with
CD and delayed puberty was a 14-year-old boy with spine Z-score of -1.5 at
diagnosis and -1.8 after 1 year. Delay in growth may be a confounding variable if
comparison is made with adolescents with normal growth. In this study only the 14-
year-old boy referred to above had a bone age less than chronological age with
height on the 3rd centile and recalculation of his Z-score using bone age did not
alter the significance level of the difference between CD and UC in spine Z-scores.
Since forearm Z-scores were only available in adults aged 20 or over, these results
do not suffer from the confounding influence of growth and sexual development.
Despite the fact that 20 of 23 patients received systemic corticosteroid therapy, at
1-yr follow-up there was no evidence of any further bone loss either in CD or in UC.
As a result of treatment, only 2 patients overall (1 CD, 1 UC) had continuing active
disease after 1 year - other series who report continuing loss of bone during follow
up have not been so successful in treating their patients.
Several studies have confirmed that osteopenia in patients with IBD is
unassociated with calcium homeostasis defects (Compston et al 1987, Stallmach et
al 1988, Motley et al 1988, Bernstein et al 1993, Bjarnason et al 1993). Two recent
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studies reported as abstracts have recorded greater prevalence of osteopenia in
CD compared with UC (Tromm et al 1993, Bernstein et al 1993). The two studies
however identify ileal involvement and greater steroid use respectively as the
factors responsible for the difference from UC. None of these factors appeared to
be relevant in this study.
The study failed to confirm the rapid bone loss reported previously (Motley
et al 1988) in some patients with IBD. In my series of patients, therapy generally
resulted in remission of activity of the disease with no further bone loss; indeed, a
slight increase in Z-scores occurred in some patients. Studies that have randomly
recruited patients from follow-up outpatient clinic for bone density studies are likely
to be biased towards patients with complicated long-standing disease as they are
likely to attend more frequently. However, I reiterate that my follow-up period is
only 1 year and the conclusions should not be extrapolated to patients on more
prolonged steroid therapy.
The mechanism of osteopenia in CD is unclear. The possibility that there is
a primary disorder of osteogenesis so that bone formation is less than normal
cannot be excluded. Abnormality of the mononuclear phagocytic system resulting
in excessive resorption by osteoclasts or mediators from the inflamed gut triggering
osteoclast activity are other possibilities which need investigation. Bone resorption
is mediated by the unique multinucleated bone cell, the osteoclast, the formation
and activity of which is regulated by a family of cytokines (Raisz et al 1988). The
cytokines that regulate osteoclast function include IL-1, IL-6, TNF-a, TGF-a, y
interferon, IL-1 receptor antagonist and IL-4 (MacDonald et al 1992). Various
cytokine abnormalities have been described in CD (Mazlam et al 1992, Fais et al
1991) and differences from UC have been highlighted. Further studies are needed
to elucidate the interaction of osteoclasts and cytokines in CD.
The findings in this study may have important clinical implications. It is likely
that control of disease activity with appropriate therapy may actually improve bone
mineralisation which may counterbalance the known osteopenic effects of steroid
therapy. Effects of other interventions such as regular exercise, calcium and
vitamin D supplementation to offset gut losses and hormone replacement therapy
in postmenopausal women need to be examined. Though small numbers make it
impossible to analyse the effects of secondary amenorrhoea and hormone
replacement therapy, the results show that it is not a confounding factor in
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explaining the difference between CD and UC. A recent study has reported
prevention of bone loss in postmenopausal women by hormone replacement
therapy (Clements et al 1993). In order to assess results of interventions it is
important to identify cases with intrinsic low bone mineralisation and those at risk of
accelerated bone loss.
10.2. Bone mineral density in longstanding IBD
It was important to explain why other published studies did not find any
difference in BMD between CD and UC. The results in patients with long-standing
IBD provide an explanation. Previous studies (Clements et al 1992, Compston et al
1987, Pigot et al 1992, Bernstein et al 1995) had recruited unselected patients from
those attending a tertiary referral centre. Such cohorts may be biased towards
long-standing complicated disease and indeed, the average duration of disease in
the published series ranged from 5 to 10 years. I deliberately recruited a cohort
with long-standing disease - median disease duration of 8 years for CD and 7
years for UC. All patients had inactive disease to further avoid the direct effect of
disease as shown in my study on newly diagnosed patients.
The results show that there was no difference in mean BMD between CD
and UC. The two groups of patients were well matched in the confounding
variables, such as duration and cumulative dose of steroids and in the grade of
physical activity. In CD, it was interesting to note that the mean Z-score in the
patients with long-standing disease was almost identical to that in the newly
diagnosed cohort at diagnosis and after one year of follow up. The mean Z-scores
reported by other groups were also very similar. This is illustrated in figure 10.1.
The usual biochemical parameters of calcium homeostasis were normal and this
was the experience of all previously published studies which had measured these
parameters (Compston et al 1987, Pigot et al 1992, Motley et al 1988, Abitbol et al
1995).
In UC, disease duration and spine and forearm Z-scores were significantly
correlated inversely. A similar inverse correlation could be demonstrated between
cumulative steroid dose and BMD Z-scores. In contrast, in CD disease, no such
correlation could be found between BMD and duration of disease or with
cumulative steroid dose. This would indicate that duration of disease and
cumulative steroid dose are important determinants of osteopenia in UC. In CD, the
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1=CD (Pigot 1992)
2=IBD (Abitbol 1995) no steroids
3=UC (Pigot 1992)
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10.1. Average duration of disease (mean or median) and mean spine Z-scores in
IBD reported by different authors, including my study, on long-standing IBD
(chapter V). The mean spine Z-scores were not related to disease duration, but all
studied patients with long-standing disease.
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situation is more complicated - osteopenia caused by the disease itself is
counterbalanced by effective treatment with steroids which itself induces some
bone loss.
10.3. Mechanism of osteoporosis in patients with IBD
Results of bone turnover markers were available only from a small number
of patients with newly diagnosed IBD prior to treatment and I am cautious in
drawing any firm conclusions. Urinary pyridinium crosslinks excretion, a marker of
bone resorption was increased in some patients with CD, but in none with UC.
Plasma osteocalcin and bone alkaline phosphatase, bone formation markers, were
close to normal levels in all patients. The results contradict the finding of low serum
osteocalcin concentration in IBD reported by Abitbol et al 1995. It must be noted
that more than half of the patients studied by this French group had received
steroid therapy which decreases serum osteocalcin level (Reid et al 1986). In
contrast, Bjarnason et al 1994 showed normal osteoblast markers and increased
osteoclast markers in IBD. Increased bone resorption in some newly diagnosed CD
patients prior to institution of therapy found by me would support the hypothesis of
cytokine-induced activation of osteoclasts, as detected in vitro (Bertolini et al 1986).
However, as discussed later in chapter XVI, gut production of pro-inflammatory
cytokines such as IL-ip and IL-6 studied by the technique of whole gut lavage fluid
analysis showed no difference between CD and UC.
In this study, it could not be established that the changes in BMD found in
this study are related to systemic inflammation. No correlation was found between
CDAI and BMD Z-scores and other indices of systemic inflammation such as CRP,
platelet count and white cell count did not correlate with BMD Z-scores. Serum IL-6
was not measured in this study.
10.4. Statistical considerations
The number of IBD patients in the BMD studies mentioned above are small,
and the findings are prone to type II error. However, combining the newly
diagnosed patients in chapter IV and chapter VI gives 21 CD and 19 UC patients.
This gives 80% power to detect a significant difference in Z-scores at p=0.05 level.
In chapter V, the number of patients with long-standing IBD is too small to exclude
136
a type II error with confidence. However, further experience with much larger
number of patients with long-standing IBD (manuscript submitted for submission)
supports the lack of difference between CD and UC. As a consequence of the
small numbers, multiple discriminant analysis of the relevant factors affecting BMD
(such as smoking, menstrual status, oral contraceptive pills) did not provide
meaningful results. Data on these factors are however provided to establish the
fact that CD and UC patients were well matched as to these confounding
variables.
10.5. Methods of assessing body composition
The ideal instrument for assessment of body composition in patients should
yield accurate and reproducible results, be inexpensive, portable, easy to operate
and to interpret the readings, safe for the patient, should not involve irradiation,
and repeated measurements should be possible. None of the available methods
fulfill all, or even most, of these criteria and clearly this explains the limited use of
body composition data in clinical practice. Furthermore, there are no accurate
reference data for the general population on the Iean:fat ratio, analogous to the
regularly updated information which is collected on height, weight and BMI, related
to age, sex, UK region and social class.
The lightweight, portable hand-held bioelectrical impedance analyser used
in the present study proved to be a very satisfactory instrument for measuring body
composition. The evaluation against two standard instruments currently used for
such studies by medical physicists showed that the three gave virtually identical
values for lean body mass in normally nourished and undernourished adults. The
Bland and Altman method showed satisfactory agreement in LBM measurements
between DEXA and the hand held machine with a bias of 2.6%. However, the limits
of agreement can be -9% to 14%. Since the hand-held and in-house machines
gave identical readings of bioelectrical impedance, the portable instrument should
also be satisfactory for the assessment of lean and fat in children, once prediction
equations appropriate to this age group have been developed.
Non-medical staff could be taught to use the machine in a few minutes, the
program is driven by a simple menu and the results could be directly read out and
stored without the need for additional software or access to a computer. If further
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studies in larger clinical groups support our current findings, this type of instrument
is likely to have wide applications in medical practice and could also be used to
collect reference population data. Since the patient has to be weighed in order to
calculate lean body mass, some degree of mobility is necessary.
Apart from macerating a corpse (which has been done!), every technique
for measuring body composition has theoretical problems and will be unsuitable for
certain groups of patients. In studies of obesity, quite different criteria are used to
select an appropriate method, than will be used for research in starvation,
malabsorption or IBD. Studies in my institution which involved comparisons with
prompt neutron activation analysis (PNAA) and total body water (TBW)
determination using tritiated water have shown that DEXA is a reproducible and
accurate method of estimating lean body mass (Hannan et al 1994). I now report
that lean body mass values, derived from impedance measurements made with a
hand-held instrument (costing £400) were almost identical to that measured by
DEXA (using a machine which cost £80,000 six years ago), both in healthy and
diseased subjects. Use of prediction equations derived for specific disease groups
(i.e. eating disorder, IBD) instead of the manufacturer's built-in equation for the
hand-held machine, actually worsened the correlation with values obtained by
DEXA.
The limitations of BMI in respect of the proportions of lean and fat are well
recorded (Garn et al 1986, McLaren 1987, Smalley et al 1990), but this is not
widely appreciated by clinicians. Though decrease or increase in both lean and fat
occur with weight loss or weight gain, the relationship between the two
compartments may change. A good example of this is the increase in percentage
of body mass as lean, associated with the use of anabolic steroids. The data
illustrate that undernourished patients segregate into different groups
predominantly depleted either of fat, of lean, or of both. Clearly, both underlying
pathogenesis and appropriate management of the undernutrition, will differ greatly
in these groups. More widespread use of two-compartment body composition
analyses as well as body mass index in these situations should provide valuable
information on the complex interplay between low nutrient intake, inflammation,
nutrient loss and the effects of physical inactivity and of drugs. Body composition
analysis will also ensure accurate and universal recording of height and weight,
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basic nutritional parameters often neglected in clinical practice (Barton et al
1989a).
The two compartment model, although invaluable conceptually, is still a
highly over-simplified statement of the clinically relevant body constituents in states
of undernutrition. The "fat" compartment includes brain, and the non-fat "lean"
mass includes total body water, visceral proteins and bone mass. In stable
conditions, total body water is remarkably constant at 73.2% of lean (Lukaski
1987), and this principle underlies the use of total body water by isotope dilution
techniques, in studies of body composition. However this also means that data on
so-called "lean" will be misleading in the presence of oedema, dehydration, ascites,
cardiac failure, and in conditions with rapid fluid shifts such as the immediate
postoperative period. In patients on TPN, some shift in body water may be
anticipated.
I have presented our findings as percent body weight as lean, and
discussed the data in terms of percent fat or percent lean. However, with further
experience and larger numbers of patients studied, and particularly when reference
population data are available, better and even more informative ways of expressing
these data may emerge.
The primary purpose in this work was to improve our clinical assessment of
patients with gastro-intestinal diseases, particularly IBD. Young adults with CD are
abnormally thin (Ferguson et al 1994b), and newly diagnosed patients with CD
have significant bone demineralisation (Ghosh et al 1994). These features are not
associated with a particular distribution of disease or inflammatory disease activity,
nor with corticosteroid treatment. Results from the few IBD patients in the present
study further emphasise the heterogeneity of nutritional status in these diseases. A
simple technique for assessing body composition will further improve the capacity
to analyse the many contributions to overall illness in IBD and other diarrhoeal
diseases as a basis for rational treatment (Ferguson et al 1994a).
10.6. Body composition in IBD
In chapter VIII, I have presented body composition analysis data in IBD
patients. It again emphasises the nutritional morbidity of CD disease compared with
UC. Ten patients had a BMI less than 20 and nine of them had CD (Figures 8.1
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and 8.2). The only patient with UC who was underweight was a young girl with a
definite history of anorexia nervosa needing psychiatric support. The data support
the contention made in the previous section that in IBD, underweight patients often
have lost proportionally more fat than lean, as both for male and female patients, a
significant inverse correlation could be observed between the percent lean and
BMI. An interesting observation was the inverse correlation between spine and
forearm Z-scores and percent lean in CD but not in UC. Bone is part of the lean
compartment, and one would normally expect a reduction in bone mass to be
accompanied by a reduction in percent lean; in CD, osteopenia parallels depletion
of body fat. In chapter II I have discussed the theoretical basis for the hypothesis
that metabolic alterations resulting from inflammation play a role in nutritional
abnormalities in systemic inflammatory conditions such as CD. Both bone and fat
metabolism are influenced by classical 'cachectins' TNF-a and IL-ip (Raisz 1988,
Bertolini et al 1986, Camussi et al 1991, Grunfeld et al 1992), as discussed in
chapter II. Though indirect, the evidence in this thesis suggests that further
experimental work in this area is warranted. Evidence implicating TNF in causing
malnutrition in chronic lBD is, however, lacking (O'Connell et al 1994).
10.7. Special considerations in adolescents
Adolescents with IBD are worthy of special consideration. Studies in our
institution (Barton et al 1990, Ghosh et al 1994c) and in other centres (Griffiths et al
1993, Hildebrand et al 1994, Motil et al 1993) have reported considerable
nutritional morbidity in this group of children, especially in those with CD. Though
the cohort of adolescents recruited for the bone mineralisation study consisted of
complicated patients referred to a tertiary care centre, the degree of osteopenia
present in them was certainly worrying. In some but not in all cases this was
accompanied by vitamin D deficiency. Osteopenia was also present in adolescents
with long-standing UC who had received considerable cumulative steroid doses.
Vertebral collapse and loss in height were seen in two of the patients, testifying to
the potential devastating effect of osteopenia in this age group. Growing bones are
metabolically very active and it is possible that they are susceptible to multiple
metabolic influences very easily. Lack of physical activity almost certainly is
another contributing factor, though in my study, it was impossible to obtain an
accurate measure of their premorbid physical activity status as the onset of illness
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was several years prior to measurement of BMD. Issenman et al 1993 reported low
bone density in paediatric CD compared with normal children, though the
difference was less when compared with height-matched controls. Again, adequate
treatment with steroids (alternate-day) over 2 years did not result in further bone
loss. Growth and sexual development are obviously important factors related to
bone density in children (Issenman et al 1993) and both are directly affected by CD
in childhood (Barton et al 1990).
It was important to investigate the nutritional morbidity in unselected
patients from the community, rather than the selected group discussed above, and
the audit of delivery of medical care to Scottish children provided an ideal
opportunity to look at a geographically defined cohort. It is fortunate that Scotland
has an excellent epidemiological tool in the Scottish Hospital Inpatients' Statistics
(SHIPS) which links all NHS hospital admissions in Scotland based on ICD coding
(Kendrick et al 1993). Virtually all children with IBD in Scotland are hospitalised at
least once (Barton et al 1989b) and hence identification of a geographically defined
cohort from the SHIPS database is likely to give a representative sample of
juvenile-onset IBD children in Scotland. It was encouraging to note that some of the
deficiencies in monitoring of growth and development variables in Scotland
reported previously by my predecessor (Barton et al 1989a) had improved in the
more recently diagnosed cohort. However, the monitoring was far from perfect and
deficiencies in recording height, bone age and sexual development were still not
uncommon. Some aspects of morbidity showed evidence of improvement in the
more recently diagnosed cohort, such as the frequency of resectional surgery and
the duration of hospitalisation in juvenile onset CD patients. This coincided with
more frequent use of systemic steroids, immunosuppressives and elemental diet in
the more recently diagnosed CD cohort. However, there was no significant
improvement in the frequency of height and weight retardation between the
previous and the more recently diagnosed cohort. The prospect of the juvenile-
onset IBD patients achieving their projected adult height was quite good and this
was shown by height measured at the time of the interview when most of the 1984-
88 cohort were adults. This was also the conclusion of a previous report from my
institution which specifically looked at long-term outcome of growth and
developmental delay in juvenile-onset IBD patients (Ferguson et al 1994). A
Canadian study reached a similar conclusion (Griffiths et al 1993).
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These two studies in adolescents confirm the profound nutritional effects of
CD and complement the studies in the adults. In fact, they identify this group as
being particularly vulnerable to the effects of nutritional depletion as reflected by
osteopenia and growth retardation. It is encouraging to note that monitoring of
growth and developmental parameters is improving in this group, but further
awareness of the problem is needed to ensure the ideal of universal monitoring
which is essential in this group.
10.8. Conclusions and implications
The aim of this thesis was to explore the direct effects of IBD on specific
aspects of nutrition. A number of previously unrecognized effects of disease on
nutrition were identified. The study of bone mineralisation in newly diagnosed IBD
clearly demonstrates osteopenia in CD, but not in UC. The influence of the
confounding variables discussed mask this difference in long-standing disease.
Small numbers make it difficult to rule out type II errors in analysing the effects of
smoking and menstrual status. Change in body composition, particularly a
preferential loss of fat over lean was detected in parallel with osteopenia. The
metabolic basis of this finding needs further investigation. Adolescents were
identified as particularly vulnerable to nutritional problems associated with CD, and
nutritional monitoring in this group, though improving, needs to be universal.
Bedside methods of measurement of body composition are needed to explore
these issues further in large, preferably community-based cohorts, and a simple,
user-friendly bioelectrical impedance analysis machine shows promise as a
suitable method. Finally the results provide further evidence that CD and UC are
different diseases - CD is a systemic disease with widespread immunological and
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Chapter XI
LABORATORY METHODS FOR OBJECTIVE ASSESSMENT
OF COMPONENTS OF INTESTINAL INFLAMMATION
11.1.Objective clinical assessment of gut inflammation and injury
In order to study the gut immune system in clinical situations, a range of
components should be assessed. As discussed in chapter II, tests on components
of the systemic immune system such as blood antibodies and circulating cells and
cytokines are generally useless as indices of mucosal immunity at gut level.
Published evidence from our laboratory has shown that data based on analysis of
faeces is highly misleading (Ferguson et al 1995). My predecessors in the
gastrointestinal laboratory have established that analysis of the clear fluid obtained
after whole gut lavage is a powerful method of assessing intestinal immunity,
inflammation and gut losses of protein and blood (O'Mahony et al 1990, Brydon et
al 1992 and 1993). Whole gut lavage fluid (WGLF) analysis has been reviewed in
chapter II.
11.2. Whole gut lavage
The patients drank an isotonic polyethylene glycol-electrolyte fluid (Klean-
prep, Norgine Ltd., Headington, Oxford, UK) at a rate of 250mL every 15 minutes,
supervised by an experienced nurse (Choudari et al 1993). The first completely
clear fluid specimen passed per rectum was collected for analysis. Aliquots of
unfiltered, unprocessed specimens were stored at -70°C until assayed for GE. The
rest of the specimen was filtered through glass microfibre filters (Whatman GF/A,
Whatman International Ltd, Maidstone, England) with a pore size of 1.6pm and
aliquots were stored without further processing for assay of free GE. Other
aliquots of the filtered specimen were processed by the addition of protease
inhibitors. The following processing reagents were added to the filtered fluid with
mixing after each addition : soybean trypsin inhibitor in phosphate buffered saline
(PBS) (80 pg/mL), sodium ethylenediaminetetraacetic acid in PBS (15 mmol/L),
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phenyl methyl sulphonyl flluoride in 95% ethanol (2 mmol/L), sodium azide (1
mmol/L) and newborn calf serum (5% volume). Aliquots of processed WGLF were
stored at -70°C and later assayed for IgG by enzyme-linked immunosorbent assay
(Choudari et al 1993), and for cytokines as described later in this chapter.
The study protocol was approved by the Medicine Subcommittee of the
Lothians Area Ethics of Research Committee.
11.3. Assessment of neutrophils in whole gut lavage fluid
11.3.1. Cytology
Each specimen of WGLF (25mL) was centrifuged at 850g for 10 min. The
supernatant was discarded and the pellet resuspended in 5mL Hanks' balanced
salt solution (Sigma Chemical Co. Ltd, Poole, UK). This was layered on top of a
discontinuous density gradient using Histopaque 1119 and 1077 (Sigma). After
centrifugation for 30 min at 700g the 2 resultant layers were harvested separately.
The suspensions were washed with Hanks' balanced salt solution and the pellets
resuspended in 1 mL. Cell counts were performed with a haemocytometer, and
slides of the 2 suspensions were made using a Cytospin cytocentrifuge (Shandon
Southern Products Ltd, Runcorn, UK) operated for 10 min at 90g. The slides were
air-dried and then fixed in methanol before being stained by the May-Grunwald-
Giemsa protocol. Slides were examined with an Ortholux II microscope (Leitz,
Wetzlar, Germany), and the cell types present were recorded. Additionally the
number of neutrophils in the preparation was subjectively graded as a) few or
none, b) moderate numbers or c) very many. Slides were also immunostained
using monoclonal antibodies foranti-CD3 (Scottish Antibody Production Unit,
Carluke, UK), anti-L26 (DAKO Ltd, High Wycombe, UK) and anti-CD68,KP1
(DAKO) to detect T lymphocytes, B lymphocytes and macrophages. The three-
stage streptavidin-biotin-alkaline phosphatase technique was used (Hsu et al
1981).
11.3.2. Granulocyte elastase (GE)
i)Total GE: The highly specific substrate for GE, L-Pyroglutamyl-L- prolyl-L-
valine-p-nitroanilide (Kramps et al 1983), was obtained from Quadratech (Epsom,
UK) and was dissolved in dimethylsulphoxide and diluted four times in water to give
145
a final concentration of 2 mmol/L. Approximately 1pL of Triton X-100 (Sigma) was
mixed into 500pL of thawed, unfiltered, unprocessed WGLF {the precise amount of
Triton is not critical (Kramps et al 1980)}. Each sample was sonicated at 0°C for 1
min 3 times using a Rapidis A180G sonicator (Ultrasonics Ltd., Shipley, UK) to
disrupt the cells present and release the enzymes contained in the granules. 200p.L
of sample was added to 200pL of buffer (Tris 0.1 mol/L, NaCI 0.96 mol/L, pH 8.3)
and the mixture was incubated at 37°C. 200pL of substrate at 37°C was added and
after exactly 3 min the reaction was stopped with 200pL of 20% acetic acid. Blank
tubes were run for all samples in the same way, but with the acetic acid added
before the substrate. Absorbance was measured at 405nm and GE concentration
calculated using the formula provided by Quadratech: (test A405 - blank A405) x
2310 nkat/L. A crude human granulocyte extract was prepared by a modification of
the method of Kramps et al 1980 and was included as a standard.
ii)Free: Thirtynine patients who had total GE detectable by the above assay
also had GE measured in a filtered, unprocessed sample. The method described
above was used without the sonication step. The process of filtration removed the
granulocytes and hence any GE detectable in this specimen represented free or
non-particulate GE.
11.4.Pro-inflammatory cytokines
11.4.1. Interleukin-ip (IL-1 p)
Quantitative measurement of IL-1 p in stored WGLF was carried out using a
commercial, high sensitivity IL-1 p ELISA kit (Cistron Biotechnology, New Jersey,
USA). WGLF which had been filtered and processed by the addition of protease
inhibitors, as described above, was used. The ELISA procedure was a four-stage
test carried out in microtitration wells which were supplied coated with monoclonal
antibody to IL-1 p. In the first stage, the samples or IL-1 p standards were added to
the wells and incubated. IL-1 p present in the sample was bound to the solid-phase
anti-IL-1 p. If IL-1 p was not present, all sample components were removed in the
subsequent washing step. In the second stage, polyclonal rabbit anti-IL-1 p was
added to the wells. The antibody was bound specifically to IL-1 p bound to the solid
phase. In the third stage, goat anti-rabbit IgG conjugated to horseradish peroxidase
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enzyme was added to the wells. The conjugate bound specifically to any bound
rabbit IgG. Between stages, washing steps removed any unbound components
from the wells. In the fourth stage, the enzyme-substrate system was added to the
wells. The substrate was oxidised in the presence of conjugate, resulting in a
coloured end product. Acid was added to stop the reaction and fix the colour. The
colour intensity was measured with a microtitration plate reader at a wavelength of
450nm. A standard curve was constructed and test results read from it. The lower
limit of detection by this assay was 4pg/ml_.
11.4.2. lnterleukin-8 (IL-8)
Stored WGLF which had been filtered and processed by the addition of
protease inhibitors was used. A commercially available quantitative sandwich
enzyme immunoassay technique was used (Quantikine, R&D Systems,
Minneapolis, USA). The 96-well polystyrene microtitre plate was supplied coated
with a murine monoclonal antibody against IL-8. Recombinant human IL-8
standard and samples were pipetted into the wells and any IL-8 present was bound
by the immobilised antibody. After washing away any unbound proteins, a
polyclonal antibody specific for IL-8 conjugated to horseradish peroxidase was
added to the wells to 'sandwich' the IL-8 immobilised during the first incubation.
Following a wash to remove any unbound antibody-enzyme reagent, a substrate
solution was added to the wells and colour developed in proportion to the amount
of IL-8 bound in the initial step. The colour development was stopped and the
intensity of the colour development measured with a microtitration plate reader at a
wavelength of 450nm. A curve was prepared plotting the optical density versus the
concentration of IL-8 in the standard wells. By comparing the optical density of the
samples to this standard curve, the concentration of IL-8 in the unknown samples
was then determined. The lower limit of detection of IL-8 by this assay was
18 pg/mL.
11.4.3. Interferon-y (IFN-y)
WGLF that was filtered and processed by the addition of protease inhibitors
was used. IFN-y was assayed by an in-house ELISA. Immulon 2 plates (Dynatech
Laboratories Inc., Virginia) were coated with a monoclonal anti-IFN-y antibody
(Chromogenix AB, Molndal, Sweden) and incubated overnight at 4°C. The wells
147
were then blocked with 1% bovine serum albumin (Sigma) in PBS for 1 hour. The
1st British Standard for human leukocyte IFN-y (NBSB, NIBSC, Potters Bar) was
used as a standard. Serial dilutions of standard and 1/2 dilutions of samples were
added to the wells and incubated at room temperature for 3 hours. Washing was
carried out between all steps. Biotinylated monoclonal antibody (Chromogenix)
against IFN-y was added and incubated overnight at room temperature. ExtrAvidin
alkaline phosphatase conjugate (Sigma) was added which bound to any
biotinylated monoclonal antibody present, and incubated for 1 hour, followed by
development with pNitroPhenylPhosphate substrate (Sigma) in 10%
Diethanolamine buffer. The plate was read at 405 nm, and the sample results
calculated from the standard curve. The lower limit of detection was 0.64 lU/mL.
11.4.4. Interleukin-6 (IL-6)
Filtered processed WGLF was used. IL-6 was assayed by an in-house
ELISA. Costar high binding capacity plates (Costar UK Ltd, High Wycombe) were
coated at room temperature for 2 hours with polyclonal sheep antibody to human
IL-6 (CLB, Amsterdam). After washing, they were blocked with 5% bovine serum
albumin (Sigma) in PBS overnight. The standard used was recombinant DNA
human type IL-6 reference preparation (NBSB, NIBSC, Potters Bar). It was serially
diluted in 50% PBS/Tween 20/ABS, 50% polyethylene glycol with protease
inhibitors to maintain compatibility with the samples. Samples(1:2 dilutions in
PBS/Tween 20/ABS) were added and the plates incubated at room temperature for
2 hours. Washing steps were carried out between each reagent. Murine
monoclonal antibody to human IL-6 (CLB) was then added and incubated for 2
hours at room temperature. Next biotinylated sheep anti-mouse Ig, species specific
whole antibody (Amersham International Pic, Amersham) was added and
incubated for 1 hour at room temperature. ExtrAvidin alkaline phosphatase (Sigma)
and pNitroPhenylPhosphate substrate were added in two subsequent steps as
described under IFN-y. After reading at 405nm, a standard curve was constructed
and used to obtain test results. The lower limit of detection was 20 pg/mL.
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11.5. Growth factor peptides
11.5.1. Insulin-like growth factor -1 (IGF-1)
Preliminary experiments established that IGF-1 could be detected in WGLF
samples that had been filtered and processed by the addition of protease
inhibitors, but not in fluid to which protease inhibitors had not been added. Hence
stored WGLF samples which had been filtered and processed were used. A
recently available commercial two-site immunometric assay (Octeia® IGF-1 IEMA,
IDS Ltd, Tyne and Wear, UK) for the quantitative determination of IGF-1 was used.
The method incorporated a sample pre-treatment to avoid interference with IGF-1
binding proteins.
The lavage samples were incubated briefly with the releasing agent to
inactivate binding proteins, and then diluted for assay. The polystyrene microtitre
wells were supplied coated with a purified sheep polyclonal anti-IGF-1. The pre-
treated diluted samples were then incubated, together with horseradish
peroxidase-labelled monoclonal anti-IGF-1, in antibody coated wells for 2 hours at
roam temperature. The wells were washed and a single component chromogenic
substrate (a formulation of tetramethylbenzidine) was added to develop colour. The
absorbance of the stopped reaction mixture was read in a microtitre plate reader at
450nm, the colour intensity developed being directly proportional to the amount of
IGF-1 present in the sample. A set of 6 calibrators were supplied as standards and
two controls for quality control of assays. As the concentrations of IGF-1 in the
samples were low, the absorbence of the calibrators were plotted against the
concentration of low calibrator values on a linear-linear graph paper. Results for the
unknowns were read directly from the curve. The lower limit of detection of the
assay was 1.1pg/mL.
11.5.2. Transforming growth factor P^TGF-Pt)
This was measured in stored, filtered, processed WGLF. A commercial
TGF^ ELISA kit was used (Predicta® TGF^ kit, Genzyme diagnostics,
Cambridge, MA, USA). The Predicta TGF-Pi ELISA kit contains a 96-well microtitre
plate with immobilized mouse monoclonal antibody to TGF-p^ Activation of TGF-Pi
was required prior to its measurement in vitro. The samples, standards and controls
were diluted by a factor of 2.17 and acidified using Hcl for one hour. Following
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incubation, acidified samples and standards were neutralized to pH 7.0-7.4 with
NaOH, and were ready to be assayed.
Activated samples, standards or controls were added to each test well and
incubated to allow any TGF-p! present to be bound by antibodies on the microtitre
plate. The wells were then washed and a direct-labelled Horseradish peroxidase-
conjugated polyclonal anti-TGF-p! was added which bound to the captured TGF^
during incubation. After washing, a substrate solution was added to the wells,
producing a blue colour in the presence of peroxidase. The colour reaction was
then stopped by the addition of acid which changed the blue colour to yellow. The
absorbence of each well was read at 450nm and a standard curve was constructed
to quantitate TGF-Pi concentrations in the controls and samples. The lower limit of
detection of the assay was 50 pg/mL.
11.6. Statistical Methods
These are discussed in the results sections of individual chapters that
follow. Non-parametric statistics were used as the data were not normally




INVESTIGATION OF NEUTROPHIL MIGRATION INTO THE GUT
BY CYTOLOGY OF WHOLE GUT LAVAGE FLUID.
12.1. Introduction
Whole gut lavage is a relatively new technique for non-invasive
investigation of gut immunity (O'Mahony et al 1990, O'Mahony et al 1991), and can
be used for research on mucosal immunoglobulins and antibodies, to measure gut
losses of blood and protein, and for studies of local immunoregulatory and pro¬
inflammatory cytokines. It has been known for several years that tumour cells may
be found by cytological investigation of WGLF in patients with gastro-intestinal
cancers (Brandt et al 1989, Rozen et al 1990, Gordon et al 1991, Wuerker et al
1993).
Experiments with intravenously administered mixed leukocyte preparations
labelled with 1 ^11n or 99mjc have shown that these cells rapidly localise in
inflamed bowel, migrate into the bowel lumen, and are excreted in faeces
(Saverymuttu et al 1983, Scholmerich et al 1988). Quantitation of the faecal
excretion of these radiolabeled cells has been used to assess disease activity in
patients with IBD (Saverymuttu et al 1983b, Saverymuttu et al 1986, Pullman et al
1988). It seemed probable that leukocytes in the gut lumen would also be
detectable by tests on WGLF, and if so, a simple, non-isotopic method to research
this aspect of gut inflammation could be developed.
In this chapter, I have assessed how luminal neutrophilia relates to the type
and distribution of IBD, and to disease activity in a series of well characterised
patients with IBD and other conditions. The cells in WGLF were counted and
examined microscopically by Mrs Louise Handy.
12.2. Subjects and methods
12.2.1. Subjects
WGLF samples from 56 patients were used for cytological assessment.
Each patient had the gastrointestinal tract assessed by an appropriate
combinations of upper endoscopy, colonoscopy, jejunal biopsy, other histology and
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contrast radiology. Laboratory investigations performed included determinations of
haemoglobin, white cell count, ESR, albumin and C-reactive protein. All
medications and diet at the time of lavage were recorded.
Thirteen patients were immunologically normal, with anatomically normal Gl
tracts and were used as controls. Twenty-nine patients had IBD. They included: (a)
12 active Crohn's disease (CD): 5 colonic CD (including additional small bowel
involvement), 4 small bowel CD, 3 other CD (e.g. perianal); (b) 10 inactive CD: 5
colonic CD, 2 small bowel CD, 3 other CD; (c) 3 active ulcerative colitis (UC); (d) 4
UC in remission. Of the UC patients, 4 had pancolitis, one had distal colitis and two
had proctitis. IBD was classified as active when the WGLF IgG concentration was
greater than 10pg/mL (see below). Six patients had other benign, upper Gl tract
diseases, and seven had colonic diseases other than IBD (radiation colitis (2),
benign polyps (2), infectious colitis, diverticulitis, stercoral ulcer). An eighth patient,
with colon carcinoma complicating long-standing inactive UC, was classified as
being in this "miscellaneous colonic disease" group.
12.2.2. Lavage protocol
The patients drank an isotonic polyethylene glycol-based fluid (Klean-prep,
Norgine Ltd., Headington, Oxford, UK), supervised by an experienced nurse, as
described in chapter XI. The first completely clear fluid specimen passed per
rectum was collected for analysis. Cytological assessment was performed
immediately after collection as described below. Aliquots of the specimen were also
filtered, processed by the addition of protease inhibitors, stored at -70°C and later
assayed for IgG by enzyme-linked immunosorbent assay (Choudari et a11993).
The protocol was approved by the Medicine Subcommittee of the Lothian's
Area Ethics of Research Committee.
12.2.3. Disease activity in IBD patients
One of the advantages of using WGLF for IBD research is that disease
activity can be graded by measurements of IgG concentration in WGLF. This has
previously been validated by Choudari et al 1993 who found that the Crohn's
disease activity index (CDAI) for CD and the Powell Tuck index (PTI) for UC
correlated well with WGLF IgG concentration. In the same series of patients, an
experienced physician's global assessment was also very reproducible and
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correlated with CDAI or PTI, and with WGLF IgG concentration (Ferguson et al
1994a).
For the purposes of analysis and statistical comparisons, I have classified
IBD patients as active when the IgG concentration in WGLF was >10 pg/ml, and
inactive when IgG level was <10 pg/ml. In the present study, I have again
compared values for WGLF IgG concentration in the 29 IBD patients with a
physician's overall clinical decision as to whether the disease was active or inactive
(based on symptoms, clinical signs and results of haematological and biochemical
blood tests). The categorisation as active or inactive based on IgG concentration
was the same as the clinical classification in all cases. The conventional laboratory
indices of disease activity in the IBD patients (serum albumin, CRP, white cell count
and ESR) along with the physician's clinical classification into active or inactive
disease are given in table 12.1.
Table 12.1. Conventional laboratory markers of disease activity in 29 IBD
patients and physician's g lobal assessment
No.
Serum C-reactive White cell ESR classified as
IBD group albumin protein(mg/ count (mm/1 st active
(g/L)median dl)median & (x109/L) hr)median & disease by




Colonic 37 7.6 11.6 46 5
(n=5) (35-42) (<1.5-16.5) (9.5-14.5) (20-89)
Small bowel 38 <1.5 8.5 34 4
(n=4) (23-41) (6.0-10.2) (7-74)
Others 40 1.5 7.3 27 3
(n=3) (22-43) (<1.5-2.0) (5.4-7.8) (4-44)
INACTIVE
CD
Colonic 42 <1.5 8.7 2 0
(n=5) (34-45) (6.5-15.9) (1-13)
Small bowel 38,41 <1.5 5.1,9.4 4,12 0
(n=2)
Others 42 <1.5 5.8 27 0
(n=3) (40-45) (5.5-6.2) (2-100)
ACTIVE UC 39 <1.5 8.4 13 3
(n=3) (39-43) (7.5-9.3) (2-24)
INACTIVE 45 <1.5 6.6 12 0
UC (n=4) (41-46) (5.4-7.2) (6-40)
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12.2.4. Cytology preparations
This has been described in details in chapter XI.
12.2.5. Statistical analysis
Comparisons between different groups of subjects were done by the Mann-




During initial attempts at cytological examination of WGLF, either samples
filtered through 2 layers of surgical gauze before centrifugation, counting and
cytocentrifugation, or samples centrifuged and layered onto one high density
separation medium only were used. These methods produced slide preparations
which contained considerable amounts of debris and many bacteria, in addition to
variable numbers of cells. Modification of the technique, as described in 'Methods'
section by using two density separation media, greatly reduced bacterial
contamination and debris.
It was anticipated that neutrophils and lymphocytes would layer separately
at the two interfaces during gradient centrifugation, but this was not the case. Most
cells were recovered from the upper of the two layers, and the cell types seen in
the top layer were also seen, though in fewer numbers, in the bottom layer. The
data reported below are total cell counts for both layers added together, and
cytological descriptions for both layers have also been combined.
The cells present were neutrophils, squamous cells, enterocytes,
eosinophils, macrophages, erythrocytes, and, very occasionally, lymphocytes; cells
from a patient with active CD are illustrated in Figure 12.1. Some samples
contained yeasts, and bacteria were ubiquitous.
12.3.2. Cell counts
Figure 12.2 shows the counts for the different disease groups. Specimens
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Figure 12.1. Typical appearance ofWGLF cytology from a patient with Crohn's
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Figure 12.2. Number of cells/mL WGLF plotted against diagnostic group,
highlighting cases with many neutrophils. O = many neutrophils seen, • = all other
cases. shows the count/mL equal to the mean + 2SD of the normal group.
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the mean + 2SD of the cell count was 3.7 x 105/ml WGLF, and this value has been
taken as the upper limit of the reference range. In the single normal subject with
a cell count above this level, microscopy showed that these were predominantly
squames. Nine of the 22 patients with CD and three of the seven with UC had
high cell counts, as did one of the 14 other diseased patients (cell count 3.8 x
10^/mL, in WGLF from a patient with infective colitis). Information on the cell types
in WGLF from IBD patients are given below. Two of the 14 other patients had
many neutrophils in cytospins of WGLF, a patient with infective proctitis (with high
WGLF IgG also) and the patient with colonic carcinoma and long-standing inactive
UC.
12.3.3. Cell counts in IBD according to disease activity and anatomy of
involvement
Figure 12.3 shows the cell counts in WGLF from IBD patients, subdivided
into UC, colonic CD, small bowel CD and CD with other distribution. Results are
presented in relation to IgG concentration in WGLF, the objective measure of
disease activity. Table 12.2 summarises the values for selected subgroups of
patients, together with the results of statistical analyses. In general, patients with
active IBD had higher counts than those with inactive disease (p<0.05) , and
despite the relatively small numbers studied, differences were significant for active
IBD when compared with normals (p < 0.05). However the subgroup with active
small bowel CD did not conform ; cell counts were in the normal range in three of
the four patients concerned (Figure 12.3).
12.3.4. Cell types in IBD according to disease activity and anatomy of
involvement
Cytospin preparations revealed many neutrophils in 6 of the 10 specimens
from colonic CD patients (p < 0.01 when compared with normals), from one of 12
other CD patients (not significant) and from 4 of the 7 samples from UC patients
(p< 0.02).
When these data are further examined in relation to disease activity, a clear
influence of site of IBD emerges. Very many neutrophils were seen in cytospin
preparations from all three patients with active UC, all five with active
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colonic CD, and in only one of the 4 patients with active small bowel CD, a patient
with ileal disease complicated by an abscess who was also on high dose
nonsteroidal anti-inflammatory drugs for ankylosing spondylitis (table 12.3). There
was no relationship between disease distribution and neutrophils in cytospin
preparations from patients with inactive IBD.
12.3.5. Other cell types.
Eosinophils were seen in preparations from 3 of the 22 CD cases, 3 of the 7
UC patients and in the patient with colonic carcinoma complicating UC; in all of
these, neutrophils were also present in the WGLF. Enterocytes and squamous
cells were commonly seen in slides both with and without neutrophils. Erythrocytes
occurred occasionally in slides from IBD patients, and macrophages were seen
occasionally in a variety of clinical conditions. Lymphocytes were very rarely
observed and occurred in low numbers, mostly in IBD cases. Immunostaining of the
few specimens which contained lymphocytes confirmed the presence of B cells,
plasma cells, and T cells, but the general paucity of lymphocytes was striking. No
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Figure 12.3. Cell count/mL WGLF plotted against WGLF IgG concentration for IBD
cases, o = colonic CD, A = small bowel CD, □ = other CD, • = UC. shows
the count/mL equal to the mean + 2SD of the normal group and shows the
upper limit of normal for IgG concentration.
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Table 12.3. Presence of neutrophils in different diagnostic groups.
Diagnostic group n none/ few some very many
Normal 13 13 0 0
Active IBD:
Colonic CD 5 0 0 5
Small bowel CD 4 3 0 1#
Other CD 3 2 1 0
UC 3 0 0 3
Inactive IBD:
Colonic CD 5 3 1 1
Small bowel CD 2 2 0 0
Other CD 3 3 0 0
UC 4 2 1 1
Other non-colonic disease 6 5 1 0
Other colonic disease 8 5 1* 2**
# complicated by abscess and long term high dose NSAID for ankylosing
spondylitis.
* diverticulitis
** infective colitis and colon carcinoma complicating UC
12.3.6. Conclusion
Cytology of WGLF is a valuable technique for investigating neutrophil
migration into the gut lumen. Luminal neutrophilia is a feature of active UC and




INVESTIGATION OF NEUTROPHIL MIGRATION INTO THE GUT
BY ASSAY OF GRANULOCYTE ELASTASE IN WHOLE GUT
LAVAGE FLUID
13.1. Introduction
In the previous chapter, I described cytological examination of whole gut
lavage fluid (WGLF) for investigation of neutrophil migration into the lumen of the
gut. Cytology is, however, time consuming, requires expert cytologists and cannot
be performed on stored samples. The granules of polymorphonuclear leukocytes
contain enzymes such as elastase (Janoff 1972) and myeloperoxidase (Borregaard
1988). Granulocyte elastase (GE) can be detected in faeces from patients with gut
inflammation (Bohe 1987, Adeyemi et at 1992), and so it is likely that assay of GE
could supplement or replace microscopy for the detection and quantification of
intestinal granulocytes in the gut lumen.
In this chapter I have described the study of gut luminal neutrophils by
assay of GE in WGLF from a large series of well characterised patients with IBD
and other conditions. I will also examine how luminal neutrophilia relates to the type
and distribution of IBD, to disease activity, and to the effects of corticosteroid and
antibiotic therapy.
13.2. Subjects and methods
13.2.1. Subjects
WGLF samples from 203 patients were analysed, in whom the
gastrointestinal tract was assessed by an appropriate combination of upper
endoscopy, colonoscopy, jejunal biopsy, other histology and contrast radiology. All
medications and diet at the time of lavage were recorded. Laboratory investigations
performed included determinations of haemoglobin, white cell count, ESR and C-
reactive protein. IBD was classified as active when the WGLF IgG concentration
was greater than 10pg/mL.
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Thirty-one patients had a normal gastrointestinal tract and acted as
controls. Forty-three patients had Crohn's disease (CD) and 25 had ulcerative
colitis (UC). Sixty-three patients had miscellaneous non-colonic gastrointestinal
diseases and 41 had colonic diseases other than IBD. Further details can be found
in Table 13.1. A woman with colonic carcinoma complicating long-standing, inactive
UC was included in the miscellaneous colonic diseases group.
In 47 of the above patients, cytological assessment was performed on the
first clear specimen immediately after collection.
Table 13.1. Details of 203 subjects studied for granulocyte elastase
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Unfiltered, unprocessed WGLF was used to assay GE using a specific
enzyme-substrate reaction. This is described in chapter XI. The assay was
developed by Mrs Louise Handy.
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13.2.3. Statistical analysis
Correlation coefficients were calculated using the Spearman Rank
Correlation test. Comparisons between different groups of subjects were carried
out using the Mann-Whitney test and x2 test with Yates correction; p values <0.05
were considered significant.
13.3. Results
13.3.1. Disease activity in IBD patients
In the present study, I again compared values for WGLF IgG concentration
in the 68 IBD patients with a physician's overall clinical decision as to whether the
disease was active or inactive (based on symptoms, clinical signs and results of
haematological and biochemical blood tests). The categorisation as active or
inactive based on IgG concentration (>10pg/mL or <10pg/ml_) was the same as the
clinical classification in 65 of the 68 cases. Of the three with discrepant results, two
had severe UC and were on intensive medical treatment with intravenous steroids;
they were clinically graded as having active disease whereas WGLF IgG levels
were 9 and 6pg/mL. The third patient had colonic CD, was on maintenance oral
steroid therapy, had few symptoms and normal inflammatory parameters in blood
apart from a raised ESR. She was clinically graded as inactive but her WGLF IgG
concentration was 16|.ig/mL.
For the purposes of analysis and statistical comparisons in this report, we
have used the objective measure, WGLF IgG concentration: IBD active when IgG
>10 pg/ml, and inactive when IgG <10 pg/ml.
13.3.2. WGLF GE measurement
The GE assay technique is based on the method used for measurement of
elastase in granulocyte extracts from whole blood. Possible interference by high
polyethylene glycol concentrations was excluded by comparing values for blood
granulocyte suspensions in balanced buffer and in surrogate WGLF preparations;
no difference was detected. The handling of the WGLF sample after collection was
also of importance. For immunoassays, including IgG measurements, WGLF
samples must be filtered and treated with a series of protease inhibitors. Such
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specimens have, of course, been depleted of cells, including granulocytes, at the
filtration stage. Also, in the presence of protease inhibitors GE cannot be detected
by the method used. Thus, total GE measurements were made on WGLF
specimens untreated apart from sonication. GE concentrations of below 39 nkat/L
were considered to be below the reliable limit of detection of the assay. The
between-assay coefficient of variation was 6%. Free GE was however measured in
specimens after filtration, which removed the neutrophils (10-15pm in diameter);
hence these specimens were not sonicated.
13.3.3. Relationship between cell count and GE concentration in WGLF
Figure 13.1 demonstrates the relationship between WGLF cell counts and
GE concentrations in the 47 patients studied by both methods. The correlation for
the whole series, for CD and for UC patients are all highly significant (all cases
r = 0.80, p <0.001; CD r = 0.79, p <0.001; UC r = 0.98, p = 0.001). There were 33
specimens in which GE was less than the 39 nkat/L detection limit.
13.3.4. GE concentrations in WGLF
Figure 13.2 shows GE concentrations for the specimens by disease group.
Of the 31 normals (median <39, range <39-113 nkat/L) GE was detectable in only
4 samples (values of 60,74,74,113 nkat/L). I have therefore analysed results in the
various patient groups as absolute GE values, and as the number of patients with
any detectable GE; values >100 nkat/L WGLF are considered abnormally high.
Detection of GE was significantly more frequent than in normals for CD (19 of 43,
p < 0.01) and for UC (12 of 25, p < 0.01), and absolute values were also
significantly higher than in normals for CD (median <39, range <39-1435 nkat/L, p
< 0.001) and for UC patients (median <39, range <39-1550 nkat/L, p < 0.001). As
shown in Figure 13.2, only 3 of 63 patients with miscellaneous non-colonic disease
and 5 of 41 patients with miscellaneous colonic disease had detectable GE.
Neither these frequencies nor the absolute values differed significantly from those
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Figure 13.1. Cell count/mL WGLF plotted against GE concentration in WGLF.
o = CD, • = UC, x = all other diagnosis. = shows the count/mL equal to
the mean + 2SD of the normal group.
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Figure 13.2. Concentration of GE in WGLF plotted against diagnostic group,
showing patients with high WGLF IgG concentrations as a measure of active
disease, o = WGLF IgG > 10 pg/mL, • = WGLF < 10 pg/mL.
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13.3.5. GE concentration in IBD according to disease activity and anatomy of
involvement
As summarised in Table 13.2, both the frequency of detection and absolute
values for GE concentrations were significantly higher than in normals for the
active CD and active UC patients, but not for inactive disease. Active CD
specimens also had significantly higher GE levels than inactive CD (p < 0.01), but
the difference between active and inactive UC failed to reach statistical
significance.
When the frequency of detection and absolute values for GE were
examined in active CD patients after subdivision by distribution, differences
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emerged between colonic and non-colonic CD, confirming what we had observed
by cytology in a smaller series, that an excess of granulocytes in WGLF is a
feature mainly of colonic disease. The active colonic CD group contained
significantly more samples with detectable GE (10/11) than the active non-colonic
CD group (4/12) (p<0.02). The GE concentration in active colonic CD was greater
than that in active non-colonic CD (p<0.02) or, that in small bowel CD alone
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(p<0.05). There was no such differences with inactive disease. No difference in
the frequency of GE detection could be shown between patients with pancolitis,
distal colitis and proctitis, but the numbers in each of these subgroups were small.
13.3.6. Correlation ofWGLF IgG with GE
For the 43 patients with CD, WGLF IgG correlated weakly with GE (r = 0.36,
p < 0.02), with a stronger correlation in UC (r = 0.58, p = 0.002). For all colonic CD,
GE significantly correlated with IgG (r = 0.44, p < 0.01), but for those with small
bowel CD there was no such correlation (r = 0.01, p = NS). In all, 43 patients had
detectable GE and in these patients GE correlated significantly with WGLF IgG
concentration (r=0.77; p<0.0001).
There were 9 patients with CD and 4 UC patients who had raised IgG
concentrations but undetectable GE. More details of these atypical patients are
given in Table 13.3. It can be seen that CD patients with raised WGLF IgG
concentration but undetectable GE had either small bowel disease or were recently
treated with antibiotics. There were no similar common factors in UC patients apart
from the fact that they were all on either systemic or local steroids.
13.3.7. Correlation of GE with conventional laboratory indices of activity
For CD patients, GE levels in WGLF were significantly correlated with
plasma CRP (r = 0.49, p = 0.001) but not with ESR, white cell or platelet count in
the blood. For the UC group, GE was significantly correlated with ESR (r= 0.50, p
< 0.01) but not with blood white cell or platelet count, or with CRP.
13.3.8. GE concentrations according to treatment status
Table 13.4a shows the GE results for the IBD patients, subdivided
according to disease activity and treatment status. When separately stratified by
disease activity, patients who were or were not receiving systemic steroid therapy
had generally similar frequency of detection and concentrations of GE. In fact, GE
concentrations were significantly higher in patients with active CD who were
receiving systemic steroids (p < 0.05) than in active CD patients not receiving
steroids, although the WGLF IgG concentrations were similar for the two groups.
Three patients with CD were on azathioprine and they have not been included in
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the table. Two of them had inactive disease with undetectable levels of GE; one
had active Crohn's colitis with a GE concentration of 450 nkat/L.
Table 13.3. IBD patients with raised IgG (>10 pg/mL) but undetectable GE (<39
nkat/L) in WGLF
Macroscopic On steroids IgG (pg/mL) Comments
distribution
Crohn's disease
Jejunal/ileal No (TPN) 53 Multiple resection,
fistulae




Ileal/perineal No 40 Anastomotic
recurrence
Ileal No 142 On tetracycline
Sclerosing No 76 Macroscopically
cholangitis normal but colonic
histology showed CD
Colonic No 182 Had received long
course of tetracycline




Pancolitis Yes 119 On 40mg
prednisolone
Pancolitis Yes 25 On 7.5mg
prednisolone
Pancolitis Yes 217 On 60mg
methylprednisolone
Proctitis Yes 28 On predfoam enema
Note: TPN = Total parenteral nutrition
13.3.9. GE in non-IBD patients
One subject classified as normal, and 5 with diseases other than IBD had
high GE concentrations (> 100 nkat/L). These patients are described in Table 13.5.
All these 5 patients had clinical disorders compatible with exudation of neutrophils
into the lumen. Acute radiation colitis, diverticulitis and pericolic abscess
communicating with the lumen are well known to have pus on the mucosa. The
other two patients were on NSAIDs. The normal subject was a volunteer in a study
investigating mucosal immunity in smokers; a repeat lavage done after 3 weeks did
not detect GE in WGLF.
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Table 13.5. Non-IBD patients with markedly raised GE (>100 nkat/L) in WGLF
Diagnosis IgG pg/mL GE nkat/L Comments
Acute radiation colitis 236 2285 Radiotherapy for
carcinoma cervix
Diverticulitis 27 132 Settled with antibiotics
Diverticular disease 3 240 On NSAIDs
Carcinoma colon 44 109 Caecal tumour with
pericolic abscess
Systemic lupus 1 210 On NSAID &
erythematosus prednisolone
10 mg/day
Volunteer 1 113 Normal volunteer;
repeat lavage after 3
weeks did not detect
GE.
13.3.10. Total and free GE
Aliquots of WGLF which had been filtered, but not treated in any other way,
were available for 39 of the 43 specimens in which GE had been detected in
unfiltered specimens. Results of GE assays in these paired samples are
summarised in Table 13.6. Figure 13.3 shows the relationship between total
(particulate+free) and free GE. There was a significant correlation between free GE
and total GE (r=0.8; p<0.0001). Eleven out of the 29 IBD patients with detectable
total GE had detectable free GE, whereas none of the 3 normals and only 1 out of
the 7 diseased controls (the patient with radiation colitis) had detectable free GE. In
the whole group, the concentration of total GE in those with detectable free GE
(median 703nkat/L;range 55-2285nkat/L) was significantly greater (p<0.001) than
that in those with undetectable free GE (median 159nkat/L; range 39-1157nkat/L).
This was also true for CD patients in whom the concentration of total GE in those
with detectable free GE (median 714nkat/L; range 300-1435nkat/L) was
significantly greater (p<0.05) than that in those with undetectable free GE (median
215nkat/L; range 39-1157nkat/L). In UC patients, the difference in total GE
concentration between those with detectable free GE (median 532nkat/L;range 55-
1550nkat/L) and those with undetectable free GE (median 162nkat/L;range 44-
432nkat/L) did not reach statistical significance.
In a series of 18 CD patients, disease activity was comparable in the 7
who had free GE (median WGLF IgG 32pg/ml;range 18-89pg/ml) and 11 with no
free GE (median WGLF IgG 9; range 2-216pg/ml; p=NS). Five of these patients



































































Figure 13.3. The relationship between free and total GE in 39 patients with
detectable total GE. x = Normals (n=3); o = CD (n=18); o = UC (n=11); □ = Miscell.
upper Gl (n=2); A = Miscell. colonic (n=5).
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Table 13.6. Detection of free GE in 39 patients with detectable total GE.




Miscell upper Gl 2 0
Miscell colonic 5 1*
"radiation colitis
NSAIDs and had abscess communicating with ileum), and 1 had perianal disease
with rectal involvement. Just as was the case with total GE, free GE was detectable
more often in CD patients on steroid therapy (table 4b). Five out of 8 CD patients
on steroids and 1 on azathioprine had detectable free GE whereas only 1 out of 9
CD patient not on steroids had detectable free GE (p<0.05). The WGLF IgG
concentration between this steroid (or azathioprine) treated and untreated group
did not differ significantly (median 29(4-89) Vs 23(2-216)pg/ml).
Out of the 11 UC patients with detectable total GE, 4 had free GE. WGLF
median IgG concentration in 4 UC patients with detectable free GE was
26pg/ml(range 5-244pg/ml) and in 7 UC patients with undetectable free GE was
9pg/ml (range 6-195pg/ml; p=NS). Two out of 4 UC patients with free GE
detectable were on steroids and WGLF IgG concentrations in UC patients on
steroids was not different from UC patients not on steroids.
13.4. Conclusion
GE in WGLF is a good surrogate marker of neutrophils in WGLF. Since the
method may readily be combined with preparation for radiological or colonoscopic
investigation of the bowel, material from patients with gut lesions other than IBD
may readily be studied to determine the specificity of particular immunological
parameter for a defined pathology. Regulatory mechanisms underlying anatomical
differences between small and large bowel diseases may be studied, the effects of
pharmacological agents such as steroids, antibiotics and NSAIDS may also be
investigated and therapeutic endpoints such as remission of inflammatory activity




INVESTIGATION OF PROINFLAMMATORY CYTOKINES IN
GUT BY ANALYSIS OF WHOLE GUT LAVAGE FLUID
14.1. Introduction
Cytokines and their roles in IBD are discussed in chapter II. A major
difficulty in studying the role of cytokines in relation to inflammatory and metabolic
aspects of IBD is that serum levels of cytokines are unlikely to reflect events at the
gut mucosal level. Until now, it has therefore been necessary to study tissues
(biopsies) by a variety of methods, immunologic, immunohistochemical or
molecular (Brynskov et al 1992a, 1992b). Tissues from stomach, duodenum and
colon from symptomatic patients are relatively easily obtained at endoscopic
procedures. However, the small bowel mucosa is difficult to study and data from
resection specimens must be interpreted with great caution. Endoscopic biopsy of
the large bowel is invasive and serial studies to investigate changes with therapy
are difficult to conduct. Healthy controls are almost impossible to recruit for invasive
studies. My predecessor (Mwantembe, PhD thesis, University of Edinburgh, 1992)
had established that cytokines such as TNF-a could be detected in whole gut
lavage fluid (WGLF). I aimed to extend his study to investigate the potential of
WGLF analysis for investigating proinflammatory cytokines (IL-1p, IL-8, IL-6, IFN-y)
thought to be involved in gut inflammation.
14.2. Subjects and methods
Filtered and processed WGLF from 234 patients were analysed for IL-ip
and IL-8. The methods of assaying for these cytokines are described in chapter XI.
All specimens were also assayed for IgG and granulocyte elastase (GE) as
described in chapter XI. Table 14.1 describes the patient characteristics. Both a
normal control group and two groups of diseased controls, those with upper Gl and
small bowel diseases and those with colonic diseases other than IBD were studied
along with IBD patients. Some were the same patients described in chapters XII
and XIII.
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Table 14.1. Patient characteristics
Patient group n Age median (range) Sex (M:F)
Normal Gl tract 25 43 (22 - 67) 14:11
Crohn's disease
Active 51 34 (14-62) 30:21
Inactive 29 31 (16-59) 18:11
Ulcerative colitis
Active 17 30 (18-60) 8:9
Inactive 15 34 (22-58) 9:6
Other non-colonic 57 46 (20-76) 30:27
Other colonic 40 48 (19-82) 22:18
The patient cohort was slightly different for IL-6 and IFN-y assays. 226
filtered and processed WGLF samples were analysed for IL-6 and IFN-y. These
included 42 patients with normal Gl tract, 48 patients with Crohn's disease (CD) (24
active disease with WGLF IgG > 10pg/mL; 24 inactive disease with WGLF <
10pg/mL), 22 patients with ulcerative colitis (UC) (7 active; 15 inactive), 66 patients
with miscellaneous noncolonic Gl diseases and 48 patients with miscellaneous
colonic diseases.
The methods of analyses of cytokines are detailed in chapter XI.
Commercial ELISA kits were used for assaying IL-1 p and IL-8, while IL-6 and IFN-y
were measured using in-house assays developed by Mrs Louise handy. Statistical
analysis was performed using the Mann-Whitney U test and Spearman rank
correlation test.
14.3. Results
IL-1 p, IL-8, IFN-y and IL-6 could be detected in WGLF from some patients.
In patients with IBD, the results were analysed according to the activity of disease
determined by WGLF IgG concentration as described in previous chapters.
Granulocyte elastase (GE) concentration was used as a surrogate marker of
luminal migration of neutrophils as described in the previous chapter.
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14.3.1. WGLF IL-ip concentration
Figure 14.1 shows WGLF IL-1 p concentration in the various diagnostic
groups. IL-1 p was detectable in low concentrations (6.8, 8.6 and 14.4 pg/mL) in 3
patients with normal Gl tract and in the remaining 22 with normal Gl tract, it was
undetectable. One of the three with detectable IL-1 p was a healthy volunteer for
research on intestinal immunity in smokers. One patient had a normal Gl tract but
had presented with weight loss. The remaining patient with detectable IL-1 p and
normal Gl tract had a history of alcohol abuse and depression but a normal Gl
tract. Both these patients also had detectable GE in WGLF and admitted to
occasional analgesic use.
In the 51 patients with active (as defined in chapter XII) CD, WGLF IL-1 p
concentration was significantly greater than the normals (table 14.2). All but one
patient with active CD had detectable IL-1 p (table 14.3). The exception was a
woman with colonic CD and pyoderma gangrenosum who was on metronidazole
and salazopyrin. Interestingly, granulocyte elastase too, was undetectable in her
WGLF. The concentration of WGLF IL-1 p in active CD was significantly greater
than in inactive CD (table 14.2). It can be noted that out of the 29 inactive CD
patients, 14 had detectable IL-1 p and the median concentration of WGLF IL-1 p
was significantly greater than that in the normals.
All 17 patients with active UC had detectable IL-1 p in WGLF and IL-1 p
concentration was significantly greater than that in the normals (table 14.2). Ten
out of the 15 patients with inactive UC also had detectable IL-1 p (table 14.3) and
the median concentration was significantly greater than that in the normals but
significantly less than that in active disease. There was no significant difference in
WGLF IL-1 p concentration between UC and CD, either for active or for inactive
disease.
Twenty-one out of the 57 patients with a variety of non-colonic diseases
had detectable IL-1 p in WGLF, but the concentrations were low (maximum 71.6
pg/mL) and the median concentration was not significantly different from that in the
normals. Three of these patients were on nonsteroidal anti-inflammatory drugs, 3
patients were investigated for iron-deficiency anaemia (one had gynaecological
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diagnosis remained unresolved), 3 patients had bacterial colonisation of the small
bowel, and 1 patient each had mesenteric ischaemia, diarrhoea following renal
transplant, autonomic neuropathy, common variable immunodeficiency, chronic
pancreatitis, giardiasis, bile acid malabsorption, diarrhoea in a patient with
lymphoma in remission, short bowel syndrome following resection for malrotation
and intestinal atresia in infancy, and diarrhoea in a patient with multiple problems
including previous radiotherapy and IgA deficiency. The remaining two patients had
transient idiopathic diarrhoea which resolved within a month of the whole gut
lavage.
Eighteen out of 40 patients with a variety of colonic diseases had
detectable IL-1p in WGLF (table 14.4). Four of these patients had a concentration
greater than 100pg/mL as shown in table 14.5. Of the remaining patients with
detectable IL-1 p, 5 had carcinoma of the colon, 3 had radiation colitis, 2 had
infective colitis, and one each had ischaemic colitis, bleeding colonic polyp,
tenesmus with possible proctitis and anal fissure (possible Crohn's). The median
concentration of IL-1 p in this other colonic diseases group was significantly greater
than normal but less than active CD or UC.
14.3.2. WGLF IL-8 concentration
This is shown in figure 14.2 and table 14.6. None of the 25 patients with
normal Gl tract had detectable IL-8 in WGLF (table 14.7). Twenty-three out of the
51 patients with active CD had detectable IL-8 (table 14.7) and the median IL-8
concentration was significantly higher than that in normals (table 14.6). Only one
patient with inactive CD had detectable IL-8 in WGLF. This patient with very
complicated juvenile CD, multiple surgery and an intra-abdominal abscess had a
WGLF IgG concentration of 8pg/mL (upper limit of normal=10pg/mL) and a GE
concentration of 65 nkat/L. His IL-1 p concentration was 163.8pg/mL.
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Table 14.3. Detection of IL-ip in WGLF according to disease activity in IBD.
WGLF IL-1 p undetectable WGLF IL-1 p detectable
Crohn's disease
WGLF IgG <_10pg/mL 15 14
WGLF lgG> 10pg/mL 1 50
Ulcerative colitis
WGLF lgG< 10pg/mL 5 10
WGLF lgG> 10p.g/mL 0 17
Table 14.4. Detection of IL-1 p in WGLF in non-IBD patients
Diagnostic groups IL-1 p undetectable 11-1 p detectable
Normals
WGLF lgG< 10pg/mL 22 3
WGLF lgG>10pg/mL 0 0
Miscell. non-colonic
WGLF lgG< 10pg/mL 36 20
WGLF lgG>10pg/mL 0 1
Miscell. colonic
WGLF lgG< 10pg/mL 21 12
WGLF lgG>10pg/mL 1 6
Table 14.5. Non-IBD patients with WGLF IL-1 p conc. > 100pg/mL
Diagnosis Number of patients (pg/mL)
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Figure 14.2. WGLF IL-8 concentrations in the different diagnostic groups.
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Nine out of 17 patients with active UC had detectable IL-8 in WGLF (table
14.7) and the median IL-8 concentration was significantly higher than that in the
normals (table 14.6). Only 1 patient with inactive UC had elevated IL-8
concentration; her WGLF IgG concentration was 7pg/mL, GE concentration was
370nkat/L and IL-ip concentration was 232pg/mL.
Unlike IL-1 p, only 8 out of the 97 diseased control patients had detectable
IL-8 in whole gut lavage fluid (table 14.8). The details of this group are provided in
table 14.9. Most of these patients had low concentrations of IL-8 except one patient
with cirrhosis and jejunal varix.
Table 14.7. Detection of IL-8 in WGLF according to disease activity in IBD
WGLF IL-8 undetectable WGLF IL-8 detectable
Crohn's disease
WGLF lgG< 10pg/mL 28 1
WGLF lgG>10pg/mL 28 23
Ulcerative colitis
WGLF lgG< 10pg/mL 14 4 t L- 1
WGLF lgG>10pg/mL 8 9
Table 14.8. Detection of IL-8 in WGLF in non-IBD patients
Diagnostic groups IL-8 undetectable IL-8 detectable
Normals
WGLF lgG< 10pg/mL 25 0
WGLF lgG>10pg/mL 0 0
Miscell. non-colonic
WGLF lgG< 10pg/mL 1 2
WGLF lgG>10pg/mL 54 0
Miscell. colonic
WGLF lgG< 10pg/mL 30 3
WGLF lgG>10pg/mL 4 3
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Table 14.9. Non-IBD patients with detectable WGLF IL-8.
Diagnosis Number of patients (pg/mL)
Carcinoma of the colon 2 (18.9,19.5)
Jejunal varix, cirrhosis 1 (56.2)
Idiopathic diarrhoea 1 (24.7)
Microscopic colitis 1 (20.0)
Carcinoma colon complicating UC 1 (29.0)
Crippling tenesmus, no diagnosis 1 (19.6)
reached
Radiation colitis 1 (194.8)
14.3.3. WGLF IL-ip and IL-8 concentrations in Crohn's disease according to
anatomy of involvement
Table 14.10 shows WGLF IL-1 p and IL-8 concentrations according to
anatomy of involvement after classification by disease activity. For a given disease
activity, there was no difference between colonic and ileal involvement for both
IL-1 p and IL-8. For all anatomical regions of involvement, the concentrations of both
cytokines were significantly higher in active disease compared with inactive disease.
Table 14.10. WGLF IL-1 p and IL-8 conc. in Crohn's disease according to
anatomy of involvement and disease activity.






























NOTE. No significant difference in WGLF IL-1 p and IL-8 conc. between diseases
affecting different anatomical regions for a given disease activity.
14.3.4. Effect of therapy on WGLF cytokines
The effect of therapy on WGLF IL-1 p and IL-8 concentrations is shown in
table 14.11. For a given disease activity, there was no difference between those on
no therapy and those on systemic steroids or an aminosalicylic acid preparation.
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The concentrations in those on azathioprine were also similar though the number of
patients were small and most were on additional steroid therapy. Clearly, the
concentrations become lower once the disease is rendered inactive with therapy,
but as shown above, a considerable proportion of these patients continue to have
detectable IL-ip in WGLF.
14.3.5. Correlation between neutrophil migration into the gut lumen and IL-8
Concentration of IL-8 in WGLF probably reflects the amount in the lumen.
Neutrophil migration into the gut lumen was assessed by GE assay in WGLF as
described in chapter XII. I investigated whether luminal IL-8 was the
chemoattractant molecule responsible for luminal migration of neutrophils. A
correlation between the presence of neutrophils in the lumen (represented by GE
concentration in WGLF) and IL-8 is expected, if IL-8 determines neutrophil
migration. Correlation of GE with IL-8 concentrations for UC and CD are shown in
figures 14.3 and 14.4. In UC, there was a significant correlation between GE
concentration and IL-8 concentration (r=0.78; p<0.0001). In contrast, in CD, there
was no correlation between GE concentration and IL-8 concentration (r=0.16;
p=NS); this was also true for colonic CD only (r=0.20; p=NS).
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WGLF granulocyte elastase conc. (nkat/L)
ULCERATIVE COLITIS
Figure 14.3. Correlation of WGLF GE concentrations with IL-8 concentrations in
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Figure 14.4. Correlation of WGLF GE with IL-8 concentrations in Crohn's disease.
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Table 14.11. WGLF IL-ip and IL-8 concentration according to treatment at the
time of lavage, for a given disease activity.
Drugs and activity WGLF IL-ip conc. Median
(range)







Steroids + Azathioprine (n=4)
Azathioprine (n=1)































































All statistical comparisons against patients on no therapy. (E028=elemental diet)
14.3.6. WGLF interleukin- 6 concentration (Figure 14.5)
Table 14.12 shows the data for detection of IL-6 in WGLF. Four patients with
apparently normal Gl tract had detectable IL-6. One woman with idiopathic
constipation and one man diagnosed as irritable bowel syndrome had other WGLF
parameters normal. Of the remaining two, one was a female volunteer in a study
on the effect of smoking on intestinal immunity (her WGLF haemoglobin was also
raised at 9.6 pg/mL) and another was a patient known to abuse alcohol and
suffered from depression (his WGLF GE was modestly raised at 74 nkat/L, IL-1 p
was detectable at 6.8 pg/mL and WGLF haemoglobin was 9.0 pg/mL).
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Table 14.12 Detection of IL-6 in WGLF
Diagnostic groups IL-6 undetectable IL-6 detectable IL-6 conc. median
(range) pg/mL
Normal (n=42) 38 4 <20 (<20 - 46.6)
Crohn's disease
Active (n=24) 19 5 <20 (<20 - 66.8)
Inactive (n=24) 19 5 <20 (<20- 132.4)
Ulcerative colitis ■
Active (n=7) 5 2 <20 (<20 - 35.8)
Inactive (n=15) 12 3 <20 (<20 - 62.6)
Other noncolonic 58 8 <20 (<20 - 39.8)
(n=66)
Other colonic 43 5 <20 (<20- 109.4)
(n=48)
Five patients with colonic diseases other than IBD had detectable IL-6. Two
of them had acute radiation colitis (one woman had very abnormal WGLF
parameters with IgG of 236pg/mL, GE 2285 nkat/L, IL-ip 280.2 pg/mL, IL-8 194.8
pg/mL, arantitrypsin 60 pg/mL, haemoglobin 143 pg/mL; one man had WGLF IgG
29 pg/mL, GE 39 nkat/L, IL-ip 12.6 pg/mL, albumin 78 pg/mL, haemoglobin 5.2
pg/mL). One patient had a carcinoma of the colon (IgG 44 pg/mL, IL-1 p 31.8 pg/mL,
albumin 115 pg/mL) and one patient had a bleeding colonic polyp (WGLF
Haemoglobin 6.3 pg/mL). The remaining patient had a crippling tenesmus for which
no satisfactory explanation was found, but he had a low grade atypical proctitis
(possibly traumatic) - his IgG was 8 pg/mL, IL-1 p was 5.6 pg/mL, IL-8 was 19.6
pg/mL, albumin was 34 pg/mL.
Eight patients with non-colonic diseases other than IBD had detectable IL-6.
Three of them had idiopathic diarrhoea, and in two of them the diarrhoea was self-
limited (one was antibiotic associated) and had settled at the time of the whole gut
lavage (in one IL-1 p was detectable and in another WGLF haemoglobin was 32.4
pg/mL, in the remaining patient all other WGLF parameters were normal). One man
had diarrhoea with complex features including previous radiotherapy and IgA
deficiency (his WGLF IgG was 31 pg/mL, IL-1 p 12.4 pg/mL, albumin 29 pg/mL).
Four patients were being investigated for iron-deficiency anaemias (one of them
had a large hiatus hernia and diverticulitis with WGLF GE of 240 nkat/L, IL-1 p of
11.6 pg/mL and haemoglobin of 7.0 pg/mL; one patient had a uterine cause for her
anemia, and in the two other patients the cause of anaemia remained unresolved).
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14.3.7. WGLF interferon -y (IFN-y) concentration (Figure 14.6)
Detection of interferon - y in WGLF is shown in table 14.13
Table 14.13. Detection of IFN-y in WGLF
Diagnostic groups IFN-y undetectable IFN-y detectable Median conc.
(range)
lU/mL
Normal Gl tract 37 5 <0.64 (<0.64-1.62)
(n=42)
Crohn's disease
Active (n=24) 19 5 <0.64 (<0.64-4.60)
Inactive (n=24) 20 4 <0.64 (<0.64-3.46)
Ulcerative colitis
Active (n=7) 3 4 1.78 (<0.64-3.04)
Inactive (n=15) 10 5 <0.64 (<0.64-8.46)
Other noncolonic
(n=66) 57 9 <0.64 (<0.64-3.26)
Other colonic 42 6 <0.64 (<0.64-3.30)
(n=48)
Five samples derived from patients with apparently normal Gl tract had
detectable IFN-y. One of them with a history of alcohol abuse and depression and
another (two samples were from her on different occasions) had idiopathic
constipation being treated with whole gut lavage - both of them had detectable IL-6
and are described above. Of the remaining patients, one had irritable bowel
syndrome (all other WGLF parameters normal) and another had idiopathic
constipation (WGLF haemoglobin 5.4 pg/mL).
Six patients with colonic disease other than IBD had detectable IFN-y. Two
of them had ulcerated colonic carcinoma (one also had IL-6 and is described above,
the other had WGLF IL-ip of 138.6 pg/mL, albumin 35 pg/mL, arantitrypsin 22
pg/mL and haemoglobin 32 pg/mL). Two patients were post-radiotherapy and were
taking part in a study of intestinal immunity after radiotherapy (one of them also had
WGLF albumin of 34 pg/mL and haemoglobin of 9.1 pg/mL). One patient had a
presumptive diagnosis of infective proctitis which settled (WGLF IgG 33 pg/mL, IL-1
5.6 pg/mL, albumin 84 pg/mL, haemoglobin 22.3 pg/mL). The remaining patient had
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Figure 14.6. WGLF IFN-y concentrations in the different diagnostic groups.
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Nine patients with upper Gl or small bowel disease other than IBD (or iron
deficiency anaemia being investigated for Gl blood loss or coeliac disease) had
detectable IFN-y in WGLF. Five of them had diarrhoea due to a variety of causes
(autonomic neuropathy, postgastrectomy, post-renal transplant on
immunosuppresives and two idiopathic, sef-limited of whom one had detectable IL-6
described above). Two of them were being investigated for iron-deficiency anaemia
(one of them with hiatus hernia and diverticulitis described above and another with
inconclusive diagnosis but WGLF IL-ip of 15.8 pg/mL and haemoglobin of 6
pg/mL). One patient had bleeding oesophageal and rectal varices due to cirrhosis
and the remaining patient had erosive duodenitis with a small Gl bleed.
14.4. Conclusion
WGLF analysis is a noninvasive, convenient method to analyse
proinflammatory cytokines produced by an inflamed gut. It is complementary to
studies on biopsy specimens and enables large numbers of cases to be studied.
Both small and large bowel disease may be investigated. Both WGLF IL-1 p and IL-8
concentrations are significantly elevated in active IBD but a considerable proportion
of patients with inactive IBD as defined by WGLF IgG concentration (supported by
clinical indices of activity and physicians' global assessment) continue to have
raised IL-1 p concentration. Neutrophil migration into the gut lumen, measured by
WGLF GE assay correlates significantly with WGLF IL-8 concentration in UC but
not in CD. Other luminal chemoattractants of neutrophils, such as bacterial
peptides, may have an important role in luminal migration of neutrophils in CD.
Elevated IL-1 p and IL-8 in WGLF are not specific for IBD but may be detected in
other inflammatory and neoplastic diseases of the gut. IL-6 and IFN-y are detectable
far less frequently in WGLF than IL-1 p or IL-8 and usually in association with other





DETECTION OF INSULINLIKE GROWTH FACTOR - 1 AND
TRANSFORMING GROWTH FACTOR - p IN WHOLE GUT
LAVAGE FLUID: A NOVEL METHOD OF STUDYING
INTESTINAL FIBROSIS
15.1. Introduction
Insulinlike growth factor -1 (IGF-1) is a polypeptide of 70 amino acids (7650
Daltons). It is a potent mitogen for fibroblasts and smooth muscle cells and
stimulates collagen synthesis. It is secreted by fibroblasts, macrophages and
lymphocytes. IGF-1 may be important in development of granulomatous
inflammation and fibrosis in a rat model of granulomatous enterocolitis
(Zimmermann et al 1993). Little is known about its role in human IBD. In plasma,
IGF-1 is bound to a family of IGF-1 binding proteins and needs to be released from
its bound form before assay.
Transforming growth factor - p (TGF-p), a 25 kilodalton dimer, is a major
product of platelet degranulation (Assoian et al 1983) and of macrophages
(Assoian et al 1987), has been identified as one of the mediators that specifically
induces fibrotic response in injured tissue (Sporn et al 1987). TGF-p increase
collagen synthesis by human intestinal smooth muscle cells in cell culture
experiments (Graham et al 1990). Studies in human IBD are limited and have been
reviewed in chapter II.
The aim of the study was to utilize the technique of whole gut lavage to
investigate the roles of IGF-1 and TGF-p in inflammatory diseases of the gut
characterised by fibrosis.
15.2. Subjects and methods
15.2.1. Subjects
IGF-1 was assayed in 64 filtered, processed WGLF samples. These
included samples from 7 patients with normal Gl tract, 20 patients with Crohn's
disease (CD), 12 patients with ulcerative colitis (UC), 13 patients with current or
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previous abdominal radiotherapy and 12 patients with other Gl diseases. Seven of
the patients in the radiotherapy group were taking part in a study of the effect of
radiotherapy on intestinal immunity and inflammation and 6 patients presented to
the Gl unit with radiotherapy-related intestinal symptoms.
In 56 out of the 64 samples, TGF-p was also assayed. These included 6
patients with normal Gl tract, 16 patients with CD, 12 patients with UC, 13 patients
with current or previous abdominal irradiation and 9 patients with other Gl
diseases.
15.2.2. Methods
Both IGF-1 and TGF-p were assayed using commercially available
immunoassay kits as described in chapter XI. The lower limit of detection of IGF-1
was 1.1 pg/mL and that of TGF-p was 50 pg/mL. Patients with IBD were
considered to have active inflammation if theirWGLF IgG concentration exceeded
10pg/mL.
15.3. Results
15.3.1. WGLF Insulinlike Growth Factor -1
The recovery of IGF-1 from PEG-electrolyte solution spiked with IGF-1
standard was a mean of 92% (range 88%-94%) in five experiments where the
concentration of IGF-1 ranged from 10pg/mL to 30pg/mL. IGF-1 could not be
detected in WGLF not processed by the addition of protease inhibitors. Figure 15.1
shows WGLF IGF-1 concentrations in the different disease groups. IGF-1 could not
be detected in patients with normal Gl tract. IGF-1 was detectable in 8 out of 20
patients with CD. One of these patients, a 78-year-old lady with colonic CD and
severe diverticular disease with a sigmoid stricture had a very high concentration of
IGF-1 in WGLF (158pg/mL). Only 1 out of 12 patients with UC had detectable
IGF-1. This patient had chronic active pancolitis for over 12 years only incompletely
controlled on cyclosporin and steroids - he was on antipsychotic drugs for
schizophrenia and persistently refused surgery. He eventually had a
proctocolectomy within a year of having the whole gut lavage. None of the 3


















Figure 15.1. WGLF IGF-1 concentrations in different diagnostic groups.
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had acute inflammation; WGLF IgG, albumin and arantitrypsin were within the
normal range in all three. Two of these three patients were taking part in a study
investigating the gut mucosal effects of radiotherapy and the third patient had past
radiotherapy induced colonic stricture. Other Gl diseases with detectable IGF-1 in
WGLF were a patient each with severe diverticular disease with attacks of
diverticulitis, microscopic colitis, pouchitis, ischaemic colitis and carcinoma of the
colon, all conditions known to be associated with increased fibrogenesis.
Figure 15.2 shows disease activity represented by WGLF IgG plotted
against WGLF IGF-1 concentration in CD. There is no correlation between WGLF
IgG and IGF-1 concentrations (r=-0.3; p=NS). Table 15.1 shows that IGF-1 was
detectable in 6 out of the 16 patients with active CD and 2 out of 4 patients with
inactive CD. The frequency of detection of IGF-1 was significantly higher in CD
compared with UC (p < 0.05).
Table15.1. IGF-1 concentration in IBD according to disease activity.
IgG conc. pg/mL No. of patients with IGF-1 conc.pg/L
median(range) detectable IGF-1 median(range)
Normal 2 (0-5) 0 <1.1
CD
Active(n=16) 50 (11-216) 6 <1.1 (<1.1-158)
lnactive(n=4) 1(1-3) 2 <1.1 (<1.1-4.2)
UC
Active(n=10) 38 (13-455) 1 <1.1 (<1.1-3.1)
lnactive(n=2) 5,9 0 <1.1
p<0.05 CD Vs UC (x test with Yates correction).
Four out of 7 patients with ileal or ileocolonic CD and detectable IGF-1 in
WGLF had resectional surgery within 3 months of having whole gut lavage and
small intestinal strictures were found in all them. One patient with colonic CD had
detectable IGF-1 and he had not undergone surgery within 6 months after whole
gut lavage. Only one out of the 12 CD patients with undetectable IGF-1 in WGLF
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Figure 15.2. WGLF IgG concentrations plotted against IGF-1 concentrations in
Crohn's disease.
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15.3.2. Transforming Growth Factor - p
The recovery of TGF-p from PEG-electroIyte solution spiked with TGF-p
standard was a mean of 96% (92-98%) in five experiments, where the TGF-p
concentration ranged from 50pg/mL to 500pg/mL. TGF-p concentration was 10-fold
less in WGLF not processed by addition of protease inhibitors compared with
processed fluid. The concentration of TGF-p in unfiltered fluid was comparable to
filtered fluid. Hence filtered, processed fluid was chosen as an appropriate sample
for the assay.
In contrast to IGF-1, TGF-p was detectable in all WGLF samples that were
tested. There was no significant difference between those with normal Gl tract and
any of the different diagnostic groups (Figure 15.3). However, the concentration of
TGF-p in patients with current or previous radiotherapy was significantly lower than
that in either CD or UC (p < 0.01). There was no correlation between WGLF TGF-p
and IGF-1 or IgG concentrations.
15.4. Conclusions
The two growth factor peptides, IGF-1 and TGF-p can be detected in
WGLF using recently available commercial assays. Detectable WGLF IGF-1 is a
feature of CD and other diseases well known to be associated with fibrosis. In
contrast, it is infrequently detectable in UC. Disease activity and IGF-1 are not
correlated. Detection of IGF-1 in WGLF shows promise as a relatively noninvasive
method of studying gut fibrosis in both the small bowel and colon. In contrast,
TGF-p was detectable ubiquitously in lavage fluid, but concentrations in patients
who had undergone radiotherapy were lower than that in IBD. TGF-p is involved in




































Figure 15.3. WGLF TGF-p concentrations in different diagnostic groups.
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Chapter XVI
DISCUSSION: INVESTIGATION OF IBD PATIENTS BY
ANALYSIS OF COMPONENTS OF INFLAMMATION IN WHOLE
GUT LAVAGE FLUID
There is clearly a need for simple and objective clinical tests to tease apart
the different components of inflammation, so that their relevance to different parts
of the gut affected, effects of different drug and nutritional therapies and inter¬
relationship with the gut flora can be evaluated. This work has confirmed that cells
of the intestinal lumen can be investigated by peroral whole gut lavage. The
influence of the site of macroscopic disease involvement or the effect of drug
treatment, such as corticosteroid therapy, on a specific feature, such as luminal
neutrophilia, can be examined. Moreover, the finding based on my predecessor's
work that the concentration of IgG in whole gut lavage fluid (WGLF) is related to
disease activity now allows us to subdivide and stratify IBD patients into groups
with comparable disease activity. By applying WGLF analysis to studies of other
forms of gastrointestinal disease, it can be determined whether a particular
immunological phenomenon is a specific feature of one or both forms of IBD or is
simply an expression of a common form of tissue injury in the gut.
When my predecessors studied WGLF concentrations of proteins in IBD
patients in relation to "disease activity" (defined on the basis of the widely used
CDAI for CD or PTI for UC), highly significant correlations emerged, particularly for
IgG (Choudari et al 1993). Continuing experience, including the results for patients
in this study, has confirmed that WGLF IgG concentration of <10 pg/mL is
measuring the same phenomenon of "inactive disease" as these, mainly subjective,
global scores. Such scores are widely used as end points in clinical trials of IBD
treatment, and it is possible that objective tests based on WGLF analysis may be
valuable as supplementary evidence of efficacy of new treatments. However
research on WGLF proteins, together with the work of others using endoscopy
(Cellier et al), clearly show that "disease activity" is a separate phenomenon from
destructive, ulcerative, gross anatomical disease, particularly in CD. Clinical
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research methods and laboratory tests to investigate the latter are likely to differ
from those which detect disease activity. For example, in a rarely cited but
comprehensive study, many patients with "inactive " IBD (on the basis of
CDAI<150) in fact had significant gut inflammatory activity as measured by
radiolabeled leukocyte excretion (Saverymuttu 1986b).
16.1. Investigation of neutrophil migration into the gut lumen by
cytology of whole gut lavage fluid
Many approaches are being used to study gut inflammation and its
pathogenesis. These include immunocytochemical investigations of biopsies and
resected specimens, radiolabeled leukocyte studies, perfusion of isolated loops of
small bowel or colon with measurements of proinflammatory mediators, and various
immunological tests on faecal extracts. Radiolabeled leukocyte tests have
provided most of the recent descriptive information on the migration of cells into the
bowel wall and thence into the gut lumen, but more direct methods are needed to
investigate the mediators and chemotactic agents involved.
The use of whole gut lavage for research on intestinal antibodies was
described by Gaspari et al 1988. Work done by my predecessors and colleagues
have simplified and standardised the clinical protocol to create what is essentially a
whole gut perfusion system, relatively unaffected by disease, age, drugs or diet
(Brian and Ferguson, submitted for publication). After appropriate specimen
processing, WGLF analysis can be used to investigate gut immunoglobulins and
antibodies (O'Mahony et al 1990), to detect plasma protein leak (Brydon et al
1993) and bleeding into the gut (Brydon et al 1992), and for studies of mucosal
cytokines (Ferguson et al 1994a), with minimal degradation of cells and molecules
of interest.
The results presented in chapter XII show that peroral whole gut lavage can
also be used to investigate inflammatory cells within the intestinal lumen. Studies of
cells and their products can be combined with biochemical and immunological
assays on WGLF, to provide detailed analysis and characterisation of
immunological and inflammatory events in the gut. The capacity to investigate the
relatively inaccessible small bowel is clearly advantageous, and, for research in
IBD, measurement of IgG concentration in WGLF provides a simple and objective
measure of disease activity. A heterogeneous group of IBD patients can thus be
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subdivided and stratified into subsets with comparable disease activity, to allow
investigation of other factors such as corticosteroid or diet treatments, or disease
distribution (Ghosh et al 1994a). By applying WGLF analysis in other forms of
gastrointestinal disease, it is possible to determine whether a particular
immunological phenomenon is truly a feature of UC or CD, or is simply a non¬
specific expression of tissue injury in the gut.
Since it is already known that smears from centrifuged WGLF provide
specimens for cytological diagnosis of colonic carcinoma (Rosman et al 1994), and
since neutrophils can be found in faeces of IBD patients (Saverymuttu 1983b,c) it
is not surprising that inflammatory cells have been detected in WGLF samples.
With the method used, gut luminal cells can be counted as well as characterised
cytologically, and the results show high counts of luminal cells, mainly neutrophils,
in most patients with active IBD. However, it appears that this luminal neutrophilia
is not a feature of small bowel CD. Only one of our patients with ileal CD had a
high WGLF cell count, and there were two associated, complicating factors, NSAID
intake and an abscess communicating with the gut.
Only one study has reported that faecal excretion of radio-labelled
leukocytes is much higher in colonic than in small bowel CD (Saverymuttu et al
1986b); in other reports, regional data are not presented (Saverymuttu et al 1986a,
Saverymuttu et al 1983a), or there is no observed effect of regional distribution
(Teahon et al 1991). Most of these reports concern small numbers of patients, as is
the case with the present study, based on WGLF cytology.
Eosinophils, though detected less frequently in WGLF than neutrophils,
were observed in WGLF from 6 of 15 patients with active IBD and from one patient
with carcinoma complicating UC. In all of these patients, there were also many
neutrophils in the WGLF specimens. Preliminary work on assay of a biochemical
marker for eosinophils, eosinophil cationic protein, supports this finding (Croft et al
unpublished data).
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Further studies with WGLF may help to elucidate the stimuli for
inflammatory cell migration into the gut, and local activation. Various substances
may act as chemoattractants, including IL-8, bacterial peptides such as FMLP,
leukotriene-B4, complement factors such as C5a, and platelet-activating factor
(PAF) (Ghosh et al 1994a). In chapter XIV, I have investigated the role of IL-8.
16.2. Granulocyte elastase assay in whole gut lavage fluid
Cytology is time consuming and needs fresh specimens. Hence it is difficult
to obtain data on large numbers of patients during the course of routine clinical
investigations. Following on from the cytology of WGLF, I have evaluated a
biochemical assay, specific for the neutrophil granule protein GE. Enzyme-linked
immunosorbent assays for GE measure the enzyme as a complex with a-1-
proteinase inhibitor (a-1-antitrypsin)(Neumann et al 1984). The concentration of
a-1-proteinase-inhibitor in WGLF is normally very low and is affected by
disease(Brydon et al 1993), and so an ELISA for GE was unsuitable for the assay.
A different technique, independent of the presence or concentration of a-1-
proteinase-inhibitor, was therefore used. GE was released from the cells by
sonication, then assayed using a chromogenic substrate (L-pyroglutamyl-L-prolyl-L-
valine-p-nitroanilide) specific for GE, and a colorimetric method. Free GE in the
fluid can also be measured, in pre-filtered specimens, thus providing further
information on cell activation.
The present study shows that WGLF GE concentration significantly
correlates with cell count, confirming that GE is an excellent surrogate marker for
luminal neutrophilia. Results of GE assays in this large series confirm and extend
our cytological findings, that most, but not all, patients with luminal neutrophilia
have IBD. When stratified separately by disease distribution (based on X-ray and
endoscopic findings) and by disease activity (based on concentration of IgG in
WGLF), it emerges that luminal neutrophilia is a feature of active UC and active
colonic CD but is not normally present in patients with active CD of the small bowel.
This confirms the results of cytology.
There is an alternative although unlikely explanation of the regional
differences in WGLF GE concentration in active disease, namely that there is a
difference in the relationship between WGLF IgG concentration and disease
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activity (as measured, say, by CDAI) if small bowel and colonic disease are
considered separately. Re-examination of the raw data from my predecessors^
earlier report does not support this (Choudari et al 1993).
Neutrophils and GE are also present in the WGLF from patients with
diseases other than IBD, particularly in those whose clinical background was
compatible with neutrophil migration through the gut wall. Acute radiation
proctocolitis and diverticulitis are conditions obviously associated with pus present
on the mucosa. A pericolic abscess communicating with the lumen may discharge
pus, which is the likely explanation in our patient with carcinoma of the colon with
elevated GE. Non-steroidal anti-inflammatory drug (NSAID) use has been shown to
be associated with isotope-labelled leukocyte excretion into the lumen, probably
from small intestine (Bjarnason et al 1987); two of our patients with markedly raised
WGLF GE but normal IgG concentrations, were taking NSAIDs. The gut bacterial
flora may have a role in NSAID enteropathy, as there is evidence that the
neutrophil chemoattractant may be a metronidazole-sensitive micro-organism
(Bjarnason et al 1992). Flowever, metronidazole may affect neutrophil chemotaxis
by inhibiting endothelial cell adhesion as shown in rat models, independent of its
antimicrobial action (Arndt et al 1994).
The patient with active colonic CD who had undetectable GE in WGLF
deserves further comment. This 25-year-old British man had developed diarrhoea
while working in India, and had received prolonged courses of tetracycline to treat
what was presumed to be tropical sprue before the diagnosis of CD was made.
Another patient with active perianal CD and undetectable GE had received
prolonged courses of metronidazole. Effects of antibiotic treatment on luminal
neutrophils and luminal chemo-attractants will be a fruitful area for further research.
The relationship between disease activity (IgG in WGLF or the physician's
global score) and WGLF GE was not so clear-cut in UC patients. All those with
active UC and undetectable GE were receiving systemic or local steroids, which
presumably modified their inflammatory immune response, though no significant
effect of steroid therapy could be detected when analysing the whole group of IBD
patients. Serial studies with whole gut lavage to assess the response to treatment
(which are in progress) may clarify the effect of steroid treatment better than these
cross-sectional studies and, indeed, preliminary unpublished data for CD show that
WGLF IgG and GE do not diminish at comparable rates when patients are treated
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with systemic steroids. In the present series, six of the 15 patients with inactive UC
had detectable GE in WGLF, three of whom were on systemic steroids. This
reinforces the difference between clinical definition of activity and the objective
measure of inflammation provided by a marker of neutrophils. Measurement of
specific parameters of mucosal inflammation may allow much better definition of
full remission.
There were a few IBD patients in whom results of total and free GE assays
showed the presence of both cell-bound and cell-free GE in WGLF, indicating
neutrophil degranulation; other IBD patients had cell-bound (or, strictly speaking,
particulate) GE only. Total GE levels were significantly higher in the former group,
but disease activity, as measured by WGLF IgG concentration, was similar in those
with and without free GE. I had expected that free GE would not be present in
steroid-treated patients, because of the stabilising effect of these drugs on cell
membranes, but in fact the opposite was found. These data can be explained
within the framework which is being promoted by our institution (Ferguson et al
1994a), that IBD "illness" is due to a combination of inflammatory, destructive,
infectious and other factors. Thus although a group of steroid-treated patients have
a comparable level of disease activity to a group of non-steroid-treated patients (by
CDAI, global assessment orWGLF IgG concentration), there may remain striking
differences in overall illness severity, as reflected in our patients by luminal
neutrophilia.
The effect of corticosteroids on luminal migration of neutrophils has not
been well investigated in longitudinal studies and hence it is not known whether
steroids may actually promote neutrophil migration into the lumen when the
disease is still active. As emphasised above, it is probable that WGLF IgG and GE
are in fact dissecting different facets of inflammation and giving different
information about the inflammatory state of the mucosa.
16.3. Investigation of proinflammatory cytokines in WGLF
The role of cytokines in intestinal inflammation can be investigated by a
variety of techniques. The cytokine protein may be directly detected by ELISA or its
biological effects may be measured by bioassay. Bioassays are unsuitable for
measurement of gut-derived cytokines and this has been shown by previous work
in our laboratory - the bioactivity of these proteins is often lost in the gut lumen as a
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result of enzymatic action. Gut tissue homogenates (Brynskov et al 1992a) or
isolated mucosal mononuclear cells (Mahida et al 1989, Pullman et al 1992) in
culture are often used to detect cytokine proteins by ELISA.. The cytokine message
may be detected by in-situ hybridization (Cappello et al 1992) using nucleic acid
probes. This is useful if the protein is quickly destroyed in-vivo, and this method is
also widely used for cellular localisation of the production of these cytokines.
Expression of the cytokine gene or tiny amounts of message may also be detected
by the polymerase chain reaction (PCR) (Isaacs et al 1992, Izutani et al 1995) or
reverse-transcriptase PCR (Eckmann et al 1993). Access to tissues is generally
needed for all the above methods, thus limiting their application to when surgery or
colonoscopy is performed. Investigation of the role of cytokines in small bowel
disease is difficult unless the patient had a surgical resection. Data obtained from
resection specimens are subject to a number of confounding variables such as the
duration of inflammation, prior medical therapy, complications such as abscess
formation and the surgical manipulation itself and hence must be interpreted with
great caution. Though colonic disease is accessible to colonoscopy, this is an
invasive procedure and not particularly suited for research use. In CD, patchiness
of involvement leads to sampling bias and the bowel preparation technique may
influence results. Even in colonic disease, serial studies to investigate changes
resulting from therapy are virtually impossible., and establishing a baseline prior to
modification by therapy may be difficult. A particular problem has been in obtaining
'real' healthy controls - for ethical reasons this is hardly ever possible.
Some of this drawbacks may be circumvented in clinical practice by the use
of the WGLF analysis technique. Work done my predecessor (Mwantembe, Ph.D.
thesis, 1992, University of Edinburgh) had shown that cytokines such as TNF-a or
their receptors such as IL-2R could be detected in WGLF. In this thesis I have
concentrated on IL-1 p and IL-8, IL-6 and IFN-y. Interest in IL-8 was a logical
continuation of the previous work on neutrophil migration, as IL-8 is a potent,
specific neutrophil chemoattractant (Baggiolini et al 1989) and is probably the first
neutrophil chemoattractant to be produced by activated mononuclear cells as a
result of immune activation (Harada et al 1994). IL-1 p is one of the cytokines
stimulating mononuclear cells to produce IL-8. Furthermore, as discussed in
chapter II, IL-1 p is an important cytokine involved in metabolic alterations in
inflammation and attempts to measure IL-1 p in serum in IBD by other workers have
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been consistently disappointing (Satsangi et al 1987, Brynskov et al 1991). IL-6
may act as an important second messenger of IL-1 and TNF (Brynskov et al
1992b) and IFN-y activates several important inflammatory cells.
Analysis of WGLF showed that the concentration of the proinflammatory
cytokine IL-1 p was significantly raised in active IBD. The role of IL-1 p in intestinal
inflammation and metabolic abnormalities has been reviewed in chapter II. An
interesting observation was the detection of IL-1 p in WGLF in almost half of the
patients with inactive CD and in two-thirds of the patients with inactive UC. The
median concentration in inactive IBD was significantly lower than in active IBD. This
shows a dissociation between clinical remission in disease activity (which is
indicated by a WGLF IgG concentration <10pg/mL) and immunological events in
the gut mucosa. Previous studies using 111ln-labelled leukocytes had demonstrated
significant leukocyte migration into the gut lumen in inactive CD (CDAI < 150)
(Saverymuttu 1986b) and this was confirmed by analysis of GE in lavage fluid as
described in chapter XIII. Detection of IL-1 p was not specific to IBD as other
inflammatory and neoplastic diseases of the gut such as radiation enterocolitis,
infective colitis, ischaemic colitis, NSAID enteropathy and carcinoma of the colon
also had detectable IL-1 p. However, only 4 of these patients (with radiation colitis
and carcinoma of the colon) had an IL-1 p concentration greater than 100pg/mL,
which was commonly found in active IBD. There was no difference in IL-1 p
between small bowel and colonic CD. Those on systemic steroids had a similar
concentration to those not on steroids for a given disease activity.
IL-8 concentration in WGLF was significantly increased in active IBD but not
in inactive IBD. Detectable IL-8 levels were present in only about half of the
patients with active IBD. There was no difference in IL-8 levels between small
bowel and colonic CD and those on systemic steroids had a similar concentration
to those not on steroids for a given disease activity. Detectable IL-8 concentrations
were present less frequently in the diseased controls; patients with radiation colitis,
carcinoma of the colon and microscopic colitis had detectable WGLF IL-8 and
these diseases were characterised by luminal neutrophilia.
The mechanism for neutrophil migration into the gut lumen in intestinal
inflammation is likely to be multifactorial. IL-8 concentration in WGLF is likely to
reflect luminal concentration, though it is obviously diluted by the lavage.The
finding that increased amounts of IL-8 in the lumen were accompanied by
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increased number of neutrophils as measured by GE concentration in WGLF in UC
makes IL-8 a possible factor involved in luminal migration of neutrophils. This is in
accordance with rectal and sigmoid perfusion studies which found that IL-8
concentration in the perfusate correlates with myeloperoxidase released from
neutrophil granules in UC (Raab et al 1993). In contrast, in CD, there was no
correlation between IL-8 concentration and GE concentration - this was true both
for small bowel and colonic involvement. This suggests that the mechanism of
neutrophil migration into the gut lumen in UC and CD might be different. In CD,
luminal neutrophilia was mainly a feature of colonic CD but not small bowel CD. A
luminal chemoattractant such as bacterial peptide with an aboral gradient might be
involved in CD. Further support for this hypothesis comes from the finding that
neutrophils were often absent from the gut lumen subsequent to antibiotic therapy
as mentioned above. It is noteworthy that luminal neutrophilia in NSAID
enteropathy was unaccompanied by any increase in IL-8 concentrations - as
mentioned above, there is evidence that neutrophil migration in this condition is
due to a metronidazole sensitive microbe (Bjarnason et al 1992). Teahon et al
1993 has provided evidence, based on radiolabeled red and white cell
scintigraphy, that the mechanisms of neutrophil migration in CD and UC might be
different - in CD, an intraluminal signal may be involved whereas in UC, the
neutrophils are activated and degranulated within the mucosa. Furthermore,
neutrophil migration in NSAID enteropathy may have a similar mechanism to CD.
The findings presented in the previous chapters would provide further support for
this hypothesis.
IL-1 p is a potent inducer of IL-6 in both macrophages and T-cells (Bendtzen
1991b). Colonic mucosal IL-6 has been reported to be increased in IBD (Mitsuyama
et al 1991). However, IL-6 was infrequently detected in WGLF. The short half-life of
IL-6 (5 minutes) might be one possible explanation (Brynskov et al 1992b). IFN-y is
a lymphokine that acts as a potent activator of macrophages (Bendtzen 1991a).
IFN-y too was infrequently detected in WGLF. IFN-y production in the inflamed
mucosa has been variably reported by workers as normal (MacDonald et al 1990),
decreased ( Lieberman et al 1988) or increased (Fais et al 1991), and
methodologic differences are likely to be responsible for the discrepancies.
One of my reasons to explore methods of measuring gut derived cytokines
was to investigate their role in producing nutritional abnormalities, such as
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osteopenia. The results presented in chapter XIV did not show any difference
between CD and UC in WGLF IL-ip or IL-6 concentrations. It may be seen from
table 14.11 that, even in untreated patients, the concentration of WGLF IL-ip was
similar in CD and UC. This was true for the other cytokines measured, such as IL-6,
IFN-y and IL-8. Work with TNF-a is ongoing, and has not been presented in this
thesis. Though certain pro-inflammatory macrophage derived cytokines have been
measured in this thesis, biological activity of cytokines is complex. IL-1 activity, for
example, is modulated by two soluble IL-1 receptors and blockade of receptors by
the naturally occurring IL-1-receptor antagonist (Dinarello and Wolff, 1993). Unless
the relevant cytokine antagonists and soluble receptors are measured, the
interpretation of results obtained by assaying a particular cytokine is limited.
Further work is needed in analysis of WGLF by assaying, for example, IL-1-
receptor antagonist and studying the IL-1/IL-1-receptor antagonist ratio. The work
in this thesis should be considered descriptive, till such analytical data is obtained.
16.4. Growth factor peptides
Cytokines and growth factors secreted by immunocytes in the inflamed
intestine can profoundly affect the activation state of mesenchymal cells, thereby
amplifying the inflammatory response and probably contributing to fibrosis (Sartor
1994). IL-1 stimulates the proliferation of intestinal smooth muscle cells and
fibroblasts. IGF-1 and TGF-p stimulate proliferation of fibroblasts and induce
collagen synthesis by fibroblasts and smooth muscle cells. WGLF IGF-1 was
detectable in patients with CD, often associated with strictures, but was
undetectable in UC except in an atypical patient with long-standing active disease
on cyclosporin. IGF-1 was present in both active and inactive CD patients. Other
patients with detectable IGF-1 in WGLF had conditions known to be associated
with increased fibrogenesis, such as post-radiotherapy, ischaemic colitis,
diverticulitis, microscopic colitis, pouchitis and carcinoma of the colon. TGF-p!, on
the other hand, was detectable in all WGLF samples and did not discriminate
between CD and UC. TGF-p is a dominant endogenous factor in promoting
reconstitution of the integrity of the epithelium (Montesano et al 1988), and the




In conclusion, WGLF analysis is a powerful technique to investigate
immunoinflammatory events in the gut in large numbers of well-stratified
heterogeneous patients. Neutrophil migration may be directly quantitated using a
simple assay and chemoattractants involved in neutrophil migration may be
investigated. Proinflammatory cytokines such as IL-1 p which initiate a cascade of
cellular activation may also be measured. It is clear that most of the abnormalities
detected are not specific for IBD but may be found in other inflammatory conditions
of the gut. However, this technique has permitted the reporting of previously
unrecognized differences between small bowel and colonic CD disease and in the




My work described and discussed in this thesis not only confirms that
Crohn's disease (CD) is associated with increased nutritional morbidity, but also
presents evidence that direct effects of the disease may be important in causing
specific nutritional disorders such as low bone mineral density. Body composition
changes are in keeping with the hypothesis that specific metabolic derangement
occur in CD. These findings support the concept of CD as a systemic disorder with
a long premorbid period and distinguish it from ulcerative colitis (UC), a local
mucosal disease. Furthermore, children and adolescents have been identified as a
specially vulnerable group for osteopenia in addition to growth and developmental
delay. Having completed the phase of work described and in parallel with writing
up this thesis, I am now embarking on a programme of work to take further the
issues and concepts I have developed.
(1) A prospective study to address the question of osteopenia in children
and adolescents with IBD is in preparation. The severity and prevalence of this
problem would be investigated in a large cohort. Patients with spine Z-score lower
than -1.0 would be randomised to one of two intervention groups: a programme of
physiotherapy Vs physiotherapy and vitamin D/calcium supplements.
(2) It has recently become possible to investigate bone metabolism by
measuring reliable and sensitive markers of bone turnover. A collaboration has
been set up with Dr Simon P Robins who heads the bone research group at the
Rowett Research Institute, Aberdeen, to measure plasma and urinary markers of
bone turnover in a new cohort of IBD patients at diagnosis. Preliminary results of
this ongoing study are presented in chapter VI. The findings of this study may
influence choice of potential therapeutic interventions.
(3) Though corticosteroid therapy is not the only factor causing osteopenia
in CD, it is certainly contributory. In UC, it probably is the most important factor
causing osteopenia. Locally active steroids with high first-pass metabolism, such as
budesonide, have recently become available for treatment of IBD and a
multicentre study is being launched to compare bone mineral loss after treatment
with budesonide controlled-release capsules compared with conventional
prednisolone therapy.
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(4) Analysis of the laboratory studies done as a part of this thesis showed
that whole gut lavage fluid (WGLF) analysis is a powerful tool to objectively
measure immuno-inflammatory events in CD or UC. Neutrophil migration into the
gut lumen was found to be a feature of colonic CD and UC but not of small bowel
CD. IL-8 might be the relevant chemotactic factor for luminal migration of
neutrophils in UC but, in CD, other chemoattractants with aboral gradient such as
bacterial peptides are clearly worthy of further studies. There are various methods
to study neutrophil chemotaxis in vitro (Zigmond et al 1986); the neutrophil
polarisation assay has been developed by Professor Wilkinson's team in Glasgow
as a useful, robust screening test for neutrophil activation and migration (Haston et
al 1985). Studies have been set up in collaboration with Professor Wilkinson to
assess the polarisation of neutrophils in the presence of WGLF from normals and
IBD patients. This would aim to study the relative contribution of various
chemoattractants including bacterial peptides in promoting neutrophil migration into
the gut lumen.
(5) A further study is investigating the differences between small bowel and
colonic CD for a given clinical disease activity using WGLF.
(6) Body composition analysis by a portable user-friendly machine was
found to be a convenient and accurate method of measuring lean and fat
compartments at the bedside. A cross-sectional study on a large cohort of IBD
patients and healthy and diseased controls has recently been completed by a
visiting dietitian which should provide further data. Preliminary analysis of this data
clearly shows that underweight patients, who are mostly patients with CD, are
heterogeneous regarding the proportion of lean and fat, unlike in normal weight
patients where increasing body mass index is accompanied by an increase in
percent fat. Undernutrition in CD is widely regarded as being multifactorial, but the
contribution of the various factors, such as malabsorption, reduced intake,
inflammation, surgery and medical therapy may now be analysed in terms of body
composition changes. Precise therapeutic interventions for nutritional support will
depend on understanding these complex pathogenetic issues.
It is hoped that this work and the methods developed will link with other
developments by the members of the research group, including studies of
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Low Bone Mineral Density in Crohn's Disease, but Not in
Ulcerative Colitis, at Diagnosis
SUBRATA GHOSH,* STEPHEN COWEN,t W. JAMES HANNAN,* and ANNE FERGUSON*
•Gastrointestinal Unit and 'Department of Medical Physics, Western General Hospital and University of Edinburgh, Edinburgh, Scot.and
Background/Aims: The pathogenesis of low bone min¬
eral density in patients with inflammatory bowel dis¬
ease is unclear, and the relevance of secondary os-
teopenic influences is controversial. Our aim was to
study bone mineral density in newly diagnosed pa¬
tients. Methods: Bone mineral density and biochemical
parameters of bone metabolism were measured in 15
patients with Crohn's disease and 15 patients with
ulcerative colitis, all of whom were newly diagnosed.
Lumbar and forearm bone mineral densities were mea¬
sured by dual energy x-ray absorptiometry, and Z scores
were obtained by comparison with age- and sex-
matched normal values. Twenty-three patients had re¬
peat measurements 1 year later, and 20 had received
systemic steroids. Results: At diagnosis, the mean
Z score for patients with Crohn's disease (spine,
( -1.06 ± 0.86; forearm, -1.04 ± 0.86) was signifi¬
cantly lower than that for patients with ulcerative colitis
(spine, —0.03 ± 1.16; forearm, 0.11 ± 1.24). Inflam¬
matory activity, disease localization, body mass index,
smoking habits, sex, physical activity, or biochemical
parameters did not account for this difference. Spine
and forearm Z scores were significantly correlated.
Mean Z scores after 1 year were not significantly differ¬
ent from initial Z scores. Conclusions: At diagnosis,
low bone mineralization is a feature of Crohn's disease
but not ulcerative colitis. Treatment with corticoste¬
roids did not result in further bone loss in 1 year.
Low bone mineral content (BMC) has been convinc¬ingly shown in unselected groups of patients with
inflammatory bowel disease (IBD),1"'1 but the pathogene¬
sis of the osteopenia is incompletely understood. No cor¬
relation between bone loss and serum parameters of bone
metabolism has been shown." Although the deleterious
effects of corticosteroids on trabecular bone mass are well
documented,5'6 longitudinal studies in patients with IBD
have failed to show any significant correlation between
the rate of bone loss and prednisolone therapy.7 However,
conflicting evidence from cross-sectional studies indi¬
cated that cumulative corticosteroid use may be an im¬
portant8'9 or even the sole cause10 of osteopenia in patients
with IBD. This is contradicted by other cross-sectional
studies."
Various factors, such as small intestinal resection,'"
ileal involvement,9 vitamin D deficiency,13 smoking,8
body mass index,7 and height,11 have been correlated
with osteopenia in IBD, reflecting the heterogeneous na¬
ture of the patient cohorts studied by various workers.
We still do not know the extent to which bone mineral
loss in IBD occurs as an integral manifestation of the
disease as distinct from the secondary osteopemc influ¬
ences of corticosteroid therapy, surgical intervention, in¬
activity, malabsorption of calcium and vitamin D. or the
cachexia of inflammation.
There has been no comparative study on bone mineral¬
ization in patients with Crohn's disease (CD) and ulcera¬
tive colitis (IJC). CD may lie considered a systemic dis¬
ease, whereas UC is more limited to colonic mucosal
inflammation; CD also has important immunologic dif¬
ferences from UC.15
We have studied bone mineral density (BMD) in a
series of newly diagnosed patients with CD ar.J UC.
Both spine and forearm BMDs were studied so that tra¬
becular and cortical mineralization could be assessed be¬
cause there are metabolic differences between these two
types of bones.16 Newly diagnosed patients were studied
to avoid most of the secondary osteopenic influences men¬
tioned previously. The measurement of BMD was re¬
peated about 1 year after diagnosis to assess progressive
bone loss and the effects of therapy.
Materials and Methods
Subjects
A total of 30 consecutive patients (17 male and 13
female) ranging in age from 14 to 83 years (median, 26 years)
with newly diagnosed IBD were studied between Marcn 1991
and August 1993. The diagnosis and disease extent in all
patients were confirmed by histology, endoscopy, and radiol¬
ogy. In 15 patients (9 male and 6 female) ranging in age from
I t to 83 years (median, 24 years), CD was diagnosed. In
Abbreviations used in this paper: BMC, bone mineral content;
BMD, bone mineral density; BMI, body mass index; DEXA, dual en¬
ergy x-ray absorptiometry.
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another 15 patients (8 male and 7 female) ranging in age from
14 to 63 years (median, 28 years), UC was diagnosed. The
distribution of disease is given in Table I.
None of the patients were pregnant, and none had known
cholestasis, renal disease, hypogonadism, previous gastric sur¬
gery, or thyroid or parathyroid disorders.
The logistics of setting up DMD studies normally meant a
delay of 2-3 weeks. For ethical reasons, we did not attempt
to delay appropriate medical treatment during this interval.
As a result, BMD measurements were made in 14 of the 30
patients shortly after the start of oral corticosteroids; in 13
patients, the duration ranged from 4 to 14 days and, in one
case, 19 days.
Clinical Assessments
The patients were clinically assessed by one of the
investigators (S.G.), and each patient completed a diary card
for 1 week before BMDs for calculation of Crohn's Disease
Activity Index (CDAI).' The hematocrit for CDA1 was ob¬
tained from the full blood count. For patients with UC, both
the CDAI and the Powell-Tuck index" were calculated.
Smoking status, bone fracture history, and experience of con¬
traceptive pill and hormone replacement therapy were re¬
corded. The CDAI with or without the Powell-Tuck index
were again calculated just before follow-up measurement of
bone density. Height and weight were recorded, and the body
mass index (BMI) was calculated as weight (in kilograms)
divided by height (in meters).2 The estimated duration of
disease (in weeks) before diagnosis was also recorded. All pa¬
tients younger than 20 years old had bone age assessed from
a radiograph of the left wrist and hand (Greulich and Pyle).
Assessment of Physical Activity
The level of physical activity at the time of diagnosis
and the premorbid level of physical activity when the patient
was last free from IBD manifestations were recorded on a 1-
5 scale as follows: (1) predominantly homcbound, (2) walks
once a week for shopping, (3) average activity (no formal exer¬
cise or hard work), (4) active (gymnasium, games, formal exer¬
cise at least once per week), and (5) regular athletic activities.
The level of physical activity at the time of follow-up measure¬
ment of bone density was also recorded.
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The scale of physical activity was validated against the
Baecke habitual physical activity questionnaire, which is a
reliable self-administered measure of physical activity." Seven
study patients, 10 patients with IBD not in the study, and
10 healthy volunteers completed the Baecke habitual physical
activity questionnaire and were also graded on the scale given
above by one of the investigators (S.G.). The age range of the
participants was 18-57 years (16 men and 11 women). The
Baecke questionnaire scores three dimensions of physical activ¬
ity: work, sport, and leisure time. Grades 1 and 2, grade 3,
and grades 4 and 5 significantly differed from each other in the
mean scores of all of the three dimensions. Grade 1 significantly
differed from grade 2 only in work score, and grade 4 differed
from grade 5 only in sport score.
Bone Density Measurements
We used a I lologic QDR - 1000/W (Hologic Inc., Wal-
tham, MA) scanner to obtain dual energy x-ray absorptiometry
(DEXA) measurements of lumbar L1-L4 vertebrae20 and the
right forearm (both radius and ulna). The Hologic forearm
application protocol defines a global region of interest encom¬
passing three individual forearm sites: (1) the one-third distal
region is defined as a region 20-mm wide centered at a distance
equal to one third of the forearm length measured from the
distal tip of the ulna and contains mostly cortical bone; (2)
the ultradistal region is 15 mm in length positioned proximal
to the end plate of the radius, excludes the end plate of the
radius, and contains mostly trabecular bone; and (3) the mid-
distal region is the region between the one third and ultradistal
regions and contains both trabecular and cortical bones. At
our center, dominant and nondominant forearms were found
to be comparable. The BMC divided by the area of interest
gave the BMD in grams per centimeter square. The average
BMD values for LI -L4 and the three forearm sites were used
for calculations. Normal values for BMD readings with the
Hologic QDR-1000/W scanner were available as mean BMD
(±SD). The normal values for LI -L4 were available from age
0-85 years for both males and females; for forearm measure¬
ments, normal values were available from age 20 — 85 years for
both males and females. The normal values were provided by
the Hologic reference database obtained from healthy white
volunteers of either sex (spine, 605 female, and 294 male
subjects; forearm, 366 female, and 70 male subjects). None
were taking steroids, anticonvulsants, fluoride, diuretics, or
estrogens. Subjects older than 60 years of age had a lateral
spine radiograph, and evidence of vertebral fractures or spine
BMD below 0.82 g/cm2 were considered as exclusion criteria.
Statistical thresholds were set, and individuals below the first
and above the 99th percentiles were excluded. Because the
Hologic reference database is based on a United States popula¬
tion, we recruited 100 healthy normal volunteers from the
local Scottish population. BMD values obtained from locally
recruited control subjects were not significantly different from
the Hologic reference database; hence, this database was used
for our control values.
For scan-rescan measurements at our center, the coefficient
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of variation for the lumbar vertebrae is 0.8%, and that for the
forearm is 0.5%.
Z scores were calculated lor each patient using the formula
Z score =
Measured BMD — Normal BMD (age- and sex-matched)
SD of the Normal BMD
Z scores were available for all BMDs from L1-L4; Z scores
for the forearm could only be calculated for patients 20 years
of age or older. In one 28-year-old man with UC, forearm
BMD was not available.
Bone density measurements were performed after diagnosis
and at follow-up 1 year later.
Biochemical Measurements
These were performed at the first assessment after diag¬
nosis before measurement of BMD. These included (I) plasma
calcium and urinary calcium/creatinine ratio measured in a 24-
hour sample of urine collected in a special container containing
HCI, (2) plasma phosphate and urinary phosphate/creatinine
ratio measured in a 24-hour sample of urine, (3) plasma albu¬
min, (4) plasma alkaline phosphatase, (5) plasma 25-hydroxyvi-
tamin D, (6) plasma immunoreactive parathyroid hormone,
and (7) urinary hydroxyproline/creatinine ratio measured in a
24-hour sample of urine collected in a special container with
toluene.
Blood samples were taken after an overnight fast to avoid
any influence of meals on serum phosphate concentration. 25-
OH-D levels were measured throughout the year (4 patients
in winter, 8 in spring, 8 in summer, and 10 in autumn) and
compared with seasonally adjusted reference values. Plasma
total calcium, phosphate, alkaline phosphatase and urinary cal¬
cium, and phosphate creatinine concentrations were measured
by standard routine methods. Plasma immunoreactive parathy¬
roid hormone was measured by immunoradiometric assay21
(Nichols Allegro immunoradiometric assay; Nichols Institute
Diagnostics, Geneva, Switzerland). Plasma 25-OH-D (D_, +
Dj) was measured by a competitive binding assay.22 Urinary
hydroxyproline was measured by colorimetric method.23
Statistical Analysis
Comparison between CD and UC was made using the
unpaired r test. Comparison of initial measurements with fol¬
low-up measurements was made by the paired t test. Correla¬
tion coefficients were calculated with the Pearson's correlation
test.
Ethical Considerations
The study was approved by the Medicine Subcommit¬
tee of the Lothian Area Ethics of Research Committee. Each
patient gave informed verbal consent.
Results
The age and sex distribution, duration of symp¬
toms before diagnosis, physical activity grade, and dura-
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Table 2. Clinical Features of CD and UC
Features CD UC
Age (yr) 24 (14-83) 28 (14-63)
Sex (M/F) 9/6 8/7
Estimated duration of
disease before
diagnosis (vvA) 18.6 (18.6) 12.3 (15.5)
Duration of steroid use
before BMD
measurement (wk) 1.2 (1.1) 0.5 (0.8)
Grade of physical activity
Premorbid 3.7 (0.6) 3.9 (0.3)
At diagnosis 2.8 (0.6) 3.1 (0.9)
BMI 21.38 (3.17) 22.36 (4.33)
Active disease
CDAI > 150 or Powell-Tuck
index > 4 11 10
NOTE. All values are expressed as mean (SD) except age, which is
given as median (range).
tion of steroid use before diagnosis for CD and UC are
summarized in Table 2. The mean spine Z score was
— 0.56 (SD, 1.07) for 17 male patients and —0.48 for
1 3 female patients (SD, 1.25; P — NS). The mean of the
1 2 forearm Z scores available from male patients was not
different from the mean of 9 forearm Z scores available
from female patients ( — 0.41 ± 1.49 vs. —0.66 ± 0.99;
P = NS).
The mean BMIs in patients with CD and UC are also
given in Table 2. The spine and forearm Z scores obtained
from BMC per unit area expressed as SD from the age-
and sex-matched means were not significantly correlated
with BM1 (r = 0.20 and 0.11, respectively). However,
spine and forearm total BMC significantly correlated
with BMI (r — 0.76 and 0.75; P < 0.05), which implied
that increasing BMI was associated with larger bones
and, hence, a larger area of interest.
Four patients (2 girls with UC and 2 boys with CD)
were younger than 16 years old. The patients with UC
were on the 90th and > 97th percentile in height. The
patients with CD were on the 90th and 3rd percentile
in height. The 14-year-old boy with CD with height on
the 3rd percentile had a bone age of 12. The bone age
of the remaining three adolescents was appropriate for
age. Four other patients (3 with UC and I with CD)
were 18-19 years old, and none of them were short-
statured (2 men with UC, 182 and 178 cm; 1 woman
with UC, 157 cm; 1 woman with CD, 155 cm); their
bone ages were that of mature adults.
The mean height of 7 men 20 years of age and older
with CD (173 cm [SD, 4 cm]) was not different from
the mean height of 6 men 20 years of age and older with
UC (173 cm [SD, 5 cm]). The mean height of 5 women
20 years of age and older with CD (1 58 cm [SD, 6 cm])
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was not significantly different from the mean height of
4 women 20 years of age and older with UC (166 cm,
tSD. 4 cm]).
The mean CDA1 in patients with CD was 196 (SD,
70). CDAI was calculated for patients with UC, and this
was not different from that for patients with CD (mean,
164; SD, 105; P — NS). Eleven of the 15 patients with
CD had a CDAI > 150, indicating active disease. Ten
of the 15 patients with UC had a Powell-Tuck index
>4, indicating active disease (Table 2). There was no
correlation between the CDAI and spine or forearm Z
score (r = —0.17 and —0.20, respectively) in patients
with CD. Likewise, there was no correlation between
spine or forearm Z score and the Powell-Tuck index (r =
— 0.26 and —0.22, respectively) in patients with UC.
Nine patients with CD had colonic involvement only,
and six patients with CD had small bowel involvement.
The spine and forearm Z scores in these two groups of
patients are shown in Table 3- The Z scores for the two
CD groups with different anatomic regions involved did
not differ significantly.
Fourteen of the 30 patients were smokers, and the
remainder were nonsmokers or ex-smokers. The mean
spine Z score was —0.26 (SD, 1.15) in the 14 smokers
and —0.74 in the 16 nonsmokers and ex-smokers (SD,
1.11). The difference was not significant. The forearm Z
scores were available for 10 smokers and 1 1 nonsmokers
and ex-smokers; the mean Z scores were not different
(-0.58 ± 0.65 vs. -0.47 ± 1.51; P = NS). Among
patients with CD, 8 were smokers; their spine and fore¬
arm Z scores were not different from those of the non-
smokers.
Two patients with CD were taking hormone replace¬
ment therapy for more than 5 years; their spine Z scores
were —2.9 and —1.0. In neither case was bone disease
the reason for prescribing hormone replacement therapy.
Secondary amenorrhea was present in 1 patient with CD
(spine Z score, —1.5) and 1 patient with UC (spine Z
score, —1.1). Three patients with CD were taking oral
contraceptives (spine Z scores, —0.6, 0.6, and — 1.2), and
4 patients with UC were taking oral contraceptives (spine
Z scores, —0.4, —0.5, 1.3, and —1.2).
Table 4 shows the biochemical parameters in CD and
UC. None of the parameters were significantly different
in the two groups of patients. Plasma Ca2+ levels were
Table 3. Z Scores in CD According to Region of Involvement
Table 4. Biochemical Markers of Calcium Homeostasis






(Mean [SD)) (Mean [SD))
Spine Z score -1.09 (1.12) (n = 9) -1.02 (0.41) (n = 6)
Forearm Z score -0.86 (0.67) (n = 8) -1.35 (1.17) (n = 4)
Total calcium (mmol/L)"
(2.25-2.50) 2.29 (0.04) 2.30 (0.04)
Urinary Ca/cteatinine 0.26 (0.20) 0.29 (0.39)
Plasma P0„ (mmol/L) (0.87-1.45) 1.11 (0.16) 1.22 (0.17)
Urinary PO„/creatinine 0.50 (0.29) 0.80 (1.12)
Urinary OH-proline/creatinine 16.07 (4.46) 15.93 (3.88)
25-0H D (nmol/L) 36 (11) 41 (13)
Summer (15-100) 45 (12) 47 (14)
Winter (15-50) 28 (10) 37 (11)




hormone (ng/L) (10-55) 39 (15) 41 (17)
"Total calcium corrected for albumin where appropriate.
low in 2 patients with severe UC, both of whom had
low plasma albumin levels; corrected Ca2* levels were
normal. Although urinary hydroxyproline excretions
were above the upper limit of normal (168 [imol ■ 24 h '
per square cm 1 of body surface) in 8 of the 30 patients,
urinary hydroxyproline/creatinine ratios were within nor¬
mal limits in all patients.
Bone Density of Lumbar Spine
Figure 1 shows the lumbar BMD values related
to age in patients with CD and UC separately for males
and females. The mean spine BMD (0.88 ± 0.17) in
patients with CD was significantly less than that in pa¬
tients with UC (1.03 ± 0.14; P < 0.02). The rest of
the comparisons between CD and UC are based on Z
scores because these are indexed against age- and sex-
matched controls.
Figure 2 shows the Z scores of lumbar spine for pa¬
tients with CD and UC. The mean spine Z score for
patients with CD was —1.06 (SD, 0.86), whereas the
mean Z score of patients with UC was —0.03 (SD, 1.16).
This difference is significant (P < 0.02). The mean Z
score of the seven patients with proctitis was 0.16 (SD,
1.2), and this was not different from the mean Z score
of the eight patients with more extensive UC ( — 0.2 ±
1.17; P = NS).
The 14-year-old boy with height on the 3rd percentile
had his spine Z score recalculated using his bone age.
This altered his spine Z score from —1.5 to —0.5 but
did not alter the significance level of the difference be¬
tween CD and UC (P < 0.02).
Bone Density of Forearm
Figure 3 shows the forearm BMDs for patients
with CD and UC separately for males and females. Fore-
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arm Z scores were available lor 12 patients with CD and
9 patients with UC who were 20 years of age or older
(Figure 2). The mean forearm Z score for patients with
CD was —1.04 (SD, 0.86), whereas the mean forearm Z
score for patients with UC was 0.11 (SD, 1.24). This
difference is significant (P < 0.05).
The three different measurement sites of the forearm
were separately analyzed as shown in Table 5. The Z
scores for all three sites were significantly lower for pa¬
tients with CD compared with patients with UC.
Relation Between Forearm and Spine
Bone Density
Forearm Z scores were available for 21 of the 30
patients studied. The forearm Z scores of these patients
were significantly correlated with spine Z scores (r —
0.52; P — 0.02) (Figure 4).
Follow-up
Follow-up data could be obtained in 1 1 of the 1 5














Figure 1. BMD of lumbar vertebrae L1-L4 in patients with IBD. (A)
Male, (£) female. ■, CD; A, UC; tttt!, mean ± 1 SD in normals.
steroids. In addition, (our patients had received rectal
steroids. The mean cumulative corticosteroid dose be¬
tween the initial and follow-up BMD measurement was












































Figure 2. BMD Z scores in patients with CD and patients with UC at
diagnosis. (A) Lumbar spine; (0) forearm. The horizontal bars repre¬
sent mean values.
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prine. Two patients hat! rcsectional surgery within this
period (colectomy, 1; ileal resection, 1). The mean CDAI
(86 ± 58) had decreased significantly (P < 0.02). Only
one patient had a CDAI above I 50 at the time of follow-
up. The mean physical activity grade at follow-up was
3.1 (SD, 0.8), and this was not significantly different
from that at diagnosis. The mean BMI at follow-up was
21.45 (SD, 3-85), and this too was not significantly dif¬
ferent from that at diagnosis.
In these 11 patients with CD, a repeat measurement
of bone density was performed after 1 year (Figure 5).
The mean spine Z score after I year was —1.37 (SD,
0.82), and this was not significantly different from the
mean spine Z score at diagnosis. Forearm Z scores were
available in 8 of these patients, and the mean score was
— 1.17 (SD, 0.95); this too was not significantly different
from initial measurements. In the single patient with
CDAI > 1 50, spine and forearm Z scores at follow-up
were —1.6 and 0.4, respectively, compared with —1.5
and 0.4, respectively, at diagnosis.
Follow-up data were available for 1 2 of the 1 5 patients
Tabic 5. 7 Scores for the Three Forearm BMD



















Diagnosis (Mean |SD|) (Mean [SD]) (Mean [SDJ)
CD -1.67' (0.77) -1.43' (0.82) -0.60' (0.98)
UC -0.70 (1.00) -0.32 (1.19) 0.87 (1.53)
"P < 0.02; "P < 0.01.
with UC. Nine of the 12 patients with UC had received
systemic steroids and rectal steroids, whereas the re¬
maining 3 patients had received rectal steroids only. The
mean cumulative systemic corticosteroid use during this
period was 2.25 g (SD, 2.80 g). The mean physical activ¬
ity grade was 3-4 (SD, 0.7), and the mean BMI was 22.50
(SD, 4.33); none of these was significantly different from
the relevant value at diagnosis. Two patients underwent
panproctocolectomy with ileoanal pouch during this pe¬
riod. The mean Powell-Tuck index had decreased to 3-4
(SD, 2).
Twelve patients with UC underwent repeat bone den¬
sity measurements. The mean spine Z score 1 year after
the initial measurement was 0.04 (SD, 1.06), and the
mean forearm Z score (9 patients) was 0.11 (SD, 1.07).
None of these were significantly different from previous
measurements.
Both spine and forearm Z scores continued to be sig¬





Figure 3. BMD of forearm in patients with IBD. (A) Male, (B) female. Figure 4. Correlation between forearm and spine bone mineral den-
■ , CD; A, UC; H-fri, mean ± 1 SD in normals. sity 2 scores in the 30 patients with IBD. r = 0.52; P = 0.02.
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Discussion
We have not only confirmed many other reports
of low bone mineralization in 1BD but have clearly shown
that at the time of diagnosis, this is a feature of CD but
not UC. The two groups of patients were well matched
with regard to age, sex, and severity and estimated dura¬
tion of disease before diagnosis. The lower BMD in pa¬









At diagnosis After 1 year
Figure 5. Comparison of BMD Z score values at diagnosis with Z
score values at follow-up after 1 year. (4) Lumbar spine; (B) forearm.
, CD; UC. The horizontal bars represent mean values.
prising 50% ol the lumbar spine,"" and to cortical bone
found in the forearm. This is not correlated with the
CDA1 or the BMI. Although physical activity was re¬
duced at the time of diagnosis compared with usual activ¬
ity levels, the grades of activity were similar for patients
with UC and CD. Malabsorption is unlikely to be a
major factor in the etiology of bone loss because patients
with colonic disease had bone densities similar to those
with small bowel involvement. This is further supported
by the fact that bone metabolic parameters were normal
and there were no differences between patient groups.
However, calcium or vitamin D deficiency may exist in
spite of normal biochemistry, and bone histology would
be needed to definitely exclude this possibility. In view
of the small numbers involved, the lack of difference in
BMD Z scores between small bowel and colonic CD and
between smokers and nonsmokers must be interpreted
with caution because type 2 errors cannot be excluded.
Further studies with a larger number of patients are
needed before firm conclusions may be reached. Only 1
patient with l)C was an ex-smoker. She had stopped
smoking 3 years before presentation after smoking for 5
years. Her spine Z score was —0.5 and forearm Z score
was 0.1. Excluding her from the nonsmoker group did
not alter the statistical lack of significance between smok¬
ers and nonsmokers.
The results of this study underline the fact that CD
and UC are different diseases. CD is a systemic disease
wuh a long premorbid | ilia wh UC is a mucosa
disease with an acute onset. We had previously shown
in our study of Scottish children with 1BD that 1 1 of
TO young children with CD were below the 3rd per¬
centile for height, whereas none of the 1-1 children with
UC was below the 3rd percentile for height."'
Maintenance of BMD should not be equated with the
important issue of linear growth in growing children.
The effect of IBD and its treatment on growth in children
has been studied by various workers, including our
group."'1 This study is predominantly on an adult popula¬
tion, and extrapolation to growing children should be
performed with caution. Interpretation of BMD in ado¬
lescents needs additional considerations. Adolescents go¬
ing through puberty at different ages may be an im¬
portant confounding factor in interpreting serial BMD
measurements, particularly if the patients are going
through puberty at different ages from the control adoles¬
cents. In this study, however, only four patients (two
with CD and two with UC) were going through puberty,
and only one patient with CD had delayed puberty. All
of the remaining patients were sexually mature adults.
The patient with CD and delayed puberty was a 14-year-
old boy with a spine Z score of —1.5 at diagnosis and
1038 GHOSH ET AL. GASTROENTEROLOGY Vol. 107, No. 4
— 1.8 after 1 year. Delay in growth may be a confounding
variable if comparison is made with adolescents with
normal growth. In this study, only the 1 -1-year-old boy
referred to above had a bone age less than chronological
age with height on the 3rd percentile; recalculation of
his Z score using bone age did not alter the significance
level of the difference between CD and UC in spine Z
scores. Because forearm Z scores were only available in
adults 20 years of age or older, these results do not suffer
from the confounding influence of growth and sexual
development.
Despite the fact that 20 of 23 patients received sys¬
temic corticosteroid therapy, there was no evidence at 1-
year follow-up of any further bone loss either in CD or
UC. As a result of treatment, only two patients overall
(one with CD and one with UC) had continuing active
disease after 1 year; other series who report continuing
loss of bone during follow-up have not been so successful
in treating their patients.
Several studies have confirmed that osteo[>enia in pa¬
tients with IBD is unassociated with calcium homeostasis
defects.''2'7'10'" Two recent studies reported as abstracts
have recorded greater prevalence of osteopenia in CD
compared with UC.9'10 However, the two studies identify
ileal involvement and greater steroid use, respectively,
as the factors responsible for the difference from UC.
None of these factors appeared to be relevant in our
present study.
We failed to confirm the rapid bone loss reported
previously in some patients with IBD In our patients,
therapy generally results in control of activity of the
disease with no further bone loss; indeed, a slight increase
in Z scores occurred in some patients. Studies that have
randomly recruited patients from the follow-up outpa¬
tient clinic for bone density studies are likely to be biased
towards patients with complicated long-standing disease
because they are likely to attend more frequently. For
example, we have found low BMD in six teenagers with
longstanding CD (spine Z scores ranging from —2.8 to
— 5.2). Two of these teenagers have sustained vertebral
collapse. We reiterate that our follow-up period is only
1 year, and our conclusions should not be extrapolated
to patients receiving more prolonged steroid therapy.
The mechanism of osteopenia in CD is unclear. The
possibility that there is a primary disorder of osteogenesis
so that bone formation is less than normal cannot be
excluded. Abnormality of the mononuclear phagocytic
system resulting in excessive resorption by osteoclasts or
mediators from the inflamed gut triggering osteoclast
activity are other possibilities that need investigation.
Bone resorption is mediated by the unique multinucle¬
ated bone cell, the osteoclast, the formation and activity
of which is regulated by a family of cytokines.25 The
cytokines that regulate osteoclast function include in-
tcrleukin 1, tumor necrosis factor, transforming growth
factor (X, interferon gamma, interlcukin 1 receptor antag¬
onist, and interleukin 4."° Various cytokine abnormalit¬
ies have been described in CD,*7'28 and differences from
UC have been highlighted. Further studies are needed
to elucidate the interaction of osteoclasts and cytokines
in CD.
Our findings may have important clinical implica¬
tions. It is likely that control of disease activity with
appropriate therapy may actually improve bone mineral¬
ization, which may counterbalance the known osteopenic
effects of steroid therapy. Effects of other interventions,
such as regular exercise, calcium and vitamin D supple¬
mentation to offset gut losses, and hormone replacement
therapy in postmenopausal women, need to be examined.
Although our small numbers make it impossible to ana¬
lyze the effects of secondary amenorrhea and hormone
replacement therapy, our results show that it is not a
confounding factor in explaining the difference between
CD and UC. A recent study has reported prevention of
bone loss in postmenopausal women by hormone replace¬
ment therapy.29 To assess results of interventions, it is
important to identify cases with intrinsic low bone min¬
eralization and those at risk of accelerated bone loss.
We have found that BMD of lumbar vertebrae and
forearm is reduced at diagnosis in patients with CD com¬
pared with UC. This is unrelated to abnormalities of
calcium homeostasis, BMI, smoking, or prednisolone use.
Treatment with corticosteroids does not necessarily result
in further bone mineral loss.
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We read with great interest, the recent report on nonalcoholic
steatohepatitis (NASH).1 In their report, Bacon et al. describe the
diversity of causes and outcomes of NASH and point out important
clinical and pathological characteristics of the disease. 1 Iowever, prog¬
nosis and life expectancy still remains uncertain. In a recent study,
we defined prognosis and life expectancy in 620 patients with chronic
liver disease. After a follow-up period of 15 years (mean, 6.5 years),
life expectancy was retrospectively calculated (Kaplan-Meier survival
curves) and compared with an age- and sex-matched normal popula¬
tion (log-rank tests). Ninety-five patients (15%) (mean age, 46.8
years; 78% men) were found to have fatty liver disease. Diagnosis is
based on clinical and, in 89%, on histological criteria. Sixty-five
patients (68%) had evidence of alcoholic steatohepatitis, and 30 pa¬
tients (32%) fulfilled the clinicopathologic criteria of NASH.2'3 Five-
year survival probability of patients with alcoholic steatohepatitis was
38%, and 10-year survival probability was 15%. In comparison, 5-
year survival probability in NASH was 67% and 10-year survival
probability was 59% (P = 0.0001). Patients with NASH had a lower
life expectancy than the age- and sex-matched normal population;
however, differences were not statistically significant.
Besides the divergent pathogenesis and clinical presentation of
alcoholic steatohepatitis and NASH, life expectancy also differs sig¬
nificantly. However, progression of NASH seems to be slow because
life expectancy was not statistically different compared with that of
the normal population. Our data are in accordance with those of
Bacon et, al. and support the view that NASH should no longer be
considered a largely benign and nonprogressive liver disease.1 NASH
includes a notable variety of potential causes and does not only affect
obese women with diabetes. Further investigations are needed to
elucidate the cause of NASH in each patient to offer a specific therapy
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Reply. We thank Propst et al. lor their comments, which are in
agreement with the findings and conclusions of our recent report on
NASH. As they have pointed out, a major deficiency in our knowledge
of this disease is the rate and frequency of progression of the disease
and the long-term prognosis and survival. It will be possible to attain
answers to these questions with longitudinal evaluation of a carefully
described series of patients with NASH. More elusive will be an
understanding of the underlying pathophysiological mechanisms of
this disease, which will be required to provide logical and hopefully
useful therapy to retard disease progression.
BRUCE R. BACON, M.D.
BRENT A. NEUSCHWANDER-TETRI, M.D.
Saint Louis University Health Sciences Center
St. Louis. Missouri 63110-0250
Determinants of Bone Density in
inflammatory Bowel Disease
Dear Sir:
Ghosh et al. have reported that patients with newly diagnosed,
untreated Crohn's disease have diminished bone density, whereas pa¬
tients with newly diagnosed, untreated ulcerative colitis have normal
bone density. Furthermore, in their study, once disease is treated with
corticosteroids and rendered inactive, bone density remains un¬
changed and does not decrease further. The authors therefore suggest
that disease diagnosis alone is critical to determining bone density
and use their data to refute the notion that corticosteroid use is a key
factor in determining the bone density of these patients.1
The clinical characteristics of the small groups tested necessitate
that their data and conclusions for newly diagnosed patients with
inflammatory bowel disease be corroborated. Twenty percent (3 of
15) of their patients with Crohn's disease were either prepubertal
with a markedly abnormal bone age or postmenopausal. Only 40%
(6 of 15) of patients with Crohn's disease had any evidence of small
bowel disease. Table 3 of the report shows the differences between
bone density in the colonic disease group compared with the small
bowel disease group. Although the colonic group forearm bone den¬
sity (Z, = —0.86) is reported as not statistically different from the
small bowel group forearm bone density (Z = —1.35), the apparent
differences raise the possibility that a larger study might provide
alternate results. 1 wonder how close this comparison came to the
"magic" I' value of <0.05? Nearly half (7 of 15) of the patients in
the ulcerative colitis group only had ulcerative proctitis, potentially
not providing as much of a systemically ill group of newly diagnosed
patients with ulcerative colitis.
The main conclusion of this study was in contradistinction to the
main conclusion ol a study of bone density in patients with inflamma¬
tory bowel disease conducted by our group.2 We found that the main
predictor of decreased bone density was whether or not patients were
using corticosteroids and was independent of disease diagnosis. With
closer scrutiny, our two disparate conclusions may not be mutually
exclusive. Ghosh et al. studied a group ol newly diagnosed patients.
Our study evaluated patients with a mean disease duration of Crohn's
disease of more than 15 years and of ulcerative colitis of almost 9
years. Therefore, it" both investigative groups ate correct, it is possible
that, at initial diagnosis, patients with Crohn's disease may have
lower bone density than patients with ulcerative colitis; however,
over time and with considerable corticosteorid use, the diagnosis no
longer becomes a critical determinant and the daunted effects of
corticosteroids on bone become paramount.
It is noteworthy that the Z score for spinal bone density of Ghosh
et al. of patients with Crohn's disease was — 1.06, whereas after several
years of disease, the Z score for spinal bone density of our patients
with Crohn's disease was a near identical —1.01 (using the same
DEXA scanner; Hologic Inc, Waltham, MA). The group of patients
with Crohn's disease ol Ghosh et al. had a mean age of 24 years,
including 2 postmenopausal women, implying that, overall, this was
a very young group ol patients. The mean age of the patients with
Crohn's disease in our group was 33 years, and postmenopausal
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Table 1. Spine Bone Mineral Density (Z Scores) in Patients
















otHIIc 33 (20-58) 5/5 7 -1.17 (1.63)
Ulcerative colitis
(n = 10) 38 (25-61) 6/4 7 -1.06 (0.46)
NOTE. Patients had inflammatory bowel disease for more than 5 years and at least 6 months
of systemic steroids.
"Crohn's disease vs. ulcerative colitis; P = NS.
women were excluded. It is possible that having a systemic disease
will have more exaggerated effects on the bones of younger patients
who may not have completely established their adult bone density.
If it is true that, at initial diagnosis, patients with Crohn's disease
have significantly lower bone densities than patients with ulcerative
colitis, this does not necessarily imply a cause and effect relationship
between developing Crohn's disease, having elevated circulating cyto¬
kines that may accelerate bone resorption, and the lowering of bone
density. In fact, more than 25% of the patients with Crohn's disease
in the study by Ghosh et al. had inactive disease at the time of study
enrollment. It is possible that having Crohn's disease leads to an
increased incidence of lactose intolerance in some patients, a decreased
intake of high calcium containing foods, and, ultimately, diminished
bone density. This could be tested by determining the calcium intake
of those who present with low bone density compared with those
who have normal bone density. Alternatively, these patients may
have simultaneous genetically directed defects in the maintenance of
normal intestinal and normal bone homeostasis.
Our group's data refute the notion that disease diagnosis affects
bone density. We compared the small groups of patients who did
not use corticosteroids with Crohn's disease (n = 9) and with ulcera¬
tive colitis (n = 7) and found no difference in bone density. Nonethe¬
less, each study has asked similar questions of different stages of
disease, allowing for both conclusions to be true. More data are re¬
quired to sort through these differences, and, more importantly, an
effective therapeutic approach at improving bone density is required.




1. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral
density in Crohn's disease, but not in ulcerative colitis, at diagno¬
sis. Gastroenterology 1994;107:1031-1039.
2. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan
F. Decreased bone density in inflammatory bowel disease is re¬
lated to corticosteroid use and not disease diagnosis. J Bone
Miner Res (in press).
Reply. We thank Dr. Bernstein for his comments. We fully agree
that osteopenia is a common complication of inflammatory bowel
disease, but we suggest that it is likely to be multifactorial. Cortico¬
steroids, malabsorption, dietary factors, and surgery arc all highly
relevant, but the abnormal bone mineralization that we have found
in patients with Crohn's disease at the time of diagnosis indicates a
primary contribution by the disease itself. Dr. Bernstein's data are in
complete agreement with those of other investigators and with the
interim results of a study in progress, summarized in Table 1, that
there is significant osteopenia in patients with both forms of inflam¬
matory bowel disease of long duration. We had found no significant
change in bone mineralization at 1 year after diagnosis and had
emphasized in the discussion of our report that these short-term
results should not be extrapolated to a longer duration of follow-up.
It is indeed interesting that the median Z score for spine bone
mineral density of our patients with Crohn's disease at diagnosis is
virtually identical with that for Dr. Bernstein's group of patients
with long-standing disease (mean disease duration, 15 years). How¬
ever, because we have not seen Dr. Bernstein's data in full, we cannot
comment on variables such as cumulative steroid dose, disease activ¬
ity, and anatomy. In our experience, very low Z scores (< —3.0),
although infrequent, seem to be a feature of long-standing, compli¬
cated Crohn's disease, particularly in adolescents. Our failure to detect
a significant difference in bone mineral density between patients with
colonic and small bowel Crohn's disease might be due to type 2 error,
as we mentioned in our discussion. It would hardly be surprising if
malabsorption due to small bowel disease contributed to osteopenia;
however, this could not explain the overall differences between
Crohn's disease and ulcerative colitis.
The osteopenic properties of corticosteroids are fully established;
indeed, the main reason for our prospective study design was to
control for this confounding variable. Our results add further support
to the concept of Crohn's disease as a systemic condition with a long
premorbid phase, whereas ulcerative colitis is of acute onset and
normally localized to the colonic mucosa.1 The fact that, in 4 of
our newly diagnosed patients, Crohn's disease was clinically inactive
(Crohn's Disease Activity Index <150) reinforces the importance of
recognizing that inflammatory disease activity is only one component
of inflammatory bowel disease illness. This has been clearly shown
by our direct clinical studies of gut inflammation using whole gut
lavage fluid.2'*
In this part of the United Kingdom, the prevalence of lactase
deficiency in adults is less than 5%.A In any event, lactose intolerance
is no more common in patients with Crohn's disease than in the
general population5 unless there is diffuse involvement of the small
bowel, which was present in only 1 of our 15 patients. Bone mineral
density results in patients with extensive colitis were similar to those
with only ulcerative proctitis.
We agree that more data are needed. This is particularly relevant
to the study of important subgroups such as adolescents and post¬
menopausal women. Furthermore, well designed studies on the patho¬
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tions in the patient with inflammatory bowel disease. Scand J
Gastroenterol 1994;29(Suppl 203):15-19.
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tion into the gut by cytology of whole gut lavage fluid. Eur J Gas¬
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Neurobiology of Sleep and Human
Colonic IVHofor Patterns
Dear Sir:
The relationship between sleep patterns and human colonic motor
patterns' is supported by the association of poor sleep quality with
the severity of irritable bowel syndrome symptoms in women with
high anxiety and moderate depression.2 The neurobiology is suggested
by reports linking panic, wakefulness, and a shared smooth muscle
disorder between the bladder and the bowel in young women to
dopamine lateralized to the right hemisphere in which the metabolic
rate is higher in women. This hypothesis is supported by subclinical
impairment of lung airways and an abnormal parahippocampal region
and its afferent and efferent connections in panic disorder.3-7 It is also
supported by diurnal variation of serotonergic-mediated inhibition of
dopamine8 leading to frequent propagating contractions in the morn¬
ing that are likely to promote early-morning defecation' by monoami-
nergic interaction in the central nervous system'1 and by diurnal symp¬
toms that patients with irritable bowel syndrome believe may be
sleep-related.2
The fact that delay-dependent speeding of reaction time, indicating
motor readiness, is abolished by depletion of dopamine4 prompts the
evaluation of adaptation to centrally mediated stimuli such as stress'"
by monitoring speech hesitation and switching pauses. This method
is supported by the construct validity of response latencies, easily
obtainable through microcomputer testing of spontaneous speech in
emotionally charged dialogues, reflecting properties of neuronal activ¬
ity and firing.3'"
ERNEST H. FRIEDMAN, M.D.
Departments ofMedicine and Psychiatry
Case Western Reserve University
1831 Forest Hills Boulevard
Cleveland, Ohio 44112-4313
1. Furukawa Y, Cook IJ, Panagopoulos V, McEvoy RD, Sharp DJ,
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2. Wingate D, Goldsmith G. An association between poor sleep
quality and the severity of IBS symptoms (letter). Dig Dis Sci
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1271.
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rat. Comp Biochem Physiol 1991;98C:193-202.
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(editorial). Gastroenterology 1994;107:1548-1550.
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impairment after ischemia (letter). Stroke 1994:25:1526.
is Aberrant Abnormal?
Dear Sir:
Thanks to the pioneering technique of Bird,' foci of colorectal
mucosa that are positively identified by methylene blue staining are
popularly called aberrant crypts nowadays, and there is almost a race
to use this as a surrogate for cancer, i.e., an intermediate marker in
evaluating everything from carcinogenesis to cancer prevention. In
this regard, the editorial by Augenlicht2 in the December 1994 issue
of Gastroenterology is most illuminating because of the timely
contribution it makes in tying the molecular mechanisms of carcino¬
genesis with the morphological changes in colorectal cancer.
Some of Augenlicht's statements need to be corrected. "ACF were
first reported by Bird in azoxymethane-induced mouse . . . "; not
so, I submit, humbly. The foci of abnormal and dysplascic crypts
in rodents were independently observed by Pozharriski, Ward, and
Deschner around the same time in mid-1970s but first reported by
Deschner in 1974.3 That these are putative preneoplastic lesions in
the human colon was observed (called abnormal, another word for
aberrant as per Webster's dictionary!) by Shamsuddin et al. in 1981,4
a decade earlier than what Augenlicht believes to be the joint discov¬
ery by Roncucci and Pretlow.2 That these abnormal (or aberrant!)
crypts do express carcinoembryonic antigen and p21 and p21scr (Ki-
ras) was also reported first from my laboratory 8 years ago.5 Aside
from straightening the record, it is hoped that this communication
would save the modern day investigators some time and effort in
similar rediscoveries should they care to perform a literature search.
A. K. M. SHAMSUDDIN, M.D.
Department of Pathology
University ofMaryland School of Medicine
10 South Pine Street
Baltimore, Maryland 21201-1116
1. Bird RP. Observation and quantification of aberrant crypts in the
murine colon treated with a colon carcinogen: preliminary findings.
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2. Augenlicht LH. Adhesion molecules, cellular differentiation, and
colonic crypt architecture. Gastroenterology 1994; 107:1894-
1897.
3. Deschner EE. Experimentally induced cancer of the colon. Cancer
1974;34:824-827.
4. Shamsuddin AKM, Weiss L, Phelps PC, Trump BF, Colon epithe¬
lium IV. Human colon carcinogenesis. Changes in human colon
mucosa adjacent to and remote from carcinomas of the colon. J
Natl Cancer Inst 1981;66:413-419.
5. McKenzie KJ, Purnell DM, Shamsuddin AKM, Expression of car-
cino-embryonic antigen, T-antigen and oncogene products as mark¬
ers of neoplastic and preneoplastic colonic mucosa. Hum Pathol
1987;18:1282-1286.
Reply. Dr. Shamsuddin is correct that he, Deschner, and others
made important and early contributions to our understanding of the
histological changes in the normal appearing flat mucosa that precede
Analysis of Disease Distribution, Activity and Complications in
the Patient with Inflammatory Bowel Disease
A. FERGUSON. S. GHOSH. L. M. HAftijY. C. CHOUDARI. O. MWANTEMBE.
M. A. McINTYRE
Dept. of Medicine and Dept. of Pathology. Western General Hospital. Edinburgh. UK
Ferguson A. Ghosh S. Harny LM. Choudari C. Mwantcmbc O. Mclntvrc MA. Analysis of disease
distribution, activity and complications in the patient with inflammatory bowel disease. Scand J Gastro¬
enterol 1994:29 Suppl 203:15-19.
Management strategies in Crohn's disease and ulcerative colitis should be based on up-to-date infor¬
mation on disease distribution, extent, activity and complications. A system of structured analysis is
suggested, with separate consideration of destructive ulceration, inflammatory activity and other factors.
Direct investigation of gut immunity by using whole gut lavage fluid (WGLF) is a valuable new technique
of clinical investigation in IBD and related disorders. Recent studies have shown that the concentrations
of plasma-derived proteins in WGLF provide objective measures of disease activity: and that this activity
is a separate phenomenon from destructive ulceration and fibrosis. Neutrophils in the lumen can be in-
investigated by cytology, or by assay of neutrophil clastasc in WGLF. Cytokines and other immuno-
regulatorv mediators can also be detected. These new techniques can provide a description of intestinal
immunity and inflammation, based on a non-invasive test of 2-4 h duration. Work in progress shows
that patients who respond clinically to elemental diet treatment have unusually high concentrations of
soluble IL2 receptor in WGLF; cytokine profiles may facilitate the selection of patients suitable for
other new treatment modalities.
Key words: Crohn's disease: cytokines; gastrointestinal protein loss; gut neutrophils: intestinal immu¬
nology; intestinal inflammation; ulcerative colitis
A. Ferguson, Professor, Dept. of Medicine, Western General Hospital, Edinburgh EH4 2XU, UK
What do physicians, gastroenterologists and society want
and need in relation to IBD management? Most con¬
tributions to this Symposium volume concern techniques for
assessment of the patient during an acute episode of illness.
However, in the context of the long-term care of patients
with IBD, it is important to widen the frame of reference.
Although epidemiological studies are difficult, there is
general agreement that the incidence of Crohn's disease (but
probably not of ulcerative colitis) is steadily rising. Scottish
Hospital In-Patient Statistics (SHIPS) are collected pro¬
spectively on all admissions to NHS hospitals in Scotland,
and by using record linkage the incidence of a disease rather
than merely episodes of illness can be studied. We are using
this powerful database to monitor trends in the incidence of
juvenile-onset IBD. We recently reported that the recorded
incidence of Crohn's disease in Scottish children, based on
hospital admissions data, rose from 6.6 per million children
in 1968 to 22.9 per million in 1983 (1). This trend continues,
as shown in Fig. 1, with an unexplained excess of males in
the period 1984-86. The overall incidence in 1988 was 29
per million children.
As with other chronic, treatable but incurable diseases,
IBD patients deserve continuity of medical care at a single
centre where multidisciplinary expertise is available for both
assessment and management. Unless a cure for IBD is
discovered, by the early years of the next century all of our
specialist GI units will be caring for hundreds of patients,
such as the woman whose life history is summarized in
Table I.
STRATEGY FOR ANALYSIS OF OVERALL
DISABILITY IN THE IBD PATIENT
Although general guidelines for the management of IBD
patients can be presented in textbooks and journals, it must
Fig. 1. Incidence of Crohn's disease in Scottish children: numbers
of boys and girls having a first admission to an NHS hospital with a
recorded diagnosis of Crohn's disease, per year.
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Table I. Continuity of carc during 50 years of Crohn's disease
Mrs F. born 1916
1934. vulval abseess
1937 diarrhoea? TB ileum; resection of ileum and ascending colon
1954 rectal stricture
1957 anterior resection; temporary colostomy, complications, total
of four operations within a year; intermittent courses of cor¬
ticosteroids in next 10 years.
1969 diarrhoea, recto-vaginal listula. colectomy, ileostomy; there¬
after. significant nutritional problems
1978 jaundice, cholecystectomy, stone in common bile duct
1984 sub-acute obstruction, division of adhesions
1987 died, bronchial carcinoma (lifelong smoker)
Treated at the Western General Hospital. Edinburgh for 50 years,
by the following physicians and surgeons;
Mr Charles Illingworth (later Professor Sir Charles Ulingworth)
Mr John Bruce (later Professor Sir John Bruce)
Dr (later Professor) Wilfrid Card
Dr Wilfrid Sircus
Mr (later Professor) Adam Smith
Mr Charles Falconer
Mr David Hamer-Hodges
Dr (later Professor) Anne Ferguson
be recognized that in individual cases management must be
tailored to the patient's current anatomical, functional and
disease activity status.
We recommend that an attempt be made to analyse, in a
systematic way, the components of overall disability of
patients with IBD, not only at presentation but during fol¬
low-up. and particularly when any change in therapy is being
considered. A possible scheme is shown in Table II. This
type of analysis can profoundly influence treatment plans.
For example, it may be dangerous merely to increase the
dose of corticosteroids if a patient's abdominal pain is, in
fact, caused by local perforation and abscess.
In the last few years we have been developing a range of
Table II. A system for analysis of a patient with IBD
Extent and distribution of destructive chronic inflammation, i.e.
macroscopically ulcerated, stricturcd or grossly inflamed
segments.
Disease 'activity', i.e. inflammatory activity as assessed by fever,
anorexia, tiredness, arthropathy, diarrhoea, pain.
Mechanical obstruction, which may be partly reversible if mucosal
inflammation is a contributory factor.
Complications (e.g. abscess, listulation between loops of gut to
other organs such as the urinary tract or to the skin).
Nutritional status and related factors, e.g. anorexia, malabsorption,
gut losses of blood and protein, and metabolic response to
inflammation.
Iatrogenic factors both medical (e.g. steroid-induced diabetes) and
surgical (e.g. bile salt and B12 malabsorption after resection of
the terminal ileum).
Disease of other organs (related or unrelated to IBD) (e.g. duodenal
ulcer, gallstones, ankylosing spondylitis).
Social and psychological factors affecting the patient and family.
Tabic III. Studies required for comprehensive investigation of the
human GALT
1. Specific IgA antibodies.
2. Potentially immunopathogenic but also potentially useful IgM.
IgG. IgE antibodies.
3. Antigen specific T cells (currently the only method available
is based on intestinal antigen challenge, multiple biopsies and
morphomeiric analysis of these biopsies).
4. T cell and macrophage activation by immunological marker
studies or measurement of activation products.
5. Polymorphonuclear activation.
6. Immunorcgulatory molecular signals.
7. Inflammatory cytokines.
8. Other molecular mediators of inflammation.
methods to allow clinical measurement of the various aspects
of gut inflammation and immunity. These can now be used
to assist the clinical analysis in IBD, and should be invaluable
new toois for the objective evaluation of new forms of
therapy.
INVESTIGATION OF THE HUMAN GUT IMMUNE
SYSTEM
Ideally, in order to study the gut immune system in clinical
situations, a range of components should be assessed (Table
III). Animal and clinical studies show that, with very few
exceptions, tests on components of the systemic immune
system (blood antibodies and circulating cells and cytokines)
are virtually useless as indices of mucosal immunity at gut
level. Some general information on the function of the
mucosa-associated lymphoid tissues can be obtained from
studies of saliva or tears, but these materials cannot provide
organ-specific information relevant to the gut.
There have been a number of studies on fluid aspirated
from the proximal jejunum. If appropriately processed by
addition of protease inhibitors, this is a valuable source of
material. However, we now have good evidence that data
based on analysis of faeces will be highly misleading, and
despite the ease of specimen collection, such studies should
be discouraged.
USE OF WHOLE GUT LAVAGE FLUID TO STUDY
GUT LOSSES OF BLOOD AND PROTEIN, AND
DISEASE ACTIVITY
The technique of whole gut lavage with non-absorbable
polyethylcne-glycol-based solution has been widely applied
in clinical practice for cleansing of the bowel prior to barium
enema, colonoscopy or colonic surgery. This is also a radical
but excellent technique for the treatment of intractable
constipation.
After gut cleansing is complete, the clear fluid passed per
rectum, whole gut lavage fluid (WGLF) is essentially a whole
gut perfusate. Our studies in adults and children have shown
that this material can readily be used for biochemical and
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immunochemical assays to assess intestinal immunity,
inflammation and gut losses of protein and blood (2-10).
Measurement of Gl blood loss
Occult GI bleeding can be measured by using a highly
sensitive technique. HemoQuant. for assay of haemoglobin
in WGLF (8). In patients with a normal GI tract. WGLF
Hb concentration ranged from 0.5 to 5.1 pg/ml equating to
an estimated daily occult blood loss of 0.1-1.2 ml. High
values for WGLF Hb, indicative of chronic bleeding, were
found not only in patients with colorectal cancer, but also
in 7 of 16 patients with active inflammatory bowel disease
(8).
GI protein loss—index of activity in IBD
Fluid obtained by whole gut lavage normallv contains
traces of IgG, albumin and ayantitrypsin. Normal values,
based on results for 63 immunologically normal patients or
volunteers are: IgG (by ELISA) <1-10 (xg/ml; albumin (by
imrnunoturbidimetrv) <1-26 (.ig/ml; A1AT (by immuno-
turbidimetry) < 1—19 iig/'ml (7). In our initial technical
appraisal of the technique we had found that higher con¬
centrations of these proteins were found in WGLF from
patients with IBD (2. 5). Our further experience has shown
that assay of these proteins in WGLF cannot be used as a
diagnostic test for IBD: normal results are obtained in some
patients with unequivocal radiological or endoscopic abnor¬
malities when disease is clinically inactive.
We carried out a prospective study of gut lavage in IBD
patients (7) in whom disease activity was simultaneously
assessed by using the Crohn's Disease Activity Index
(CDAI) (11) or the Powell Tuck Index (PTI) (12). For IgG.
concentrations in lavage fluid correlated closely with activity
indices: in Crohn's disease, r = 0.723 (p < 0.0001), in ulcer¬
ative colitis, r - 0.714 (p < 0.0001). Results for lavage fluid
albumin and ayantitrypsin concentrations were generally



































































Fig. 2. Concentrations of IgG, albumin and alpha-l-antitrypsin in WGLF from patients with Crohn's disease and ulcerative colitis, plotted
against CDAI and PTI, respectively.
IS A. Ferguson el id.
Table IV. Concentrations of proteins in WGLF from patients with
IBD: correlations with objective and subjective components of the
CDAI and PTI (from further analysis of data in Fig. 2)
Correlation between lavage protein concentrations and the
objective and subjective components of activity indices
Surprisingly, for both CD and UC, concentrations of
WGLF proteins correlated more closely with subjective par¬
ameters of the CDAI and PTI respectively (e.g. pain,
malaise) than they did with objective parameters (Table IV).
Studies of luminal cells
Studies of radiolabeled cells have shown that there is
increased faecal loss of leucocytes in active IBD. It is thus
of interest to establish whether WGLF can be used in the
investigation of gut leucocytes. By using Ficoll/Hypaque
density gradients, we have found that cells can readily be
separated from WGLF—these include squamous cells,
enterocytes, neutrophil polymorphs, and also in some
patients, eosinophils.
The enzyme neutrophil elastase is a specific marker for
polymorphonuclear leukocytes. Table V shows results of
assay for this marker carried out in WGLF from control
subjects (in which only one of 32 specimens was above the
level of detection, 0.03 per ml), together with non-IBD and
IBD patients. The three non-IBD patients with high values
all had abscesses communicating with the gut.
Table V. Concentration of neutrophil elastase in WGLF from a
series of patients with GI disease, and controls
Neutrophil clasiasc (unityVnl)
<0.038 0.038-0.2 >0.2
Volunteers or trivial 31 1
Anaemia 33 1 2
Small bowel disease 23 — —
Colonic disease 29 3 1
Miscellaneous 22 2 —
IBD: Crohn's active
(IgG > lOpg/ml) 12 — 16
Crohn's inactive 21 6 1
UC active
(IgG > 10 pg/ml) 3 — 4
UC inactive 12 3 1
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Fig. 3. Concentrations of sIL2R in serum and WGLF from patients
with IBD before and at the end of a period of elemental diet
treatment.
In the case of IBD, WGLF IgG content allows the sep¬
aration of those with active and inactive disease. The results
clearly show that whereas clastasc content was low or absent
in all but two of the patients with inactive IBD, those
with unequivocally active disease clearly segregated into two
groups, with either very high or absent neutrophil elastase.
Preliminary analysis suggests that, at least in Crohn's disease,
a high value for neutrophil elastase is associated with disease
of the colon rather than the small bowel.
Cytokines
There is considerable interest in immunoregulatory and
inflammatory cytokine networks within the gut mucosa. In
preliminary studies we found that WGLF was unsuitable for
bio-assays of cytokines, but that ELISA and radio immuno¬
assay techniques could readily be applied.
As part of a programme of research on the immunological
effects of treatment with elemental diet, studies of the
marker of T cell activation, soluble IL2 receptor, have been
carried out in a group of patients before and at the end of a
2-3 week period of treatment with the elemental diet E028.
This was a heterogeneous group of patients, many of whom
had failed other treatments. As shown in Fig. 3, the elemen¬
tal diet treatment had no effect on serum levels of sIL2R,
which were higher overall in the group of non-responders.
However, the few patients who responded clinically to
elemental diet treatment were characterized by an initially
high level of sIL2R in WGLF, and the clinical response to
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diet treatment was associated with a fall in this marker of
gut T cell activation.
This is the first evidence of an immunological effect of
elemental diet treatment in IBD: characterization of the
pattern of immune activation in IBD patients may be a new
way to identify patients likely to respond to novel forms
of immunomodulatory intervention, and we are currently
investigating this issue.
CONCLUSIONS
Imaging techniques, based on radioisotope labelled leu¬
kocytes, are invaluable in the assessment of pyogenic com¬
plications of IBD, and will also show the distribution of
actively inflamed, ulcerated, macroscopicallv affected gut.
The newly introduced technique of whole gut lavage provides
a complementary approach to the analysis of inflammation
and disease activity which is likely to be most valuable in
the 5-10% of patients with complex or long-standing disease,
and in the setting of clinical trials.
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EDITORIAL REVIEW
Mucosal immunology research design should address not just cytokines and
cells, but also clinical data and controls
S. GHOSH & A. FERGUSON Department ofMedicine, University of Edinburgh, Western General Hospital, Edinburgh, UK
(Acceptedfor publication 31 March 1994)
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic,
incurable, disabling, inflammatory bowel diseases (1BD) which
affect about 70 000 people in the UK. Although symptoms of
the two conditions are similar, and they share some pathologi¬
cal and immunological features, they should be considered for
research purposes as completely separate diseases of unknown
and probably different etiologies. Disease activity and inflam¬
mation wax and wane unpredictably and, particularly in CD,
indolent tissue destruction with fibrosis can cause bleeding,
perforation, fistula formation and stricture—potentially life-
threatening complications.
In clinical practice a range of techniques of clinical inves¬
tigation are available, including several based on immunologi¬
cal approaches and reagents, to characterize the separate
components of the patient's ill health. We recommend careful
consideration of the distribution of grossly affected intestine,
peri-anal disease, IBD disease activity, destructive ulceration,
malnutrition, infection, side effects of drugs, gut losses of blood
and protein, psychological factors, 1 BD-associated and inde¬
pendent diseases of other organs, and occasionally other, rarer
problems. By this means, the clinician can devise appropriate
management strategies for that particular patient at that time.
An appreciation of this clinical heterogeneity is also essen¬
tial for the proper design of research studies in IBD, whether
based on the sciences of epidemiology, nutrition, pharmacol¬
ogy, microbiology or immunology. Profound abnormalities of
immunological status or the inflammatory response may be due
to factors entirely unrelated to the primary disease process,
such as global or single nutrient deficiency, immunomodulatory
or cytotoxic drugs, or antibiotics. Account must also be taken
of sex and age distribution of affected individuals, and the fact
that by some means or other, material from healthy age- and
sex-matched controls must be obtained to allow a proper
interpretation of the findings in disease. Some cellular and
molecular events are common to all ulcerative diseases, and
some of the strikingly abnormal findings in IBD (e.g. high titres
of serum and mucosal antibodies to bacterial and food anti¬
gens) may be merely epiphenomena, and occur in any situation
where mucosal integrity is extensively breached. Thus, ideally,
material should also be examined from patients with other
ulcerative diseases of the gut, such as radiation colitis or
infection.
Correspondence: Professor Anne Ferguson, Department of Medi¬
cine, University of Edinburgh, Western General Hospital, Crewe Road,
Edinburgh EH4 2XU, UK.
Many different approaches are being used in the search for
the underlying causes of UC and CD, and to identify the
presumed environmental factors which may trigger clinical
relapse. Increasingly sophisticated techniques are becoming
available to measure, both in healthy and diseased tissue, the
precise immunological effects of immunosuppressive, cyto¬
toxic, antibiotic and dietary treatments. These approaches
may be useful for the identification of those patients likely to
respond well to a particular second-line treatment—this would
surely be cost-effective in the long run, in view of the expense of
some drugs and of elemental diets.
In this difficult type of clinical research, material will
become available for study in an often unpredictable way,
particularly from the important group of newly presenting,
untreated cases. We recommend that the collaborating clinician
and immunologist agree, before the work begins, on a few
broad subdivisions of the patient mix which will allow reason¬
ably homogeneous groups, of adequate reasonable size, for
proper interpretation and statistical analysis. There will be
some patients who do not fit in to the pre-planned groupings.
Their data should also be carefully examined. Unusual results,
or a highly atypical case, may be the stimulus to entirely new
avenues of hypothesis and investigation.
Neutrophils are the predominant effector cells within the
active lesions of IBD and probably mediate much of the tissue
damage. Indium1 "-labelled leucocyte studies have demon¬
strated rapid accumulation of radiolabeled cells in the
inflamed intestine, followed by migration into the crypts and
thence into the intestinal lumen [1,2], These studies showed that
monitoring neutrophil migration could be of potential value in
the clinical assessment of IBD patients. The introduction of
"mTc-HMPAO as a leucocyte label further refined the tech¬
nique and provides much clearer scans [3],
There are several groups ofmolecule which may be acting as
neutrophil chemoattractants in IBD. These include comple¬
ment, eicosanoid and cytokine families and proinflammatory
bacterial peptides. Recent studies have focused attention on
IL-8, a non-glycosylated single peptide chain which mediates
activation and chemotactic attraction of neutrophils [4], The
human neutrophil expresses at least two distinct receptors, high
and low affinity, for IL-8 [5,6]. This cytokine was originally
isolated from endotoxin-treated monocytes, but a variety of
other cells may be induced to produce IL-8, and stimuli include
IL-1 and tumour necrosis factor-alpha (TNF-a). Evidence that
IL-8 may be implicated in the local tissue lesion of IBD comes
from rectal and sigmoid perfusion studies, which show that
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myeloperoxidase released from neutrophil granules correlates
with IL-8 in the perfusate in UC [7].
In an elegantly simple study reported in this issue, Mit-
suyama et al. [8] demonstrate that raised IL-8 content of
affected colonic mucosa in active IBD correlates with neutro¬
phil counts in the mucosa. This is strong evidence of a central
role for IL-8 in the pathogenesis of neutrophil infiltration.
These workers also observed that mucosal IL-8 levels in
macroscopically unaffected areas of the colon were similar to
those in colonic biopsies from immunologically normal control
patients. Measurement of serum IL-8 concentration was
unhelpful. The study design conformed to the criteria set out
above. The well described patient groups included a reasonable
number of untreated cases, and also patients with ischaemic
and infective colitis (several of whom had detectable IL-8,
although at lower levels than in the active IBD patients). It is
important to keep in mind, when comparing these data with
those in other reports, that their patients and biopsies were
designated as active or inactive on the basis of gross appearance
of the colonic mucosa at endoscopy. We, using the new
technique of whole gut lavage [9], and others, using a range
of clinical tests [10], have shown that inflammatory 'disease
activity' is a separate phenomenon from mucosal ulceration
and tissue destruction.
An important unanswered question is the source of IL-8 in
IBD. Mucosal monocytes and macrophages are known to
produce IL-8, and IL-8 is also expressed by human epithelial
cell lines [11]. There may be bidirectional communication
between intestinal epithelial cells and mucosal immune cells,
whereby IL-1 and TNF-a released by activated macrophages
may result in increased IL-8 secretion by intestinal epithelial
cells. However, caution is needed in extrapolating data from in
vitro studies—epithelial cell lines also express IL-1 and yet
immunohistochemical and in situ hybridization studies have
shown that lamina propria mononuclear cells and not epithelial
cells are the source of IL-1 in intestinal mucosal biopsies [12],
One potential mechanism of action of IL-8 is via regulation
of expression of leucocyte adhesion molecules. Binding of
neutrophils to the vascular endothelial cells may be mediated
through well characterized adhesion molecules such as CD1 la/
CD18 complex (LFA-1) which binds to CD54 (ICAM-1). In
active IBD, the expression of CD54 is strikingly increased [13],
Another family of adhesion molecules, the LEC-CAM, present
on neutrophils and endothelium, mediate adhesion by a lectin
domain. This promises to be one of the central areas for future
research and therapeutic intervention.
Some of the traditionally investigated chemoattractants
such as leucotriene-B4 may be a secondary consequence of
neutrophil infiltration, while other mediators such as those of
the complement family (C3b, C5a) may be important in the
final pathway of tissue injury by perpetuating the inflamma¬
tion. Though several groups have investigated the role of
platelet-activating factor (PAF) in IBD, no correlation
between degree of tissue inflammation or disease activity and
PAF has been reported. An important area that needs further
experimental clarification is the relationship of neutrophil
chemoattractants of bacterial origin such as formyl-methinyl-
leucyl-phenylalanine (FMLP) and production of tissue media¬
tors such as IL-8.
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Investigation of neutrophil migration into
the gut by cytology of whole gut lavage fluid
Louise M. Handy, Subrata Ghosh and Anne Ferguson
Objective: Radiolabelling studies have shown that neutrophils migrate into the gut
lumen in inflammatory intestinal diseases. We aimed to establish whether whole gut
lavage fluid can be used to investigate intestinal neutrophilia.
Design: A prospective single centre study comparing inflammatory bowel disease
patients, patients with other gastrointestinal diseases and normal controls.
Methods: Gut lavage with a polyethylene glycol-based solution was performed in
56 patients (29 with inflammatory bowel disease). Gut lavage fluid samples were
collected when the rectal effluent was clear. Cells were then separated by density
gradient centrifugation, counted, and cytospin preparations examined.
Results: High cell counts (>3.7x105/ml), predominantly neutrophils, were present
in 12 out of 29 inflammatory bowel disease patients and in two out of 27 others.
High cell counts and luminal neutrophilia characterized active ulcerative colitis and
active colonic Crohn's disease, but not active small bowel Crohn's disease, or inactive
disease.
Conclusion: Whole gut lavage fluid samples can be used to investigate luminal
inflammatory cells. We observed previously unrecognized differences between small
bowel and colonic Crohn's disease using this method. The mechanisms of neutrophil
migration into the gut lumen may differ with disease distribution.
European Journal of Gastroenterology & Hepatology 1995, 7:53-58
Keywords: Whole gut lavage, gut neutrophils, intestinal
inflammation, Crohn's disease, ulcerative colitis
Introduction
Whole gut lavage is a relatively new technique for the
non-invasive investigation of gut immunity [1,2]. It can
be used to examine mucosal immunoglobulins and anti¬
bodies, to measure gut losses of blood and protein, and
for studies of local immunoregulatory and pro-inflam¬
matory cytokines. It has been known for several years
that tumour cells can be identified by the cytologi-
cal examination of whole gut lavage fluid (WGLF) in
patients with gastrointestinal cancers [3—6].
Experiments with intravenously administered mixed
leukocyte preparations, labelled with l1lIn or 99mTc,
have shown that tumour cells rapidly localize in the
inflamed bowel, migrate into the bowel lumen, and
are excreted in faeces [7,8]. Quantitation of the fae¬
cal excretion of these radiolabelled cells has been used
to assess disease activity in patients with inflammatory
bowel disease (IBD) [9—11],
It appeared probable that leukocytes in the gut lumen
woulc} also be detected in WGLF and, if so, a sim¬
ple, non-isotopic method to examine this aspect of
gut inflammation could be developed. Therefore, we
collected, counted, and examined microscopically the
cells in WGLF from a series of well characterized pa¬
tients with IBD and other conditions in order to assess
how luminal neutrophilia relates to the type and distri¬
bution of IBD, and to disease activity.
The study protocol was approved by the Medicine Sub¬
committee of the Lothians Area Ethics of Research
Committee.
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Materials and methods
Subjects
WGLF samples from 56 patients were used for cytologi-
cal assessment. Each patient underwent gastrointestinal
assessment with appropriate combinations of upper en¬
doscopy, colonscopy, jejunal biopsy, other histology and
contrast radiology. Laboratory investigations included
determinations of haemoglobin, white cell count, ery¬
throcyte sedimentation rate, albumin and C-reactive pro¬
tein. All medication and diet at the time of lavage were
recorded.
Thirteen patients were immunologically normal, with
anatomically normal gastrointestinal tracts, and were
used as controls. Twenty-nine patients had IBD: 12 had
active Crohn's disease (five with colonic Crohn's disease
including additional small bowel involvement; four with
small bowel Crohn's disease; three with other, for exam¬
ple, perianal Crohn's disease); 10 had inactive Crohn's
disease (five with colonic Crohn's disease, two with
small bowel Crohn's disease, three with other Crohn's
disease); three had active ulcerative colitis; and four
had ulcerative colitis in remission. Of the ulcerative
colitis patients, four had pancolitis, one had distal col¬
itis and two had proctitis. IBD was classified as active
when the WGLF immunoglobulin (Ig) G concentration
was greater than 10 Jig/ml. Six patients had other be¬
nign, upper gastrointestinal tract diseases, and seven had
colonic diseases other than IBD (two with radiation coli¬
tis, two with benign polyps, and one each with infectious
colitis, diverticulitis and stercoral ulcer). An eighth pa¬
tient, with colon carcinoma complicating longstanding
inactive ulcerative colitis, was classified as belonging to
this 'miscellaneous colonic disease' group.
Lavage protocol
The patients drank an isotonic polyethylene glycol-based
fluid (Klean-prep, Norgine Ltd, Oxford, UK), super¬
vised by an experienced nurse, as described elsewhere
[12]. The first completely clear fluid specimen passed per
rectum was collected for analysis. Cytological assessment
was performed immediately after collection as described
below. Aliquots of the specimen were also filtered, pro¬
cessed by the addition of protease inhibitors, stored at
—70°C and later assayed for IgG by enzyme-linked im¬
munosorbent assay [12].
Disease activity in IBD patients
One of the advantages of using WGLF for IBD re¬
search is that disease activity can be graded by measuring
IgG concentration in WGLF. This has been validated by
Choudari et al. [12] who found that the Crohn's disease
activity index (CDAI) for Crohn's disease and the Pow¬
ell Tuck index (PTI) for ulcerative colitis correlated well
with WGLF IgG concentration. In the same series of pa¬
tients, an experienced physician's global assessment also
correlated with the CDAI or PTI, and with the WGLF
IgG concentration [13].
For the purposes of statistical analysis, IBD patients were
classified as active when the IgG concentration in WGLF
was greater than 10 gg/ml, and inactive when the IgG
level was 10pg/ml or less. In this study, we also com¬
pared WGLF IgG concentration values in the 29 IBD
patients with a physician's clinical opinion on whether
the disease was active or inactive (based on symptoms,
clinical signs and the results of haematological and bio¬
chemical blood tests). The categorization as active or
inactive, based on IgG concentration, was the same as
the clinical classification in all patients. The conven¬
tional laboratory indices of disease activity in the IBD
patients (serum albumin, C-reactive protein, white cell
count and erythrocyte sedimentation rate) and the physi¬
cian's clinical classification into active or inactive disease
are given in Table 1.
Cytology preparations
Each WGLF specimen (25 ml) was centrifuged at 850 g
for 10 min. The supernatant was discarded and the pel¬
let resuspended in 5 ml Hanks' balanced salt solution
(Sigma Chemical Co. Ltd, Poole, UK). This was lay¬
ered on top of a discontinuous density gradient using
Table 1. Conventional laboratory markers of disease activity in 29 inflammatory bowel disease (IBD) patients and physician's global assessment.
Median (range)
No. patients classified
Serum albumin C-reactive White cell count ESR as having active
IBD group (g/l) protein (mg/dl) (x109/l) (mm/1 st h) disease by physician
Active CD
Colonic (n = 5) 37(35-42) 7.6 (<1.5-1 6.5) 11.6(9.5-14.5) 46 (20-89) 5
Small bowel (n = 4) 38(23-41) <1.5 8.5(6.0-10.2) 34 (7-74) 4
Others (n = 3) 40(22-43) 1.5 (< 1.5-2.0) 7.3(5.4-7.8) 27 (4-44) 3
Inactive CD
Colonic (n = 5) 42(34-45) <1.5 8.7(6.5-15.9) 2(1-13) 0
Small bowel (n = 2) 38, 41 <1.5 5.1, 9.4 4, 12 0
Others (n = 3) 42 (40-45) <1.5 5.8(5.5-6.2) 27(2-100) 0
Active UC (n = 3) 39(39-43) <1.5 8.4(7.5-9.3) 1 3 (2-24) 3
Inactive UC (n = 4) 45(41-46) <1.5 6.6(5.4-7.2) 1 2 (6-40) 0
ESR, erythrocyte sedimentation rate; CD, Crohn's disease; UC, ulcerative colitis.
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Histopaque 1119 and 1077 (Sigma). After centrifuga-
tion for 30min at 700 g, the two resultant layers were
harvested separately. The suspensions were washed with
Hanks' balanced salt solution and the pellets resuspended
in 1 ml. Cell counts were performed with a haemocyto-
meter, and slides of the two suspensions were made using
a Cytospin cytocentrifuge (Shandon Southern Prod¬
ucts Ltd, Runcorn, UK) operated for lOmin at 90 g.
The slides were air-dried, fixed in methanol and then
stained by the May-Grunwald-Giemsa protocol. Slides
were examined with an Ortholux II microscope (Leitz,
Wetzlar, Germany) and the cell types present recorded.
In addition, we graded the number of neutrophils in the
preparation subjectively as few or none, some or many.
Slides were immunostained using monoclonal antibodies
for anti-CD3 (Scottish Antibody Production Unit, Car¬
luke, UK), anti-L26 (DAKO Ltd, High Wycombe, UK)
and anti-CD68,KPI (DAKO) to detect T lymphocytes,
B lymphocytes and macrophages. The three-stage strep-
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Fig. 1. Typical presentation of whole gut lavage fluid (WGLF)
cytology from a Crohn's disease patient, showing neu¬
trophils, squamous cells, a macrophage, and some de¬
generate enterocytes. (Magnification x40; May-Grunwald-
Giemsa stain).
Statistical analysis
Comparisons between the different groups of subjects
were performed by the Mann—Whitney test and Chi-




In our first cytological examinations ofWGLF, we used
either samples filtered through two layers of surgical
gauze before centrifugation, counting and cytocentrifu-
gation, or samples centrifuged and layered onto one high
density separation medium only. These methods pro¬
duced slide preparations which contained considerable
amounts of debris and many bacteria, in addition to
variable numbers of cells. A modification of the tech¬
nique using two density separation media (described in
Methods) greatly reduced bacterial contamination and
debris. We had anticipated that neutrophils and lym¬
phocytes would layer separately at the two interfaces
during gradient centrifugation, but this did not occur.
Most cells were recovered from the upper of the two
layers, and the cell types seen in the top layer were also
seen, although in fewer numbers, in the bottom layer.
The data reported below are the total cell counts for
both layers added together, and cytological descriptions
for both layers combined.
The cells observed were neutrophils, squamous cells, en¬
terocytes, eosinophils, macrophages, erythrocytes, and,
very occasionally, lymphocytes; cells from a patient with
active Crohn's disease are shown in Fig. 1. Some samples
contained yeasts, and bacteria were ubiquitous.
Cell counts
Figure 2 shows the cell counts for the different disease
groups. Specimens with many neutrophils seen on cy¬
tospin slides are highlighted. In normal controls, the
mean + 2 SD of the cell count was 3.7 X 105/ml WGLF,
and this value was taken as the upper limit of the refer¬
ence range. In the one control with a cell count above
this level, microscopy showed that these were predom¬
inantly squamous cells. Nine of the 22 patients with
Crohn's disease and three of the seven with ulcerative
colitis had high cell counts, as did one of the 14 patients
with other disease (cell count 3.8xl05/ml in WGLF
from a patient with infective colitis). Information on
the cell types in WGLF from IBD patients are given
below. Two of the 14 patients with other disease had
many neutrophils in cytospins of WGLF (one patient
with infective proctitis who also had high WGLF IgG
and a patient with colonic carcinoma and longstanding
inactive ulcerative colitis).
Cell counts in IBD according to disease activity
and anatomy of involvement
Figure 3 shows the cell counts in WGLF from IBD pa¬
tients subdivided into ulcerative colitis, colonic Crohn's
disease, small bowel Crohn's disease and Crohn's disease
with other distribution. Results are presented in relation
to WGLF IgG concentrations, the objective measure of
disease activity. Table 2 summarizes the values for se¬
lected subgroups of patients together with the results of
statistical analyses. In general, patients with active IBD
had higher cell counts than those with inactive dis¬
ease (P< 0.05). Despite the relatively small number of
patients studied, the differences in cell number were
significant for active IBD compared with normal con¬
trols (P<0.05). However, the subgroup with active small
bowel Crohn's disease did not conform; cell counts were
European journal of Gastroenterology & Hepatology 1995, Vol 7 No 1
10=-
SKT
Table 2. Cell counts in whole gut lavage fluid in inflammatory bowel




F'g- 2•, Number of cells/ml whole gut lavage fluid (WGLF)
plotted against diagnostic group, highlighting subjects with
many neutrophils. (O) many neutrophils seen; (•) all other
subjects; ( ) the count/ml equal to the mean + 2 SD of the
normal controls.
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Fig. 3. Cell count/ml whole gut lavage fluid (WGLF) plot¬
ted against WGLF immunoglobulin (Ig) G concentration for
patients with inflammatory bowel disease (IBD). (O) Colonic
Crohn's disease; (A) small bowel Crohn's disease; (Q) other
Crohn's disease; (•) ulcerative colitis; ( ) the count/ml
equal to the mean + 2 SD of the normal controls and ( )
the upper limit of normal for IgG concentration.
Cell types in IBD according to disease activity
and anatomy of involvement
Cytospin preparations showed many neutrophils in six of
the 10 specimens from colonic Crohn's disease patients
Cell count/ml
Diagnostic group n [median (range)] P
Controls 13 3.9 x104
(1 x 104-5.2x 105)
Active IBD 15 5.4 x105
(<1 x 104-8.4 x 106)
<0.05*
Inactive IBD 14 4.1 x 104
(<1 x104-8.8 x 105)
<0.05t
Active CD 12 6.5 x105
(<1 x104-8.4 x 106)
NS*
Inactive CD 10 2.3 xlO4
(<1 x1 04-6.4 x 1O5)
<0.05+
Active CD
Colonic 5 8.1 x105
(5.4x105-8.4x106
<0.01*
Small bowel 4 4.1 x 104
(<1x104-2.7 x 106)
z GO *




Colonic 5 4.9 x104
(1.3 x 104-4.8x 105)
NS*
Small bowel 2 <1 x 104, 6.5x105
Other 3 <1 x104
(<1 x 104—3.1 x 104)
NS*
Active UC 3 3.8x105
(2.4x105-3.1 x 106)
<0.05*
Inactive UC 4 1.2x105
(3.2 x 1 04-8.8 x 105)
NS§
•Versus normal controls; tversus patients with active IBD; +versus pa¬
tients with active Crohn's disease (CD); §versus patients with active
ulcerative colitis (UC). NS, not significant.
(P<0.01 compared with the controls) from one of the 12
other Crohn's disease patients (not significant) and from
four of the seven samples from ulcerative colitis patients
(P<0.02). When these data were examined in relation to
disease activity, the importance of the site of IBD became
clear. Many neutrophils were seen in cytospin prepara¬
tions from the three patients with active ulcerative colitis,
the five with colonic Crohn's disease, but in only one of
the four patients with active small bowel Crohn's disease
(a patient with ileal disease complicated by an abscess
who was also receiving high doses of non-steroidal anti¬
inflammatory drugs for ankylosing spondylitis) (Table 3).
There was no relationship between disease distribution
and the number of neutrophils in cytospin preparations
from patients with inactive IBD.
Other cell types
Eosinophils were seen in preparations from three of the
22 patients with Crohn's disease, three of the seven ulcer¬
ative colitis patients and in the patient with colonic carci¬
noma complicating ulcerative colitis; in all of these, neu¬
trophils were also present in the WGLF. Enterocytes and
squamous cells were frequently seen in slides both with
and without neutrophils. Erythrocytes were found oc¬
casionally in slides from IBD patients, and macrophages
were seen occasionally in a variety of clinical conditions.
Lymphocytes were rarely observed and occurred in low
Gut lavage fluid cytology Handy et at.
Table 3. Presence of neutrophils in different diagnostic groups.
Diagnostic group n None/few Some Many
Normal 13 13 0 0
Active IBD
Colonic CD 5 0 0 5
Small bowel CD 4 3 0 1*
Other CD 3 2 1 0
UC 3 0 0 3
Inactive IBD
Colonic CD 5 3 1 1
Small bowel CD 2 2 0 0
Other CD 3 3 0 0
UC 4 2 1 1
Other non-colonic disease 6 5 1 0
Other colonic disease 8 5 1t 2t
*Complicated by abscess and long-term high dose non-steroidal
anti-inflammatory drugs for ankylosing spondylitis; tdiverticulitis;
^infective colitis and colon carcinoma complicating ulcerative colitis
(UC). IBD, inflammatory bowel disease; CD, Crohn's disease.
numbers, mostly in patients with IBD. Immunostaining
of the few specimens containing lymphocytes confirmed
the presence ofB cells, plasma cells, and T cells, but the
general paucity of lymphocytes was striking. No malig¬
nant cells were seen.
Discussion
Many approaches are being used to study gut inflam¬
mation and its pathogenesis. These include immuno-
cytochemical investigations ofbiopsies and resected spec¬
imens, radiolabelled leukocyte studies, perfusion of iso¬
lated loops of small bowel or colon with measurements
of proinflammatory mediators, and various immuno¬
logical tests on faecal extracts [9—11,15]. Radiolabelled
leukocyte tests have provided most of the recent de¬
scriptive information on the migration of cells into the
bowel wall and then into the gut lumen, but more di¬
rect methods are needed to investigate the mediators and
chemotactic agents involved.
The use of whole gut lavage for research on intestinal
antibodies has been described by Gaspari et at. [16]. We
have simplified and standardized the clinical protocol to
create a whole gut perfusion system, relatively unaffected
by disease, age, drugs or diet (Brian and Ferguson, sub¬
mitted for publication). After appropriate specimen pro¬
cessing, WGLF analysis can be used to investigate gut
immunoglobulins and antibodies [17], to detect plasma
protein leak [18] and bleeding into the gut [19], and for
studies of mucosal cytokines [13], with minimal degra¬
dation of the cells and molecules of interest.
We have now shown that peroral whole gut lavage can
also be used to investigate inflammatory cells within the
intestinal lumen. Studies of cells and their products can
be combined with biochemical and immunological as¬
says on WGLF to provide detailed analysis and charac¬
terization of immunological and inflammatory events in
the gut. The capacity to investigate the relatively in¬
accessible small bowel is clearly advantageous, and for
research in IBD, the measurement of IgG concentra¬
tion in WGLF provides a simple and objective measure
of disease activity. A heterogeneous group of IBD pa¬
tients can thus be subdivided and stratified into subsets
with comparable disease activity to allow investigation of
other factors such as corticosteroid or diet treatments, or
disease distribution [15]. By applying WGLF analysis in
other forms of gastrointestinal disease, we can also deter¬
mine whether a particular immunological phenomenon
is truly a feature of ulcerative colitis or Crohn's disease,
or is simply a non-specific expression of tissue injury in
the gut.
It is not surprising that inflammatory cells have been de¬
tected in WGLF samples, since it is already known that
smears from centrifuged whole gut lavage fluid provide
adequate specimens for cytological diagnosis of colonic
carcinoma [20] and that neutrophils can be found in the
faeces of IBD patients [9]. Using the method described,
gut luminal cells can be counted and characterized by
cytology. Our results show high counts of luminal cells,
mainly neutrophils, in most patients with active IBD.
However, it appears that this luminal neutrophilia is not
a feature of small bowel Crohn's disease. Only one of our
patients with ileal Crohn's disease had a high WGLF cell
count and there were two associated complicating factors
(NSAID intake and an abscess communicating with the
gut).
Only one study has reported that faecal excretion of ra¬
diolabelled leukocytes is much higher in colonic than in
small bowel Crohn's disease [21]; in other reports, re¬
gional data are either not presented [10,22], or there was
no observed efFect of regional distribution [23]. Most of
these reports include small numbers ofpatients, as in this
study on WGLF cytology. WGLF cytology must be per¬
formed on fresh samples and is time consuming, but
we have found recently that the WGLF concentration
of granulocyte elastase is a useful marker of neutrophils
and correlates well with cell count. By using this assay in
large numbers of specimens, we have confirmed a strik¬
ing efFect of disease distribution on luminal neutrophils,
(unpublished data).
Eosinophils, although detected less frequently in WGLF
than neutrophils, were observed in WGLF from six of
the 15 patients with active IBD and from one patient
with carcinoma complicating ulcerative colitis. In all of
these patients there were also many neutrophils in the
WGLF specimens. Preliminary work on the assay of a
biochemical marker for eosinophils, eosinophil cationic
protein, supports this finding (unpublished data).
Further studies with WGLF may elucidate the stimuli
for inflammatory cell migration into the gut, and local
activation. Various substances may act as chemoattrac-
tants, including interleukin-8, bacterial peptides such
as formyl-methionyl-leucyl-phenylalanine, leukotriene-
B4, complement factors such as C5a, and platelet-acti-
European Journal of Gastroenterology & Hepatology 1995, Vol 7 No 1
vating factor [15], and it should be possible to study these
in parallel with the objective measures of disease severity
which we have developed already.
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Investigation of Neutrophils in the Gut Lumen by Assay of Granulocyte
Elastase in Whole-Gut Lavage Fluid
L. M. HANDY, S. GHOSH & A. FERGUSON
Gastrointestinal Laboratory, Dept. of Medicine, Western General Hospital and University of Edinburgh,
Edinburgh, Scotland
Handy LM, Ghosh S, Ferguson A. Investigation of neutrophils in the gut lumen by assay of granulocyte
elastase in whole-gut lavage fluid. Scand J Gastroenterol 1996;31:700-705.
Background: Intestinal neutrophils can be studied by radiolabelling techniques and by cytology of whole-
gut lavage fluid. Our aim was to evaluate the use of a biochemical test for the presence of these cells in
whole-gut lavage fluid. Method: Whole-gut lavage was performed by having the patients drink a
polyethylene-glycol-electrolyte solution; the clear fluid passed per rectum after complete bowel cleansing
had been collected. In 203 patients granulocyte elastase was assayed in sonicated unfiltered lavage fluid,
using the specific enzyme substrate L-pyroglutamyl-L-prolyl-L-valine-p-nitroanilide. Free granulocyte
elastase was also assayed in filtered (that is, cell-free) lavage fluid in 39 of the 43 patients in whom the
enzyme was present in unfiltered fluid. In 47 of the patients, cells were also separated by density gradient
centrifugation, and counted. Results: Granulocyte elastase concentration correlated significantly with cell
count (r = 0.80, p < 0.001). Granulocyte elastase concentration was high (>100 nkat/1) in fluid from 25
of 68 inflammatory bowel disease patients and 6 of 135 others with radiation colitis, diverticulitis,
pericolic abscess, and use of non-steroidal anti-inflammatory drugs. In patients with detectable total
granulocyte elastase, cell-free granulocyte elastase was present in 11 of 29 with inflammatory bowel
disease and 1 of 10 others. Conclusion: Whole-gut lavage fluid samples can readily be used to investigate
luminal inflammatory cells.
Key words: Granulocyte elastase; intestinal neutrophils; whole-gut lavage
Dr. S. Ghosh. Gastrointestinal Unit. Western General Hospital, Crewe Road, Edinburgh EH4 2XU,
Scotland (fax: +44 131 537 1006)
Whole gut lavage is a relatively new technique for non¬
invasive investigation of gut immunity (1,2) and can be used
for research on mucosal immunoglobulins and antibodies, to
measure gut losses of blood and protein, and for studies of
local immunoregulatory and pro-inflammatory cytokines.
Cytologic investigation of whole-gut lavage fluid (WGLF)
has shown tumour cells in some patients with gastrointestinal
cancers (3-5), and in a study of 56 patients we have recently
observed the presence of many neutrophils in WGLF from
patients with active ulcerative colitis (UC) or colonic
Crohn's disease (CD) (6).
The granules of polymorphonuclear leucocytes contain
enzymes such as elastase (7) and myeloperoxidase (8). Since
granulocyte elastase (GE) can be detected in faeces from
patients with gut inflammation (9, 10), it seemed likely that
this biochemical assay could also be used for the investigation
and quantification of intestinal granulocytes in WGLF.
The aim of this study was to explore whether GE assay in
WGLF may be used to study neutrophil migration into the
lumen of the gut in inflammatory conditions.
MATERIALS AND METHODS
Subjects
We studied WGLF samples from 203 patients in whom
the gastrointestinal tract was assessed by an appropriate
combination of upper endoscopy, colonoscopy, jejunal
biopsy, other histology and contrast radiology. Inflammatory
bowel disease (IBD) was classified as clinically active when
the WGLF IgG concentration was greater than 10 pg/ml as
validated previously by our group (11, 12). In the present
study we have again compared values for WGLF IgG
concentration in the 68 IBD patients with a physician's
overall clinical decision as to whether the disease was active
or inactive (on the basis of symptoms, clinical signs, and
results of haematologic and biochemical blood tests). The
categorization as active or inactive on the basis of IgG
concentration (> 10 pg/ml or slO pg/ml) was the same as the
clinical classification in 65 of the 68 cases. Of the three with
discrepant results, two had severe UC and were receiving
intensive medical treatment with intravenous steroids; they
were clinically graded as having active disease, whereas
WGLF IgG levels were 9 and 6 pg/ml. The third patient had
colonic CD, was taking maintenance oral steroid therapy, had
few symptoms and normal inflammatory values in blood apart
from an increased erythrocyte sedimentation rate. She was
clinically graded as inactive, but her WGLF IgG concentra¬
tion was 16 pg/ml. For the purposes of analysis and statistical
comparisons in this report, we have used the objective
measure, WGLF IgG concentration: IBD active when
IgG > 10 pg/ml and inactive when IgG < 10 pg/ml.
Thirty-one^patients had a normal gastrointestinal tract and
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Table I. Detection of granulocyte elastase (GE) in inflammatory bowel disease patients and normal subjects
WGLF GE
Diagnostic GE P versus other conc. (nkat/1) P versus other
groups* n present P versus normals relevant groups median, range P versus normals relevant groups
Normals 31 4 <39, <39-113
Active CD 23 14 <0.01 300, <39-1435 <0.001
Inactive CD 20 5 NS <0.05 versus active CD <39, <39-571 NS <0.005 versus active CD
Active UC 10 6 <0.01 103, <39-1550 <0.001
Inactive UC 15 6 NS NS versus active UC <39, <39-370 NS NS versus active UC
* CD = Crohn's disease; UC = ulcerative colitis.
acted as controls. Forty-three patients had CD, and 25 had
UC. Sixty-three patients had miscellaneous non-colonic
gastrointestinal diseases, and 41 had colonic diseases other
than IBD.
Lavage protocol
The patients drank an isotonic polyethylene glycol-based
fluid (Klean-prep, Norgine Ltd., Headington, Oxford, UK),
supervised by an experienced nurse, as described elsewhere
(11). The first completely clear fluid specimen passed per
rectum was collected for analysis. Aliquots of unfiltered.
unprocessed specimens were stored at — 70 °C until assayed
for GE. The rest of the specimen was filtered through glass
microfibre filters (Whatman GF/A, Whatman International
Ltd, Maidstone, England) with a pore size of 1.6 pm, and
aliquots were stored without further processing for assay of
free GE. Other aliquots of the filtered specimen were
processed by the addition of protease inhibitors as previously
described (11), stored at -70°C, and later assayed for IgG by
enzyme-linked immunosorbent assay (ELISA) (1).
In 47 of the above patients cytologic assessment was
performed on the first clear specimen immediately after
collection as previously described (6).
The protocol was approved by the Medicine Subcommittee
of the Lothians Area Ethics of Research Committee.
Cytology preparations
A specimen of unfiltered, unprocessed WGLF (25 ml) was
centrifuged immediately after collection at 850 g for 10 min.
The supernatant was discarded, and the pellet resuspended in
5 ml Hanks' balanced salt solution (Sigma Chemical Co. Ltd,
Poole, UK). This was layered on top of a discontinuous
density gradient using Histopaque 1119 and 1077 (Sigma).
After centrifugation for 30 min at 700 g the two resultant
layers were harvested separately. The suspensions were
washed with Hanks' balanced salt solution and the pellets
resuspended in 1 ml. Cell counts were performed with a
haemocytometer.
Granulocyte elastase assay
Total GE. The GE assay technique is based on the method
used for measurement of elastase in granulocyte extracts from
whole blood. The highly specific substrate for GE, L-
pyroglutamyl-L-prolyl-L-valine-p-nitroanilide (13), was ob¬
tained from Quadratech (Epsom, UK) and was dissolved in
dimethylsulphoxide and diluted four times in water to give a
final concentration of 2 mmol/1. Approximately 1 pi of Triton
X-100 (Sigma) was mixed into 500 pi of thawed, unfiltered,
unprocessed WGLF (the precise amount of Triton is not
critical (13)). Each sample was sonicated at 0°C for 1 min
three times, using a Rapidis A180G sonicator (Ultrasonics
Ltd., Shipley, UK) to disrupt the cells present and release the
enzymes contained in the granules. Two hundred microlitres
of sample was added to 200 pi of buffer (Tris, 0.1 mo 1/1;
NaCl, 0.96 mol/1; pH 8.3), and the mixture was incubated at
37 °C. Two hundred microlitres of substrate at 37 °C was
added, and after exactly 3 min the reaction was stopped with
200 pi of 20% acetic acid. Blank tubes were run for all
samples in the same manner but with the acetic acid added
before the substrate. Absorbance was measured at 405 nm,
and GE concentration calculated using the formula provided
by Quadratech: (test A405 - blank A405) x 2310 nkat/1. A
crude human granulocyte extract was prepared by a
modification of the method of Kramps et al. (14) and was
included as a standard. The limit of detection of the assay was
a GE concentration of 39 nkat/1. The between-assay coeffi¬
cient of variation was 6%. The possibility of interference by
the high concentration of polyethylene glycol in WGLF was
excluded by comparing values for blood granulocyte suspen¬
sions in balanced buffer and in surrogate WGLF preparations;
no difference was detected.
Free GE. Thirty-nine patients who had total GE detectable
by the above assay also had GE measured in a filtered,
unprocessed sample. The method described above was used
without the sonication step. The process of filtration removed
the granulocytes, and hence any GE detectable in this
specimen should represent free or non-particulate GE.
Statistical analysis
Correlation coefficients were calculated using the Spear¬
man rank correlation test. All 47 patients who had both
cytology and GE estimations were included in the calculation
of correlation coefficient, irrespective of whether they had
detectable GE. Comparisons between different groups of
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Table II. Non-inflammatory bowel disease patients with markedly increased granulocyte elastase (GE) levels (>100nkat/I) in whole-gut
lavage fluid
Diagnosis IgG, pg/ml GE, nkat/1 Comments*
Acute radiation colitis 236 2285 Radiotherapy for carcinoma cervix
Diverticulitis 27 132 Settled with antibiotics
Diverticular disease 3 240 On NSAIDs
Carcinoma colon 44 109 Caecal tumour with pericolic abscess
Systemic lupus erythematosus 1 210 On NSAID and prednisolone, 10 mg/day
Volunteer 1 113 Normal volunteer; repeat lavage after 3 weeks did not detect GE
* NSAID = non-steroidal anti-inflammatory drugs.
subjects were carried out using the Mann-Whitney test and
the chi-square test with Yates correction. P values <0.05
were considered significant.
RESULTS
GE concentrations in WGLF
Results of GE assays in the 203 WGLF samples are
summarized in Table I. In specimens collected from the 31
immunologically normal patients and volunteers, GE was
detectable (a39 nkat/1) in only 4 samples (values of 60, 74, 74,
and 113 nkat/1). Results in the various patient groups were
analysed and are presented as absolute GE values and as the
number of patients with any detectable GE. Values
>100 nkat/1 WGLF are considered abnormally high.
Detection of GE was significantly more frequent than in
normals, and absolute values were also significantly higher,
for specimens from CD patients (19 of 43, p < 0.01; median
<39, range <39-1435 nkat/1, p < 0.001) and from UC








<39-1550 nkat/l, p < 0.001). Only 5 of 41 patients with
other colonic diseases and 3 of 63 patients with other non-
colonic diseases had detectable GE. Neither these frequencies
nor the absolute values differed significantly from those for
the normal group.
One subject classified as normal and five with diseases
other than IBD had high GE concentrations (> 100 nkat/1).
These patients are described in Table II. Three patients had
clinical disorders compatible with exudation of neutrophils
into the lumen—acute radiation colitis, diverticulitis, peri¬
colic abscess Communicating with the lumen; in the other two
it seems likely that the explanation was non-steroidal anti¬
inflammatory drug (NSAID)-associated enteropathy. The
normal subject was a volunteer in a study investigating
mucosal immunity in smokers; in a further specimen of
WGLF collected 3 weeks later GE was undetectable.
Relationship between cell count and GE concentration in
WGLF
Fig. 1 shows WGLF cell counts and total GE concentra¬
tions in the 47 patients studied by both methods. The
correlations for the whole series, for CD, and for UC patients
are all highly significant (all cases, r = 0.80, p < 0.001; CD,
r = 0.79, p < 0.001; UC, r = 0.98, p = 0.001). There were 33
specimens in which GE was less than the 39 nkat/1 detection
limit.
Total and free GE
Aliquots of WGLF that had been filtered but not treated in
Table III. Detection of free granulocyte elastase (GE) in 39 patients
with detectable total GE
Fig. 1. Cell count per millilitre whole-gut lavage fluid (WGLF)
plotted against granulocyte elastase (GE) concentration in WGLF.
(O) = Crohn's disease; (•) = ulcerative colitis; (x) = all other
diagnoses. The dotted line shows the count per millilitre equal to the









Miscell. upper GI 2 0
Miscell. colonic 5 It
* CD = Crohn's disease; UC = ulcerative colitis; GI = gastroin¬
testinal.
t Radiation colitis.
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Fig. 2. The relationship between free and total granulocyte elastase
(GE) in 39 patients with detectable total GE. (x) = Normals
(n = 3); (O) = Crohn's disease (n = 18); (#) = ulcerative colitis
(n = 11); (□) = miscellaneous upper GI (n = 2); (A) = miscella¬
neous colonic (n = 5).
any other way were available for 39 of the 43 specimens in
which GE had been detected in unfiltered specimens. Results
of GE assays in these paired samples are summarized in Table
III, and Fig. 2 shows the relationship between total and free
GE. There was a significant correlation between free GE and
total GE (r = 0.8; p < 0.0001). Eleven of 29 1BD patients
with detectable total GE had detectable free GE, whereas
none of the 3 normals and only 1 of the 7 diseased controls
(the patient with radiation colitis) had detectable free GE.
In the whole group the concentration of total GE in those
with detectable free GE (median, 703 nkat/1; range, 55-2285
nkat/1) was significantly greater (p < 0.001) than that in those
with undetectable free GE (median, 159 nkat/1; range,
39-1157 nkat/1). This was also true for CD patients in
whom the concentration of total GE in those with detectable
free GE (median, 714 nkat/1; range, 300-1435 nkat/1) was
significantly greater (p < 0.05) than that in those with
undetectable free GE (median, 215 nkat/1; range,
39-1157 nkat/1). In UC patients the difference in total GE
concentration between those with detectable free GE (median,
532 nkat/1; range, 55-1550 nkat/1) and those with undetect¬
able free GE median, 162 nkat/1; range, 44-432 nkat/1) did not
reach statistical significance.
DISCUSSION
When the procedure is standardized and supervised by an
experienced nurse, whole-gut lavage with a polyethylene
glycol-based isotonic solution is essentially a whole-gut
perfusion system. Once the gut has been cleansed, the
concentrations of various proteins in WGLF remain steady
over serially timed samples, and the first clear sample is
representative of the rest (unpublished data, and J. Sallam,
Ph.D. thesis, University of Edinburgh, 1995). The clear fluid
passed per rectum is suitable not only for detection of
antibodies, as first described by Gaspari et al. (15), but also
for cytology (3-6), for investigations of plasma protein leak
(16) and bleeding (17) into the gut, and for studies of pro¬
inflammatory and immunoregulatory cytokines. Abundant
material for study becomes available when gut lavage is used
for bowel cleansing before clinically indicated diagnostic
imaging or endoscopic tests, and since the technique is
relatively non-invasive, healthy control volunteer subjects
can also be studied. This approach is proving particularly
useful for the investigation and analysis of gut inflammation.
Neutrophil infiltration into the tissues, migration into the
gut lumen, and activation can be investigated in several
ways—by histology and immunohistochemistry of mucosal
biopsy specimens, by using radiolabelled leucocytes (18, 19),
and by cytologic examination of whole-gut lavage fluid (6).
The use of gut lavage has the advantage that both the
relatively inaccessible small bowel and the colon can be
studied quantitatively and objectively by cytology. However
this test requires fresh specimens and is very labour-intensive.
We have therefore developed and evaluated a biochemical
assay specific for the neutrophil granule protein GE.
Some of the ELISAs for GE measure the enzyme as a
complex with -antitrypsin (20). The concentration of ar
antitrypsin in WGLF is normally very low and is affected by
disease (16), and so the ELISA for GE was unsuitable for our
purposes. We therefore used a different technique, indepen¬
dent of the presence or concentration of a]-antitrypsin. GE is
released from the cells by sonication, then assayed by using a
chromogenic substrate (L-pyroglutamyl-L-prolyl-L-valine-p-
nitroanilide) specific for GE and a colorimetric method. The
handling of the WGLF sample after collection differed from
the procedure that we have previously described. For
immunoassays, including IgG measurements, WGLF samples
are filtered and treated with a series of protease inhibitors.
Such specimens have, of course, been depleted of cells,
including granulocytes, at the filtration stage, and GE cannot
be detected by our method when protease inhibitors are
present. Thus, total GE measurements were made on
sonicated but otherwise untreated WGLF specimens. Free
GE in the fluid can also be measured in filtered but otherwise
untreated specimens, thus providing some information on cell
activation.
We have previously shown that in patients with high cell
counts in WGLF, the cells are predominantly neutrophils, and
we suggested the term 'luminal neutrophilia' to describe this
(6). The present study shows that WGLF GE concentration
correlates significantly with cell count, confirming that GE is
an excellent surrogate marker for luminal neutrophilia.
Results of GE assays in this large series confirm and extend
our cytologic findings that most, but not all, patients with
luminal neutrophilia have IBD. Further analysis (6, and
unpublished observations) is showing that when stratified
separately by disease distribution (on the basis of X-ray and
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endoscopic findings) and by disease activity (on the basis of
concentration of IgG in WGLF), luminal neutrophilia is a
feature of active ulcerative colitis and active colonic Crohn's
disease but is not normally present in patients with active
Crohn's disease of the small bowel.
Neutrophils and GE are also present in the WGLF from
patients with diseases other than 1BD, particularly in those
whose clinical backgrounds were compatible with neutrophil
migration through the gut wall. Acute radiation proctocolitis
and diverticulitis are conditions obviously associated with pus
present on the mucosa. A pericolic abscess communicating
with the lumen may discharge pus, which is the most likely
explanation in our patient with carcinoma of the colon with
increased GE level. NSAID use has been shown to be
associated with isotope-labelled leucocyte excretion into the
lumen, probably from small intestine (21); two of our patients
with markedly increased WGLF GE but normal IgG concen¬
trations were taking NSAlDs.
There were a few IBD patients in whom results of total and
free GE assays showed the presence of both cell-bound and
cell-free GE in WGLF, indicating neutrophil degranulation;
other IBD patients had cell-bound (or, strictly speaking,
particulate) GE only. Total GE levels were significantly
higher in the former group, but disease activity, as measured
by WGLF IgG concentration, was similar in those with and
without free GE.
Further studies with WGLF may help to elucidate the
stimuli for granulocyte migration into the gut in different
clinical situations. Various molecules that may act as
chemoattractants, including interleukin (IL)-8, bacterial
peptides such as formyl-methionyl-leucyl-phenylalanine
(FMLP), leukotriene-B4, complement factors such as C5a,
and platelet-activating factor (PAF), have been recently
reviewed (22). The WGLF method can be used to investigate
these possibilities. Preliminary studies of cytokines in WGLF
suggest that IL-1 and IL-8 are present in lavage fluid from
IBD patients (unpublished data). Evidence that IL-8 may be
implicated in the pathologic lesions of IBD comes from
rectosigmoid perfusion studies, which show that myeloper¬
oxidase released from neutrophil granules correlates with IL-
8 in the perfusate in ulcerative colitis (23). Furthermore, in
active IBD, increased IL-8 content of affected colonic mucosa
correlates with mucosal neutrophil counts (24).
In conclusion, the whole-gut lavage technique is a new,
relatively non-invasive clinical method for detecting and
investigating intestinal immunity and inflammation. Since the
method may be readily combined with preparation for
radiologic or colonoscopic investigation of the bowel,
material from patients with gut lesions other than IBD may
readily be studied to determine the specificity of particular
immunologic variables for a defined pathologic condition. By
using this new clinical test, it should be feasible to study the
regulatory mechanisms underlying anatomic differences
between small- and large-bowel diseases and the effects of
pharmacologic agents such as steroids, antibiotics, and
NSAIDs, and to objectively define therapeutic end points
such as remission of gut inflammation.
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